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Chapter 1. Rationale and overview 
 
Rationale 
Cerebrospinal fluid (CSF) is produced by the choroid plexus, and flows through 
the cerebral ventricles to the subarachnoid space where it is absorbed to the 
superior sagittal sinus (SSS) (1). Hydrocephalus develops when the CSF flow is 
hampered or the absorption capacity is diminished (2). When the CSF flow is 
obstructed at the level of the third or fourth ventricle’s outflow (‘obstructive 
hydrocephalus’), it can be treated by an endoscopic third ventriculostomy 
(ETV). If the CSF flow is obstructed more proximally or distally, it is treated by 
draining CSF to the peritoneal cavity or to the right atrium of the heart with a 
ventriculoperitoneal (VP) or ventriculoatrial (VA) shunt (3). Although these 
techniques are frequently used since the 1950’s, they suffer from a failure rate 
up to 50% in the first two years after implantation (4-8). An important cause 
of shunt failure is siphoning, which means that the CSF column within the 
catheter exerts suction through gravity when the patient is in a sitting or 
standing position (9). Complex and expensive devices to counteract siphoning 
exist but are not always sufficient (5, 10). Shunt failure is an important burden 
for patients and it has a high economic impact, hence, there remains a valid 
rationale for ongoing hydrocephalus research (11). 
A promising, but still experimental treatment of hydrocephalus is the 
ventriculosinus (VS) shunt (11). The VS shunt drains CSF to its natural 
resorption site, preserves the anti-siphon effect of the internal jugular vein 
(IJV) and theoretically restores a physiological intracranial pressure (ICP) (12-






minimizes the risk of mechanical failure and infection. After unsuccessful early 
attempts, El-Shafei and Børgesen independently pioneered the technique in 
the early 2000s (14, 16, 17). They report, based on retrospective data, a shunt 
survival rate of up to 95% after a mean follow up of over 6 years (13, 14).  
We felt inspired by the new technique and, as prospective studies were 
lacking, we started a monocentric prospective clinical trial. This study was 
interrupted due to an unacceptable high obstruction rate of the sinus 
catheter, caused by a thrombotic and/or endothelial sleeve around the distal 
end of the shunt (15). What caused this early and frequent thrombotic 
obstructions is not clear. We respected the technical recommendations of 
previous literature (13, 18, 19) and the surgeon who performed all 
implantations even travelled to Cairo to learn the technique from professor 
El-Shafei. Therefore, it seems highly unlikely to us that the results are due to a 
deviant surgical technique. Also, more generally, we noticed that, despite the 
substantial theoretical advantages and the excellent clinical results that were 
reported, the VS shunt did not break through. On the contrary, it has become 
very quiet about this technique that neurosurgeons seem to be reluctant to 
use.  
Therefore we suspect that certain characteristics of VS shunts predispose this 
technique to thrombotic complications (20). This hypothesis is endorsed by 
the fact that thrombotic complications are also encountered – and well 
documented - in ventriculoatrial (VA) shunts, a classical treatment of 
hydrocephalus (3, 21, 22). The incidence of these complications has proven to 
be higher than would be expected on the basis of the presence of a foreign 





The goal of the present thesis is to identify characteristics that predispose 
ventriculovenous (VV) shunts (VS and VA shunts) to thrombotic complications. 
This will be a first step in a bigger research project aiming at the development 
of a new, long-lasting VS shunt. 
Overview 
The present thesis is structured as follows: 
Chapter 2, ‘General introduction’, gives a general introduction on the 
production, circulation and absorption of CSF as well as on the medical 
condition hydrocephalus.  
Chapter 3, ‘Ventriculoperitoneal shunts’, describes the principles and results 
of this technique, currently the most used treatment of hydrocephalus. It 
addresses common causes of shunt failure with special attention to siphoning. 
Chapter 4, ‘Ventriculovenous shunts’, gives a general introduction on the 
technique and results of VA and VS shunting and discusses how VS shunts 
theoretically prevent siphoning. Next, it reports on the methodology and 
results of the prospective clinical trial to evaluate VS shunts, that was 
conducted at our department and interrupted due to frequent and early 
thrombotic shunt obstructions. It concludes that specific factors probably 
predispose ventriculovenous (VV) shunts to thrombotic complications.  
Chapter 5, ‘Factors that predispose to thrombotic complications’, reports on 
the results of a non-hydrocephalic experimental goat model, that was 
developed to identify factors predisposing VV shunts to thrombotic 
complications. During the experiment we observed pulsatile reflux of blood 






of shunt orientation (anterograde or retrograde). We also found that adding 
CSF to blood enhances blood coagulation. Both issues were further explored 
by the in vitro models described in the following chapters. 
Chapter 6, ‘Pulsatile backflow of blood into the shunt’, identifies the 
interaction between pressure waves in the brain ventricles (proximal end of 
the shunt) and in the SSS or the right atrium (distal end of the shunt), as a 
potential cause of pulsatile backflow. It discusses the methodology and the 
results of a dynamic experimental set-up, that was developed to evaluate 
whether these pressure waves are effectively responsible for pulsatile 
backflow of blood into the shunt system. 
Chapter 7, ‘Procoagulant effect of CSF’, explores if this effect, observed in the 
animal model, also exists in humans. First the influence of adding CSF to blood 
of the same patient was evaluated in a static coagulation assay. Next, a new 
dynamic in vitro model (modified Chandler loop) was applied to verify whether 
the blood-CSF-foreign material interaction effectively results in more clot 
formation on the shunt surface.  
Chapter 8, ‘Evaluation of the efficacy of novel hydrocephalus treatments’, 
discusses an attempt to develop a hydrocephalic experimental goat model. 
Such a model might be a necessary step in the development of a novel VS 
shunt, as the non-hydrocephalic model, presented in chapter 5, does not allow 
to evaluate efficacy nor long term shunt survival.  
Chapter 9, ‘Discussion’, integrates the findings of the previous chapters, and 





Chapter 10, ‘Summary – Samenvatting’, provides English and Dutch 
summaries of the present thesis. 
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Chapter 2. General introduction 
 
Cerebrospinal fluid  
CSF, found in the cerebral ventricles (Figure 1) and in the subarachnoid space 
surrounding the brain, offers hydromechanical protection of the central 
nervous system, plays a prominent role in brain development, and regulates 
interstitial fluid homeostasis (1-3). In order to enable CSF to fulfill these 
functions, its production, circulation, and absorption processes should be 
unhindered and carefully balanced. These processes are summarized in Figure 
2 and discussed in more detail below.  
CSF secretion 
400 to 600 ml CSF is secreted daily, of which 60 to 70 % is produced by the 
choroid plexuses of the lateral ventricles and the tela choroidea of the third 
and fourth ventricles (4). Choroidal secretion of cerebrospinal fluid comprises 
two steps: the first step is passive filtration of plasma from choroidal 
capillaries to the choroidal interstitial compartment according to a pressure 
gradient. The second step consists of active transport from the interstitial 
compartment to the ventricular lumen, across the choroidal epithelium, 
involving carbonic anhydrase and membrane ion carrier proteins (5). The 
active transport of CSF results in a composition that is more than a passive 
ultrafiltrate of plasma (4). The secretion of CSF is exquisitely modulated so that 







Figure 1. Brain ventricles 
Upper left, ventricles viewed from lateral surface of the brain; upper right, ventricles 
viewed from anterior surface of the brain; lower left, ventricles viewed from apical 
surface of the brain; lower right, details of ventricular structures. Reproduced from (6) 
with permission. 
The choroid plexuses receive cholinergic, adrenergic, serotoninergic and 
peptidergic autonomic innervation. The sympathetic nervous system reduces 
CSF secretion, while the cholinergic system increases CSF secretion. 






(1). 30 – 40 % of the CSF production results from a transporter-mediated 
extrachoroidal fluid transport that occurs at the cerebral capillary wall (7) and 
ventricular ependyma (8).   
Despite the daily production rate of around 500 ml CSF, only 80-180 ml of CSF 
is present around the brain and spinal cord at any given moment. The CSF 
volume is thus renewed 4-5 times every day (1). This high turnover rate relies 
on unhindered circulation and absorption of CSF.  
CSF circulation 
After its production, CSF travels through the interventricular foramina of 
Monro to the third ventricle and then through the cerebral aqueduct of Sylvius 
to the fourth ventricle and finally to the subarachnoid space through the 
lateral apertures of Luschka and the median aperture of Magendie. It then 
circulates rostrally to the villous sites of absorption or caudally to the spinal 
subarachnoid space. CSF that enters the spinal subarachnoid space, might be 
absorbed by spinal arachnoid villi (see below) or might circulate back to the 
cranial subarachnoid space (1, 9). 
Circulation of CSF is driven by static and dynamic pressure gradients (1, 9). The 
static pressure gradient is generated by the production of CSF (volume 
transmission) while the dynamic pressure gradients originate from the cardiac 
and respiratory cycles. Due to the dynamic pressure gradients, CSF flow or 
movement is neither laminar nor constantly unidirectional. Pulsatile CSF 
movement during each cardiac pumping cycle occurs as anterograde caudal 








Figure 2. CSF ‘secretion-circulation-absorption’ model 
CSF is mainly secreted by the choroid plexus and, to a lesser extent, by the interstitial 
compartment. It circulates rostrocaudally inside the ventricles and drains into the 
cerebellomedullary cistern (cisterna magna) through the median aperture (foramen of 
Magendie) of the fourth ventricle. CSF circulates in cranial and spinal subarachnoid 
spaces. In the cranial subarachnoid space, CSF flows towards arachnoid villi in the wall 
of venous sinuses from which it is absorbed. Part of the CSF is absorbed by the olfactory 
mucosa and cranial nerve sheaths (implying optic, trigeminal, facial and 
vestibulocochlear nerves) and is drained by the lymphatic system. In the spinal 
subarachnoid space, the CSF that is absorbed by the epidural venous plexus and spinal 
nerve sheaths enters the lymphatic system, while the remaining CSF circulates rostrally 
towards the cranial subarachnoid space. CSF communicates with interstitial fluid via 







CSF absorption to the dural venous sinuses by arachnoid granulations 
(Pacchionian granulations; arachnoid villi) is supported by both older (10-12) 
and more recent studies (13). Arachnoid granulations are projections of the 
arachnoid membrane into the SSS allowing drainage of CSF to the venous 
system (Figure 3) (11). The pressure gradient between the subarachnoid 
spaces and the venous sinus, necessary to ensure CSF drainage, is between 3 
and 5 mmHg (14). 
 
Figure 3. Cranial arachnoid 
granulations  
Arachnoid granulations are 
endothelium-lined finger-like 
meningeal protrusions through 
the dura mater of the superior 
sagittal sinus that ensure CSF 
drainage whenever the 
pressure gradient between the 
subarachnoid spaces and the 
venous sinus is over 3 to 5 mm 
Hg. Reproduced from (1) with 
permission. 
The proportions of CSF that efflux through each of these major pathways have 
yet to be determined with any certainty in humans. The existing evidence, 
derived from animal studies, indicate that the relative importance of the major 






seems to account for  up to 15 % of the CSF absorption in cats, 30 % in rabbits 
and almost 50 % in sheep (15).  
The CSF outflow pathways may evolve throughout development. A tracer 
injected to observe CSF drainage through the lymphatic system in embryonic 
and postnatal pigs was detectable as early as the 92 nd day of the embryonic 
period (16). Given that arachnoid granulations are scarcely visible in fetal and 
newborn sheep (17) and are not easily observed in humans until 18 months 
after birth (18), it might be speculated that the lymphatic pathway plays an 
especially important role in CSF drainage during embryonic and early postnatal 
development but takes a proverbial backseat as the arachnoid granulations 
mature and become more capable of supporting CSF absorption (19), (20). 
CSF absorption by spinal arachnoid granulations: CSF is also absorbed from the 
spinal compartment  by spinal arachnoid granulations (1). These are typically 
found adjacent to spinal nerve roots and protrude through the dura mater 
(21). Spinal arachnoid granulations evacuate CSF to the epidural venous plexus 
or to the lymphatic system (22). Spinal absorption of CSF increases in the 
upright position and during effort (22). 
Absorption by spinal nerve sheaths: CSF absorption surfaces have been 
identified on meningeal sheaths, particularly the meningeal recesses of spinal 
and cranial nerve roots (Figure 4). The best-known example is the optic nerve. 
In pathological conditions, such as hydrocephalus and benign intracranial 
hypertension, fluid thickening of the optic nerve sheaths can be visualized by 
magnetic resonance imaging (MRI). This finding suggests that the optic nerves 
participate in CSF absorption when the capacity of the usual absorption 








Figure 4. Cerebrospinal fluid absorption by spinal arachnoid villi and 
meningeal sheaths of spinal nerves 
Spinal absorption of CSF may occur by arachnoid villi in contact with the epidural 
venous plexus (a), arachnoid villi adjacent to spinal nerve roots (b). or absorption 
surfaces in the meningeal recess of spinal nerve roots (c). Reproduced from (1) with 
permission. 
Absorption through the cribriform plate: this pathway, that was studied in 
animal models, successively involves perivascular spaces, the arachnoid 
sheath of olfactory nerve fibers through the cribriform plate, and the nasal 
submucosa and cervical lymph nodes (23). Stains injected into CSF are 
subsequently found in the nasal submucosa and cervical lymph nodes (24). In 
sheep, occlusion of the cribriform plate of the ethmoid bone increases the  
intracranial pressure (25, 26), and lymphatic absorption of CSF increases with 






dog induces cerebral edema (28). Despite such evidence from animal models, 
the functional role of this lymphatic pathway in man remains unknown. 
Presumably, it provides an accessory pathway that becomes active when the 
capacities of the cranial arachnoid villi are exceeded. It may be especially 
active in neonates, as immature arachnoid villi only become fully functional 
after the age of 18 months, and in the elderly due to fibrous changes of 
arachnoid granulations (1). 
Movement of water in the central nervous system and CSF physiology 
Water can diffuse freely and bidirectionally between blood, brain and CSF (29, 
30). This fast water flow relies on the presence of aquaporins. The brain 
contains 3 types of aquaporins (31). Aquaporin 1 is expressed in the apical 
membrane of the choroid plexus, and plays a role in CSF formation (32). 
Although highly expressed in peripheral endothelial cells, aquaporin 1 is not 
found in normal brain capillary endothelium (33). As shown in Figure 5, 
aquaporin 4 is strongly expressed at the borders between brain parenchyma 
and major fluid compartments including astrocyte foot processes (brain–
blood) and glia limitans (brain–subarachnoid CSF), as well as ependymal cells 
and subependymal astrocytes (brain–ventricular CSF) (34, 35). This pattern of 
distribution suggests that aquaporin 4 controls water flow into and out of the 
brain. Aquaporin 9 has been observed in rat brains and may play a role in 
controlling the cerebral energy metabolism (31). 
Despite the evolving knowledge about the movement of water in and out of 
the brain and about the distribution and function of aquaporins, the exact 
mechanism of the huge bidirectional flux of water through the brain capillaries 






aquaporins in brain capillary endothelium or on the basal side of the choroidal 
epithelium (36). Brain capillary endothelium however does contain tight 
junctions which prevent paracellular transport of water (31). 
 
 
Figure 5. Routes of water flow out of the brain  
(a) Excess water moves from the brain, through several layers of astrocyte processes 
comprising the glia limitans externa and pia into subarachnoid CSF. (b) Excess water 
also moves from the brain, through layers of subependymal astrocyte processes (glia 
limitans interna) and ependyma into ventricular CSF. (c) Some excess water moves 
directly from the brain through astrocyte foot processes and endothelial cells into the 
blood. Note that all exit routes strongly express aquaporin 4 (AQP4). Image reproduced 






Recently a brain-wide pathway for fluid transport in mice was identified. This 
pathway includes the para-arterial influx of subarachnoid CSF into the brain 
interstitium (along the Virchow Robin spaces), followed by the clearance of 
interstitial fluid along large-caliber draining veins. Interstitial convective bulk 
flow between these influx and efflux pathways is driven by aquaporin 4 
dependent trans-astrocytic water movement and probably by the arterial and 
venous pressure waves (37). This system, called the glymphatic system (or g-
lymphatic system as it depends on glial cells), is summarized in Figure 6. 
Recent literature shows that the secretion of CSF is volumetrically less than 
1 % of the total central nervous system water diffusional exchange (38, 39). 
Based on this fact an alternative model of CSF physiology was proposed (40). 
In this model it is presumed that CSF is exclusively formed and absorbed by 
water filtration across arterial capillary walls throughout the entire central 
nervous system. The model thus contradicts the contribution of the choroid 
plexus to the production of CSF as well as the contribution of the arachnoid 
granulations to the absorption of CSF (40, 41). By consequence there is no 
‘volume transmission’ and thus no ‘CSF bulk flow’ from the brain ventricles to 
the subarachnoid space. Instead there is a pulsatile ‘to and fro’ movement of 
CSF resulting in local mixing and diffusion. Based on this alternative model of 
CSF physiology it is claimed that hydrocephalus is not the result of hampered 
CSF circulation or absorption, but is caused by intraventricular fluid 
accumulation due to increased blood vessel permeability in combination with 







Figure 6. Glymphatic pathway 
The glymphatic system supports interstitial solute and fluid clearance from the brain. 
In this brain-wide pathway, CSF enters the brain along para-arterial routes, whereas 
interstitial fluid is cleared from the brain along paravenous routes. Convective bulk 
flow between these influx and clearance routes is facilitated by the aquaporin 4 (AQP4) 
dependent astroglial water flux and drives the clearance of interstitial solutes and fluid 
from the brain parenchyma. From here, solutes and fluid may be dispersed into the 
subarachnoid CSF, enter the bloodstream across the postcapillary vasculature, or 
follow the walls of the draining veins to reach the cervical lymphatics. Reproducced 






This alternative model of CSF physiology is inconsistent with over 60 years of 
experimental data obtained for animals and humans (3) as well as with clinical 
observations like the effectiveness of resection/ablation of the choroid plexus 
in case of CSF overproduction (42) and of ETV in case of obstructive 
hydrocephalus (43). It is also in contradiction with iconographic data proving 
a net CSF flow through the Sylvian aqueduct (38). It is shown that, although 
the total water exchange is considerably higher at the blood brain barrier, the 
net fluid generation capacity is importantly higher at the choroid plexus 
barrier (3). 
In the light of the above, we  support the opinion that the recent insights in 
molecular exchanges (including water) between CSF, interstitial fluid and brain 
capillaries, complement rather than contradict the traditional and well 
documented bulk flow model (3).   
Cortical veins and dural venous sinuses 
Anatomy 
Blood is supplied to the brain by the internal carotid- and vertebral arteries. It 
then flows through smaller arteries and arterioles (resistance vessels) towards 
the capillary bed. Capillaries join to form venules and veins. The venous 
drainage of the brain can be separated into two subdivisions: superficial and 
deep. The superficial system contains cortical veins that drain towards the 
dural venous sinuses (Figure 7).  
The most prominent of these sinuses is the SSS which is located in the sagittal 
plane under the midline of the cerebral vault. It has a triangular section that 
augments from anterior to posterior (44-46). From the SSS, blood flows 






sagittal sinus that primarily drains the deep venous system. From the 
confluence, two transverse sinuses originate that travel laterally and 
inferiorly. Before leaving the skull, the sinuses describe an S-shape, called the 
 
Figure 7. Anatomy of the cortical veins and dural venous sinuses 
The cortical veins enter the SSS under individual angles. The SSS runs towards the 
confluence where it is joined by the inferior sagittal sinus and bifurcates to give rise to 
the transverse sinuses. These run laterally towards the sigmoid sinuses and the internal 
jugular veins. Reproduced from (6) with permission. 
sigmoid sinuses. The sigmoid sinuses drain in the internal jugular veins that 







Cortical vein - dural venous sinus junction 
The cortical veins drain in the SSS under individual angles. The angles shift 
from cranially to caudally. At the cranial side of the SSS, the veins drain in the 
direction of the blood flow, in the middle of the SSS perpendicular to the blood 




Figure 8. Angle between cerebral veins and the SSS 
Left, at the cranial side of the SSS, the veins drain in the direction of the blood flow; 
middle, in the middle of the SSS the veins drain perpendicular to the blood flow; right, 
in the caudal part of the SSS the veins drain against the direction of the blood flow 
This is the result of brain development. In the fetal brain, the cerebral veins 
run from the Sylvian fissure upwards to the SSS, which they join under a 
straight angle (90 ⁰). However during the further development of the central 
nervous system, the frontal pole is moved anteriorly and the rest of the brain 
posteriorly, while the entry of the veins in the SSS remains fixed (46).  
The thin walled cortical veins are surrounded by CSF and subjected to the ICP. 






outside the vein) becomes negative, the vein collapses (47, 48). This happens 
at the junction with the SSS (Figure 9) (48).  
 
Figure 9. Volume changes of the cerebral veins in response to ICP or Psss 
alterations 
As Psss < ICP in physiological conditions, and as the thin walled cortical veins collapse 
when the transmural pressure is negative, these veins are partly collapsed in 
physiological situations. The combination of resistance and flow through the collapsed 
vessel results in a pressure gradient over the segment. Therefore, the transmural 
pressure becomes positive in the more proximal part of the vein. Proximal to this point, 
the vein will remain open. When volume is added to the intracranial compartment, the 
ICP rises and venous blood is ‘squeezed’ out of the cerebral veins, reducing the blood 
volume and lowering the ICP again. When the Psss increases, the cerebral veins dilate, 






The pressure in the SSS, that is embedded within the stiff dura mater, is lower 
than the ICP. By consequence, the transmural pressure in the most distal part 
of the cortical veins will be negative, causing these veins to collapse (47, 48). 
The combination of resistance and flow through the collapsed vessels, results 
in a pressure gradient over the segments. Therefore, the transmural pressure 
becomes zero or slightly positive in the more proximal part of the veins. The 
veins will remain open proximal to this point  (47, 48).  
Intracranial pressure 
The normal ICP is the result of CSF formation, the total resistance of CSF 
circulation and absorption and the pressure in the dural venous sinuses. It can 
be calculated by Davson’s equation (49): 
ICP = If x Ro + Psss 
If, formation rate of CSF (ml/min); Ro, resistance to circulation and absorption of CSF 
(mmHg/ml/min); Psss, pressure in the SSS (mmHg) 
The upper limit of normal ICP in adults and older children is considered to be 
15 to 20 mm Hg, although the usual range is 5 to 10 mm Hg (49).  
In an adult human being, approximately 87 % of the volume of the intracranial 
space, typically 1500 ml, is occupied by the brain, 9 % by CSF and 4 % by blood 
(50). To protect the brain from physical injury, the intracranial elements are 
encased in a rigid structure, the skull. The intracranial elements contain mainly 
water and are considered to be incompressible. By consequence, any change 
in volume of one of the three intracranial components (blood, brain, CSF) or 






the expense of the other two, if ICP is to be maintained. This relation is 
referred to as the Monro-Kellie doctrine (49).  
Vblood + VCSF + Vbrain (+ Vother) = Vintracranial space = constant 
V, volume 
A sudden increase in volume can be compensated by displacement of cranial 
CSF to the spinal compartment (distension of the spinal dural sac) and/or by 
drainage of venous blood to the dural venous sinuses (Figure 9Figure 9). Due 
to such mechanisms, the intracranial system has some compliance. This is 
reflected in the characteristic pressure-volume curve, that is hyperbolic in 
healthy adults (Figure 10) (49). 
Along the flat portion of the curve, an increase in volume will affect the ICP 
only minimally because compensatory mechanisms can effectively keep the 
ICP within normal range. This part of the curve is called the ‘period of spatial 
compensation’. As more volume is added, the compliance progressively 
lessens; this portion is called the ‘period of spatial decompensation’ (49).  For 
ICP values over 50 mm Hg, and as it approaches the mean arterial pressure 
(‘critical ICP’), the curve tends to flatten again; thus, the complete curve is not 
hyperbolic but rather sigmoid (49).  
It is important to note that even the physiologic ICP is far from static; it rather 
constitutes a dynamic equilibrium. This is reflected by the ICP waveform not 
being flat, but pulsatile (Figure 11). The baseline, or average, level is commonly 
referred to as the ICP, whereas rhythmic components superimposed on this 








Figure 10. Intracranial pressure-volume curve. 
The relation of the ICP (y-axis) to the intracranial volume (x-axis) follows a sigmoid 
curve, that has three zones: a flat zone, expressing good compensatory reserve (period 
of spatial compensation; 1), an exponential zone, depicting poor compensatory reserve 
(period of spatial decompensation; 2), and a flat zone again, seen at very high ICP 
values (above the ‘‘critical’’ ICP) depicting derangement of normal cerebrovascular 
responses. The intracranial blood volume varies during the cardiac cycle resulting in a 
pulsatile intracranial pressure wave. In the first zone, the pulse amplitude of ICP is low 
and does not depend on the mean ICP value. The pulse amplitude increases linearly 
with the mean ICP in the zone of poor compensatory reserve. In the third zone, the 
pulse amplitude starts to decrease when the ICP is rising. Reproduced with 







Cardiac and respiratory activity creates pulsatile components by cyclical 
changes in cerebral blood volume (49).  
During the heart cycle, left ventricular contraction causes an arterial pulse, 
that results in a sudden increase in the cerebral arterial inflow.  Due to vascular 
resistance, the arterial inflow is not directly compensated by venous outflow 
and the total intracranial volume and thus the ICP will rise transiently (49, 51). 
As in the extra-cranial vasculature, the arterial pulse is damped by the 
resistance and compliance of the arterioles and the capillary flow is nearly 
pulseless (52).  Although a pulseless flow is delivered to the veins, the 
intracranial cortical veins do pulsate. This is due to the transmittance of the 
arterial pulse, through CSF and brain, to the thin walled cerebral veins, 
resulting in a pulsatile venous compression and venous outflow (53-55). The 
cyclic alteration in venous outflow towards the venous sinuses results in a 
pulsatile flow in the SSS (53). 
The respiratory contribution to the ICP waveform is the result of fluctuations 
in cerebral venous outflow during the respiratory cycle, generated by pressure 
changes in the thoracic cavity. During inspiration there is a negative 
intrathoracic pressure that increases the pressure gradient between the 
cerebral veins and the superior caval vein, therefore driving cerebral venous 
return, with a concomitant drop in cerebral blood volume and ICP (49). 
A sudden rise in thoracic pressure (Valsalva maneuver) is transmitted through 
the jugular veins and dural venous sinuses towards the cortical veins. These 
veins will dilate in response to the increased transmural pressure, thereby 








Figure 11. ICP waveform 
Upper: the rhythmic components of the ICP waveform associated with cardiac and 
respiratory activity. 
Lower: detail of the ICP waveform originating from the cardiac cycle. Several small 
components can be seen, the most constant of which are the percussion wave (P1), the 
tidal wave (P2), and the dicrotic wave (P3). The percussion wave, the most constant in 
amplitude, derives from pulsations in large intracranial arteries. The tidal wave has a 
more variable shape and is thought to arise from brain elastance. The tidal wave and 
the dicrotic wave are separated by the dicrotic notch, which corresponds to the dicrotic 







This results in a fixed relation between the pressure in the dural venous 
sinuses and the ICP: in physiological circumstances the ICP is 1.6 times higher 
than the Psss (48, 56).  
Hydrocephalus 
Definition 
Hydrocephalus, the accumulation of CSF in the brain (Figure 12), has been 
recognized as a clinical entity since the days of Hippocrates. Surgical treatment 
strategies however were only developed after Walter Dandy almost single-
handed established the true pathology between 1913 and 1929 (58). At 
present, it continues to be one of the most common neurosurgical conditions, 
both in children and adults (59). The incidence of congenital hydrocephalus is 
0.82-1.1 per 1,000 live births (60-62). The overall incidence of acquired 
hydrocephalus is not well documented. Studies typically address certain types 
or specific causes. The incidence of hydrocephalus after community-acquired 
meningitis is around 5% (63), after severe head trauma 0.7% (64) and after 
subarachnoid hemorrhage around 20% (65). The incidence of normal pressure 
hydrocephalus (NPH) is 0.2%. It increases to 5.9% in the population aged 80 
years and older (66). Although hydrocephalus is common, there is still no 
generally recognized definition of the condition. We prefer the definition 
proposed by Rekate: "Hydrocephalus is an active distension of the ventricular 
system of the brain resulting from inadequate passage of CSF from its point of 
production within the cerebral ventricles to its point of absorption into the 
systemic circulation" (67). Note that this definition excludes passive 
enlargement of the ventricles due to cerebral atrophy or due to other causes 






ventricular dilatation, to the definition. If the obstruction of the CSF flow is 
distal, near (or in) the SSS, CSF will accumulate under pressure outside as well 
as inside the brain. In this situation, no pressure difference between the 
intraventricular and the peripheral subarachnoid space will develop and the 
ventricles will not enlarge at all or only slightly (68). 
 
Figure 12. Appearance of hydrocephalus on magnetic resonance imaging 
(MRI) 
T2 axial MRI images at the level of the interventricular foramen of Monro.  
Left: normal ventricles. 
Right: marked dilatation of the ventricles in a patient with hydrocephalus.  
Etiology  
Hydrocephalus may develop at any age due a variety of etiologies. The most 
frequent causes are subarachnoid or intraventricular hemorrhage (24%), 
myelomeningocele (21%) and brain tumors (9%). Less frequent causes are 






Hydrocephalus can be categorized according to where, along the CSF pathway, 
the obstruction occurs (Table 1) (67).  
Table 1. Classification of hydrocephalus, modified from (67) with permission 
Site of obstruction Pathology Treatment 
None Choroid plexus papilloma Removal 
Foramen of Monro Tumor, congenital anomaly, 
post shunt ventricular 
asymmetry 
Tumor removal, 
septostomy, VP or VA 
shunt 
Aqueduct of Sylvius Congenital lesion, tumor, 
secondary to extraventricular 
obstruction  
ETV, VP or VA shunt 
Outlets of fourth 
ventricle 
Chronic meningitis, Chiari II 
malformation 
ETV, VP or VA shunt 
Basal cisterns Meningitis, post subarachnoid 
hemorrhage 
ETV, VP or VA shunt 
Arachnoid 
granulations 
Hemorrhage or infection  VP or VA shunt  
Venous outflow Skull base anomalies, 
congenital heart disease 
VP or VA shunt, 
treatment of vascular 
anomaly if possible 
Signs and symptoms 
Hydrocephalus gives rise to various clinical syndromes depending on the age 
of the patient and on how fast the pathology develops (68).  
In the newborn, hydrocephalus is objectified by progressive ventricular 
enlargement observed by sequential transfontanellar ultrasound. If 






age of 3, it causes enlargement of the head. It can be objectified by a deviation 
of the head circumference from the growth curve (usually a deviation of 2 
standard deviations from the mean is being used as cutoff) and by tense 
anterior and posterior fontanels. The hydrocephalic infant is irritable, feeds 
poorly, and may vomit frequently. With continued CSF accumulation, lethargy 
develops and the infant appears faint, uninterested in its surroundings and 
unable to sustain activity. Later the "setting-sun sign" develops. This paralysis 
of upward gaze (Parinaud syndrome) is due to compression on the 
mesencephalic tegmentum. If still untreated, the condition may evolve to 
coma and death (68).  
In older patients, the skull is closed and the accumulation of CSF will directly 
increase the ICP. Depending on the residual absorption rate of CSF the 
condition may develop in an acute or indolent way (68). 
Clinical symptoms of acute hydrocephalus include headache, nausea, 
vomiting, and visual disturbance. If not treated it may progress rapidly to 
drowsiness, coma and death (68). 
When there is still some absorption capacity left, hydrocephalus may develop 
more insidiously and reach a stable state. At this point, CSF formation 
equilibrates with absorption and the ICP gradually drops to reach a mildly 
higher than normal level of 150 to 200 mm H2O. Although the hydrocephalus 
has been ‘compensated’, the patient nonetheless will develop symptoms. The 
name given to this condition by Adams, Fisher, and Hakim is normal pressure 
hydrocephalus (NPH) (69). NPH is manifested by a triad of clinical findings. A 
slowly progressive gait disorder is usually the earliest feature, followed by 







When the CSF flow is obstructed at the level of the third or fourth ventricle’s 
outflow, it can be treated by ETV (Figure 13).  
 
Figure 13. Endoscopic third ventriculostomy  
Hydrocephalus caused by obstructed CSF flow out of the third or fourth ventricle 
(obstructed aqueduct in this example) can be treated by endoscopic third 
ventriculostomy. During this procedure the floor of the third ventricle is perforated (red 
arrow). This allows CSF to flow from the third ventricle directly to the interpeduncular 
cistern, thus bypassing the aqueduct, fourth ventricle and apertures of Luschka or 
Magendie. Image reproduced with modifications from Version 8.25 from the Textbook 
OpenStax Anatomy and Physiology, published May 18, 2016 and protected by Creative 
Commons 4.0. 
During this endoscopic procedure a perforation is made in the thinned floor of 






system and into the interpeduncular cistern (43, 67). ETV will not help when 
the obstruction is located proximal to the third ventricle or distal to the 
outflow of the fourth ventricle. In those cases, CSF is typically drained to the 
peritoneal cavity by a VP shunt or to the right atrium of the heart by a VA 
shunt. These techniques are discussed in detail in Chapter 3 and Chapter 4. 
Reference values 
Table 2 summarizes some generally accepted reference values that are 
relevant for the remainder of this dissertation.  
Table 2. Relevant reference values 
Subject Value Reference 
CSF production = circulation = absorption 400-600 ml/day  (1) 
CSF volume  80-180ml (1) 
Resistance to outflow of CSF  12 mmHg/ml/min (70) 
ICP 5 – 15 mmHg (49) 
Amplitude of the ICP wave  3-4 mmHg (71) 
Compliance of the intracranial space 0,008 ml/Pa (51) 
SSS length 252 mm (44, 72) 
SSS transection 0 mm from origin (base, 
height)  0 mm, 0 mm (72, 73) 
SSS transection 37 mm from origin (base, 
height)  4 mm, 4mm (72, 73) 
SSS transection 234-252 mm from origin 
(base, height)  10 mm, 7mm (72, 73) 
Number of cortical veins draining in SSS 11 on each side (44, 46, 73) 
Psss 6 - 7.5 mmHg (74) 
SSS flow rate 150 – 450 ml/min  (72, 75)  
SSS flow velocity 150 mm/s (76) 
Mass density of blood 1103 kg/m3 (72) 
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In 1955 Scott, Wycis, Murtagh and Reyes described the VP shunt (Figure 1). 
This shunt consists of a silicone tube that is led from one of the lateral 
ventricles of the brain, out of the skull through a burr hole and then under the 
skin towards the peritoneal cavity (1).  
 
Figure 1. VP shunts 
A VP shunt connects one of the lateral ventricles of the brain with the peritoneal cavity. 
The shunt system consists of a proximal (ventricular) catheter [1], a one-way 
differential pressure valve [2] and a distal (peritoneal) catheter [3]. Left: schematic 







Until now, VP shunts remain the standard treatment for hydrocephalus (2). 
However, the percentage of shunt failure remains high. The overall 1- and 2-
year shunt survival rates for all age groups are 50–70% and 47–67 %, 
respectively (3-7).  
Factors that influence the shunt failure rate, include patient age and shunting 
technique (6). Comparison of the results of different clinical series is difficult 
because of the variation in terms of patient population, surgical technique and 
shunt hardware.  
Most studies that assess shunt survival focus on the pediatric population. 
Within this population, shunt failure is significantly higher in infants younger 
than 6 months of age. One study found a 45% shunt failure for such infants, 
versus a 37% shunt failure in the other age groups (6).  
Studies focusing on the adult population report lower shunt failure rates. In 
this population the rate of shunt failure is about 15 to 30% (8-11). 
NPH patients are a specific group that consists of mainly elderly patients. Not 
all patients who fulfill the criteria for NPH will benefit from a CSF shunt even 
if it is fully functioning. One should thus differentiate between shunt response 
and shunt survival. Shunt response is around 85% after 1 year and 75% after 6 
years (12), while shunt survival is around 80% (13). 
Shunt failure rates are particularly high in the first 6 months after 
implantation, followed by persistent but lower failure rates in the 2 years 
thereafter. The early (within 6 months) failures result from both shunt 






Shunt infection may be caused during surgery or be due to local or 
hematological spreading of another infection. The infection rate drops from 
8.6 % to 5.5 % when shunt catheters impregnated with antibiotics are used 
(16).  
Mechanical failure includes obstruction, disconnection and retraction of the 
shunt system. The latter two are especially caused by growth of the – young – 
patient (15).  
Obstruction may occur in any part of the shunt system (proximal catheter, 
valve, distal catheter) with aspiration of choroid plexus into the proximal 
catheter being the most common cause of shunt failure in general (15).  
Another, particularly important cause of shunt failure is siphoning (6, 14, 17, 
18). Because of its importance, siphoning is discussed in more detail below. 
Siphoning 
When a shunt patient is sitting or standing, the CSF column within the distal 
(peritoneal) catheter exerts suction through gravity (Figure 2) (19, 20), leading 
to shunt-related intracranial hypotension and aspiration of choroid plexus into 
the proximal catheter (6, 14, 17, 18). Intracranial hypotension causes 
headaches, nausea, vomiting and even subdural hematomas while aspiration 
of choroid plexus is a major cause of shunt obstruction (6, 14, 18).  
Chronic excessive drainage of CSF may also cause a slit-ventricle syndrome (6, 
14, 18, 21).  
‘Slit’ or collapsed ventricles are typically a manifestation of chronic 






this state increases the risk for ventricular shunt obstruction. The apposition 
of the ventricular catheter to the ventricular wall increases the chance of 
ingrowth of ependymal cells or choroid plexus (21).  
 
Figure 2. Siphoning of VP shunts 
Left: schematic drawing of a VP shunt. When the patient is sitting or standing, the 
highest point of the CSF compartment is situated above the tip of the peritoneal 
catheter. Right: when two buckets are filled with liquid and connected with a tube, the 
liquid will flow because of gravity, from the bucket with the higher fluid level into the 
bucket with the lower level until both levels are equal (20). h: height difference 
between fluid level at the proximal and distal end of the tube  
The adult slit-ventricle syndrome is an ill-defined disorder.  We prefer the 
definition of Rekate (22): “The slit-ventricle syndrome consists of the triad of 
intermittent headaches lasting 10–30 min, smaller than normal ventricles on 






about 5% of the non-NPH patients (23). Although relatively few in number, 
these patients represent a disproportionate amount of clinical effort 
expended, with frequent emergency department visits and requests for office 
visits (21). The syndrome occurs more commonly in patients who have been 
shunted for many years, either as an adult or in childhood. Additionally, it is 
suggested that a significant proportion of patients with adult slit-ventricle 
syndrome previously had unrecognized non-communicating hydrocephalus. 
Common symptoms of adult slit-ventricle syndrome include intermittent 
headaches that become more frequent and intense over time (21). The 
etiology of these intermittent headaches has been unclear but may be related 
to periods of insufficient CSF drainage. In addition, collapse of the ventricular 
system lowers intracranial compliance.  According to the law of Laplace, 
relatively high pressure is needed to expand the collapsed ventricles (like 
blowing a balloon, the first blows are the hardest). Thus, when the ventricular 
catheter is temporarily obstructed by the ventricular wall and/or choroid 
plexus of the collapsed ventricle, the pressure in the ventricle has to become 
quite high to dilate the ventricle and free the catheter. At shunt revision, the 
typical intraoperative finding is near-total, but not complete, obstruction of 
the ventricular catheter. Therefore, the slit-ventricle syndrome is actually an 
underdrainage syndrome created by a preceding period of overdrainage (21). 
Valves and medical devices that counteract siphoning 
Up to 70% of all shunt patients will develop symptoms of excessive CSF 
drainage when only a standard low resistance valve is used (17). This led to 
the development of various medical devices meant to counteract siphoning 






devices, siphon control devices and gravitational valves. Basically, all these 
devices can be classified in two groups: the differential pressure valves and 
the flow regulating valves (24). In clinical practice, programmable differential 
pressure valves are often used alone or in combination with a gravitational 
or flow regulating valve. 
Differential pressure valves 
The standard valves (Figure 3) operate as differential pressure devices 
allowing unidirectional flow (25). These devices only open when the pressure 
difference across the valve surpasses a certain threshold (‘opening pressure’). 
There are a number of different mechanisms, including slit valves, diaphragm 
valves, miter valves, and metallic spring ball valves (26). However, all of these 
valves will essentially produce the same pressure/flow curve (Figure). Once 
the valves open and as long as the differential pressure is present, they 
provide very little resistance to flow. Depending on the posture of the patient, 
siphoning will thus still occur (24).  
Originally, the standard valves were supplied as low-, medium-, and high-
pressure valves. At present neurosurgeons are in favor of using – expensive – 
programmable valves. These allow the surgeon to noninvasively adjust the 
opening pressure in accordance with clinical or radiological findings (18, 27-







Figure 3. Standard differential pressure valve 
Left: schematic image of a spring ball valve as an illustration of a standard differential 
pressure valve. The valve is either closed (upper image) or open (lower image). The 
thickness of the arrow relates to the magnitude of the intracranial pressure. Right: 
pressure flow characteristics. Once the valve is open (opening pressure in this image is 
100 mm H2O), the resistance to flow is very low and large flow rates are possible. When 
the patient assumes an upright position, the valve may open due to the siphoning 
effect and excessive drainage of CSF may occur.  
A gravitational valve (Figure 4) consists of a ball that in a vertical position – by 
gravity – rolls into a conical socket, thereby increasing the differential pressure 
over the valve. When the patient is in the horizontal position, the ball leaves 
the socket, resulting in a lower differential opening pressure. A drawback of 
gravitational valves is that these have to be implanted (and stay in this 
position) with their longitudinal axis exactly along the vertical axis of the 









Figure 4. Gravitational valve 
Left: flow characteristics of a shunt system containing a standard differential pressure 
valve with an opening pressure of 80 mm H2O and a gravitational valve (0 – 200 mm 
H2O). The flow is shown in function of the degrees of verticalization. When the ICP is 
low, the flow will only gradually increase when the patient verticalizes, however 
excessive drainage may still develop. When the ICP is high, the flow rate will decrease 
during the first 30 degrees of verticalization. This is due to a fast decrease in ICP 
following the rapid evacuation of CSF and an increase in the differential pressure of 
the valve due to gravity. Beyond 30 degrees of verticalization, the siphon effect 
becomes dominant and the flow rate increases again (30). Image reprinted with 
modifications from (30) with permission. Right: when the patient is supine the balls roll 
away from the socket, allowing for undisturbed CSF flow. In this position the 
differential pressure needed to initiate flow over the device is minimal (almost zero). 
When the patient verticalizes, the balls roll into the socket through gravity, 







Flow regulating valves 
Various flow regulating devices exist.  
The ‘anti-siphon devices’ or ‘siphon controlling devices’ consist of a flexible 
membrane that closes the CSF drainage pathway – due to the atmospheric 
pressure – when siphoning starts to occur (Figure 5) (31). The device reduces 
the tendency to excessive drainage in the upright position; however, the 
pressure required to maintain the same flow rate actually only slightly 
increases (Figure 5) (24). By consequence, the anti-siphon device acts 
functionally more like a gravitational valve than as a flow regulating valve. 
 
Figure 5. Anti-siphon device 
Left: an anti-siphon device containing a flexible membrane [M] overlying a socket [S] 
Middle: when the transmural pressure (pressure in the valve – atmospheric pressure) 
becomes negative, the membrane is pressed against a central socket, hampering the 
CSF flow. 
Right: pressure flow characteristics. When the membrane is pressed against the 
socket, the differential pressure necessary to cause a certain flow is only slightly higher 















A drawback of anti-siphon devices is that, to function properly, the diaphragm 
must be freely mobile and the pressure outside the membrane must be 
atmospheric (32). This may be hampered due to scar tissue around the valve.  
The position of the siphon controlling device along the distal column of fluid is 
also important (33). The lower the device is placed along the shunt path, 
relative to the ventricles, the greater the negative pressure that may still occur 
in the ventricles. If the device is placed at the level of the abdomen, the siphon 
control portion would never be active and the valve would function exactly as 
a differential pressure valve (24).  
The Sigma valve (Integra Plainsboro, New Jersey, United States) (Figure 6) has 
quite different flow/pressure characteristics from those of a standard valve 
(34). A flexible diaphragm moves along a piston of variable diameter, basically 
resulting in three pressure/flow stages. In Stage 1, the valve functions in the 
same way as a standard differential pressure diaphragm valve, with a certain 
opening pressure and a low resistance to flow. In Stage 2, as the differential 
pressure increases, the diaphragm descends along the piston, with a 
progressively larger diameter. This reduces the flow orifice and significantly 
increases the resistance to flow. Consequently, the flow rate will only slightly 
increase in response to increased differential pressure, which prevents 
siphoning. Stage 3 is a high-pressure `safety release mechanism’. When the 
ICP reaches a high level, of around 400 mm H2O, the diaphragm moves beyond 
the end of the piston, and the resistance to flow becomes very low. The 
transition between the above stages is gradual, so the pressure curve is 








Figure 6. Sigma valve 
When the patient is in horizontal position and the differential pressure is low, the 
resistance to flow is also low [stage 1]. When the patient verticalizes and the 
differential pressure increases, the membrane is pushed to a wider part of the central 
piston, increasing the resistance to flow [stage 2]. When the intracranial pressure 
becomes very high (e.g. Valsalva maneuver), the membrane will surpass the piston and 
the resistance to flow will substantially decrease [safety release, stage 3]. 
The Siphon Guard (DePuy Synthes, Raynham, Massachusetts, United States) 
(Figure 7) is a valve with a high and a low resistance pathway. When the flow 
increases beyond 0.7-1.8 ml/min, the low resistance pathway closes and the 
high resistance pathway opens. Although the latter pathway limits the flow 
rate, it still may increase beyond 20 ml/hour. As this is higher than the CSF 
production rate of most patients, intracranial hypotension may still occur (20).  
Switching from the high- back to the low resistance pathway occurs when the 
differential pressure decreases below a certain threshold (4 to 6 mmHg). A 






due to the high hydrodynamic resistance in the vertical position, the 
differential pressure may remain higher than 6 mmHg. Hence the device will 
not switch back to the low resistance state when the patient moves to a 
horizontal position. In that case, the device may cause underdrainage (35). 
 
 
Figure 7. Siphon Guard 
Right: when the patient is supine and the flow is low, the ball moves out of the socket, 
leaving the low resistance pathway open. When the patient verticalizes the ball moves 
into the socket due to the increased flow rate. In this position the low resistance 
pathway is closed, forcing the CSF to flow through the narrow channel which offers 
high resistance. 
Left: pressure flow curve. An increase in differential pressure is initially followed by an 
increased flow rate [1]. The increased flow rate moves the ball into the socket, thereby 
closing the low resistance pathway which causes the flow rate to drop. Further 
increase in differential pressure results in a more gradual increase in flow rate [2]. 
Clinical results  
The development of new valve designs has had only a limited effect on the 






The Sigma valve is the only device to have been reported to present a 1 year 
failure rate lower than that of standard valves (20 % versus 40 % in the first 
year) (37). The lower failure rate is due to the lower incidence of too small 
ventricles (24). Only 8.2 % of the patients with a Sigma valve developed slit-
ventricles, compared to 30.9 % of the patients with a standard valve (37). The 
larger ventricles may prevent plugging of the catheter holes due to coaptation 
of the ependyma and plexus with the ventricular catheter. However, these 
promising results from uncontrolled series were not confirmed by more recent 
data stemming from a randomized controlled trial. This trial showed no overall 
beneficial effect of any valve on overall shunt survival rates. Although the use 
of a Sigma valve resulted in fewer ventricular catheter obstructions, more 
mechanical failures occurred at other sites along the Sigma shunt, including 
the valve (3). 
Clinical series also show that, even with the use of (a combination of) the most 
advanced valves and anti-siphon devices, symptomatic overdrainage still 
occurs in 5-10% of all shunt patients (17, 38-40) . This group of patients is 
seriously incapacitated by symptoms of disturbed ICP and is typically 
subjected to a high number of shunt revisions (21).  
The high cost of programmable valves and anti-syphon devices, combined 
with the reported incidence of shunt failure, causes the economic impact of 
hydrocephalus treatments to be high (41). In the United States, surgical 
revisions of VP and VA shunts are a billion-dollar-a-year cost (41).  
In conclusion, further research to optimize hydrocephalus treatments is still 
needed, as physiological CSF dynamics are not restored in a satisfactory way 
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Chapter 4. Ventriculovenous shunts 
 
 
Ventriculovenous (VV) shunts draining CSF to the venous system may be an 
alternative to VP shunts. The most interesting techniques, VA and VS shunting, 
are discussed below. 
Ventriculoatrial shunts 
In 1952 Nulsen and Spitz described the VA shunt. At present, this shunt 
consists of a silicone tube that is led from one of the lateral ventricles of the 
brain, out of the skull through a burr hole and then under the skin toward the 
right auricle of the heart. An essential part of the shunt system is a one-way 
(Holter) valve (1).  
The technique has some advantages over VP shunts. First, verification of the 
correct placement of the distal catheter is possible intraoperatively (2). 
Second, the right atrium provides a consistent low pressure outlet: an 
advantage that gains progressively more importance, as obesity, that may 
cause high abdominal pressure which may result in dysfunction of VP shunts, 
becomes a global epidemic (2, 3). 
VA shunts have similar effectiveness and complication rates as VP shunts (2, 
4-6). However, the nature and severity of the complications are different (2). 
Several studies have reported that VA shunts suffer from thrombotic 
complications that include thrombus formation at the distal catheter as well 






shunt failure due to obstruction of the distal catheter (30-50 % of the revisions 
of VA shunts are due to distal catheter obstruction) but may also cause 
thromboembolic complications. Thromboembolic complications may occur 
early after shunt insertion (8). These complications manifest only seldom 
clinically (0,3 % of patients), whereas necropsy series suggest an incidence up 
to 60 % (9). However, it may also cause late complications that occur typically 
after 10-20 years (2, 8-10) . The most important late complication is pulmonary 
hypertension (8, 10). Although the process of micro-embolization appears to 
be intermittent and mild, patients with VA shunts often develop severe 
pulmonary hypertension, that, once diagnosed, is almost universally fatal (8-
10) . The seriousness of this complication has urged surgeons to routinely 
screen patients with a VA shunt for pulmonary hypertension with 
echocardiography and pulmonary function tests. If this screening is 
performed, pulmonary hypertension is found in 8% of the VA shunt patients 
(10). 
The high incidence of thrombotic complications in patients with VA shunts is 
not explained on the basis of a foreign body in the right atrium alone, as 
patients with for example pacemaker leads do not suffer from equivalent rates 
of thromboembolism (9). The factors that predispose VA shunts to thrombotic 
complications are not clear.  
Thrombotic complications are the main reasons that VA shunts have fallen in 
disuse in such a way that, at present, most neurosurgeons reserve VA shunts 
to patients in whom VP shunts are contra-indicated or not successful (11).  







The many frustrating complications of VA shunts and VP shunts, their 
incapacitating impact on the life of patients and their high financial cost urged 
neurosurgeons to search for a better, physiologically adapted treatment for 
hydrocephalus. Pioneers such as Gartner (cited in (12)) and Ingraham (13) 
were the first to drain CSF to its natural resorption site, the dural venous 
sinuses. However, they abolished the technique due to reflux of blood and 
obstruction of the distal catheter. Later, after the introduction of one-way 
valves and silicone catheters, new attempts to VS shunting were reported by 
Sharkey (14), Hash (15) and Wen (16). Finally, El-Shafei and his son were the 
ones to understand 1) the role of the collapsible IJV in preventing siphoning 
and 2) the advantages of introducing the sinus catheter against the blood flow 
(‘retrograde’) to prevent thrombotic shunt obstruction. Their extensive 
experimental work led to the development of the retrograde ventriculosinus 
(RVS) shunt (6, 17-21). This shunt was evaluated in several retrospective 
clinical series (22-24). Similar efforts were realized by Børgesen, Gjerris and 
Eklund leading to the development of the SinuShunt® (SinuShunt A/S, 
Glostrup, Denmark) (25-27). 
This chapter gives a comprehensive overview of the experimental and clinical 
work regarding VS shunting. The theoretical advantages and promising clinical 
results of the RVS shunt inspired us to conduct a monocentric prospective 
clinical trial at our department. The methodology and results of this trial are 








Draining CSF to the natural resorption site, the SSS, theoretically reduces the 
risk of shunt failure in several ways (19, 20). A first reason is that excessive 
drainage is prevented by preservation of the natural, self-regulating anti-
siphon effect of the IJV (19). Second, the shunt system is short, less complex 
and confined to the skull, which minimizes the risk of mechanical failure and 
infection. As the VS shunt is hardly affected by growth of the patient, it is 
especially suited for infants.  
Anti-siphon effect of the IJV 
When CSF is reabsorbed to the SSS, blood and drained CSF form a fluid column 
between the SSS and the right atrium of the heart. In a sitting or standing 
position, it could be expected that the difference in height between the 
proximal and distal end of this fluid column would cause siphoning and 
intracranial hypotension, in analogy to the previous discussed liquor shunts. 
However, in physiological conditions, siphoning is counteracted and the ICP is 
not permitted to drop excessively (19).  
El-Shafei was the first to identify that the IJV might act as a physiological anti-
siphon device (19). He based this hypothesis on previous literature on venous 
hydrodynamics (28). Veins have a soft, thin wall that is unable to withstand 
even small negative transmural pressures (transmural pressure is defined as 
the pressure inside the vessel minus the ambient pressure). The pressure in 
larger veins fluctuates around the atmospheric pressure and situations in 
which the transmural pressure becomes negative are not uncommon. In these 







Figure 1. In vitro set-up 
The IJV [1, dark blue] of a human cadaver was attached in the horizontal position to 
an iron bar [2]. Proximally the vein was connected to a flow meter [3] and a constant 
head tank [4], distally to a rigid tube [5]. Pressure transducers were connected 
upstream and downstream to the IJV [A and B respectively]. Also, the ambient 
atmospheric pressure was measured [C]. The height of the constant head tank was 
adjusted until the flow through the horizontally positioned IJV equalized 400 ml/min. 
The distal end of the tube was lowered as to adjust the downstream pressure to 1.5 
cm H2O. The IJV was then rotated in such a way that the proximal end remained fixed 
while the distal end progressively was lowered. Image reproduced with modifications 






To substantiate his hypothesis, El-Shafei performed an in-vitro experiment. 
The set-up is shown in Figure 1. A constant head tank assured a flow rate of 
400 ml/min through the horizontally positioned IJV of a human cadaver. 
The vein was then progressively verticalized by lowering the distal end while 
keeping the proximal end fixed. During this maneuver, the flow rate initially 
increased and the proximal pressure decreased. By consequence, the 
transmural pressure decreased and the transection of the vein, that was 
circular at the start, changed to oval and further to biconcave (Figure 2).  
Figure 2. Transection of the 
IJV in function of the 
transmural pressure 
The transection of the IJV is 
shown in function of the 
transmural pressure (mm H2O). 
As the pressure decreases the 
section becomes oval and finally 
biconcave. The collapsed vein 
segment exerts a high resistance 
to flow.  
Image reproduced with 
modifications from (19) with 
permission 
  
Collapse started at the proximal end and progressed downward as the rotation 





vessel increased causing the flow rate and the proximal pressure to stabilize 
from 40° rotation onwards. In this stable situation the flow rate was 400 
ml/min and the proximal pressure 2.1 cm H2O. Decreasing the downstream 
pressure did not affect the flow rate nor the proximal pressure (19).  
The results of this in vitro study endorse the hypothesis of El-Shafei that the 
IJV acts as a natural, self-regulating anti-siphon device. It counteracts gravity 
and regulates the pressure in the dural venous sinuses and consequently the 
ICP within narrow limits, regardless of the position of the patient (19). 
As the ventriculosinus shunt does not bypass the jugular vein, it – theoretically 
– restores a physiological ICP. In the absence of siphoning, the drainage of CSF 
is expected to be constant without moments of active suction (18). This 
prevents aspiration of the ventricular wall or choroid plexus into the proximal 
catheter and thus avoids the most frequent cause of proximal shunt 
obstruction (29).  
It also prevents the development of slit-ventricles and might be a (or the only) 
satisfying solution for the 5-10% of shunt patients who experience intracranial 
hypotension despite the usage of resistance valves and anti-siphon devices 
(30-33).  
Besides being simple and physiological, ventriculosinus shunting is also 
affordable. The superfluity of programmable valves and anti-siphon devices 
reduces the cost of the shunt system from around € 1700 - 2200 (e.g. 
programmable valve, with or without anti-siphon device, antibiotic 
impregnated silicone catheter system) to around € 900 (e.g. fixed pressure 
valve, same catheter system). Postoperatively, there is no need for 






around € 100 per patient (mean number of 1.5 adjustments per patient with 
a VP- or VA shunt (34), counting visits to an outpatient clinic (€ 25) and skull x-
rays (€ 45)). 
Surgical technique  
Based on experimental and clinical experience, the cited authors have 
modified the technique. This led to the two most important strategies that 
exist at present: the RVS shunt or El-Shafei shunt (23) and the commercially 
available SinuShunt (SinuShunt A/S, Glostrup, Denmark) (26).  
 
Figure 3. ‘Retrograde’ position of the shunt and definition of impact and 
wake side 
The tip of the shunt is directed against the blood flow or in a ‘retrograde’ fashion. The 
solid black arrows represent the direction of the blood flow in the vessel (SSS), whereas 
the white arrows represent the drainage of CSF. The impact and wake sides of the 
shunt are defined relative to the direction of the blood flow.  
The El-Shafei shunt is characterized by the retrograde - with the tip aimed 
against the blood flow – implantation of the sinus catheter (Figure 3). In this 
position the ICP is kept above the static pressure in the superior sagittal sinus 
(Psss) by the blood flow that ‘hits’ the draining CSF column. This is called the 





assures that the ICP remains higher than the Psss regardless of the patient’s 
position, thus preventing backflow of blood to the shunt at all times (20). The 
experimental work concerning the hydrodynamics of the RVS shunt is 
discussed in detail in chapter 6.  
The retrograde position is believed to have, besides the impact effect, two 
other advantages.  
First, stream lines of the blood flow will hit the shunt’s impact zone (facing the 
blood stream), deflect and move on. However, in the wake zone (the 180° 
opposite site, facing away from the incoming flow), some of the running fluid 
separates from the stream lines and stagnates. Stagnation of blood promotes 
clot formation (Figure 4) (24). Second, in the retrograde position, drained CSF 
is deflected to flow over the shunt’s surface, forming a constantly renewing 
CSF sleeve (Figure 5). According to El-Shafei, this sleeve discourages clot 
formation (20). 
Besides the retrograde implantation, El-Shafei stresses the importance of a 
strict watertight junction between the ventricle catheter and the dura mater. 
If CSF leaks through this connection, the ICP drops below the Psss and, when 
no valve is present, blood will regurgitate to the shunt and the ventricular 
system. In case a valve is present, leakage of CSF will cause the drainage to the 
SSS to become intermittent, which promotes distal shunt obstruction (6). 
When no watertight junction could be obtained, El-Shafei did not proceed with 
the RVS shunt implantation. This was the case in 8.5% (10/119) of his patients. 
An interesting modification of the technique to implant the sinus catheter was 









Figure 4. Hydrodynamic principles of flow past a cylindrical object 
Blood hitting an object placed in the bloodstream will deflect to wrap around the 
object. Downstream of the object, blood will detach from the surface. At this point it 
will be dragged towards the wake side which causes slow and non-laminar flow (upper 
image). If the shunt is positioned retrograde, streamlines of the blood flow will hit the 
shunt tip, deflect and move on (middle image). However, when the shunt is positioned 
anterograde, the tip is situated in the wake zone where the flow is slow and non-
laminar. Note that this schematic representation is generic. The actual shape of the 
streamlines is entirely dependent on the velocity of the flow. A realistic image, based 
on CFD (Computational Fluid Dynamics), is provided in Chapter 6 (Figure 7). 
The authors used the Seldinger technique to introduce the sinus catheter. The 





needle, advancing a guide wire through the needle into the SSS, removing the 
needle, dilating the opening in the sinus with appropriate dilatators, 
introducing the sinus catheter over the guidewire into the sinus and removing 
the guidewire. This technique theoretically decreases the risk of bleeding and 
air embolism (36).  
The SinuShunt (Figure 6) was developed by Børgesen (Denmark) (25, 26). The 
device contains a one-way valve with a built-in resistance tube and is designed 
to have a total resistance equal to the physiological resistance to CSF 
absorption (8 mmHg/ml/min) (26). The intravascular catheter is implanted in 
the direction of the blood flow (‘anterograde’) in the transverse sinus. 
Børgesen stresses the importance of a perfect central position of the shunt tip 
in the sinus. A groove, drilled at the posterior border of the burr hole, serves 
to guide the drain to the center of the sinus, and to keep it there after closure 
of the wound (26).  
 
 
Figure 5. CSF sleeve effect 
The white arrows represent the CSF ‘sleeve’. This sleeve is formed by CSF draining along 
the shunt surface due to the blood flow that is oriented in the opposite direction. The 







The ventriculosinus shunt has been evaluated in several clinical series (>150 
patients in total) (13, 15, 16, 23, 26, 37) . 
The technique has been proven to be safe and effective, both in pediatric and 
adult patients, to treat high- and normal pressure hydrocephalus (23, 26, 38, 
39). None of these patients developed venous sinus thrombosis, clinically 
significant air embolism, or excessive intra-operative sinus bleeding (23, 26, 
38). Postoperative shunt response was similar to the conventional shunts in 
terms of immediate improvement of acute hydrocephalus signs and 
symptoms (23, 26, 38).  
 
Figure 6. The SinuShunt 
The device consists of a titanium inlet cone for attaching the ventricular drain [1], a 
valve mechanism preventing back-flow from the transverse sinus to the shunt or the 
ventricles [2], a pre-chamber made of silicone rubber for puncture and testing of the 
performance of the shunt [3], a resistance tube made of titanium and dimensioned to 
create a resistance to outflow equal to normal values (8 mmHg/ml/min) [4], a housing 
for the valves and the resistance tube made of silicone rubber, and a silicone rubber 
drain, diameter 2.1 mm, leading into the transverse sinus [5] (26). Image reproduced 





In patients with closed craniums, the ventricle size diminished, but not to the 
same extent as seen following shunting with standard devices (26). In infants 
with open craniums, the head circumference continued to increase but at a 
slower rate than before surgery (23). 
The shunt survival rates during the follow up period of the most recent clinical 
series are listed in Table 3.  
Table 3. Methodology and shunt survival of the most recent clinical series 
evaluating the VS shunt. 
Retro., retrograde or against the direction of the blood flow; Orient., orientation; 
Antero., anterograde or in the direction of the blood flow; Cent., tip of the shunt 
stabilized in the center of the sinus by a guiding channel in the skull; TS, transverse 
sinus; N, number of patients; w, weeks; y, years; m, months; NS, not stated; Diagnosis, 
type or etiology of hydrocephalus; OC, open cranium; CC, closed cranium; HPH, high 
pressure hydrocephalus; T, tumor; SAH, subarachnoid hemorrhage; MMC, 
myelomeningocele; FU, follow up; d, days; Sh. Surv., shunt survival. 
Author Orient. Sinus N Age Diagnosis FU  Sh. Surv. 
El-Shafei Retro. SSS 11
9 
6 w – 48 y  OC 66*; 
CC 44* 
6 y 3 
m  
95 % 
Børgesen Antero. TS 17 NS NPH 19; 
HPH 3; T 7; 
SAH 11 
344 d 53 % 
Børgesen Antero. 
Cent. 
TS 28 145 d 90 % 
Oliveira Retro. SSS 5 3 m – 6 m MMC 1 y 80 % 
During surgery, El-Shafei measured the ICP before and after opening the VS 
shunt in 90 patients. The pressure decreased from 500 mmH2O to 120 mmH2O. 






but stabilized at 40 mmH2O. When the patient was brought in the recumbent 
position again, the pressure was restored to 120 mmH2O (6). 
Another study evaluated the ICP in 1 patient using a telemetric sensor (40). 
The ICP was recorded when the patient had a VA shunt and later after the VA 
shunt was converted to a VS shunt. The ICP curve during chance of posture 
from a supine position (0° rotation) to the sitting position (90° rotation) is 
shown in Figure 7 (40). 
 
Figure 7. ICP in relation to the position of the patient (supine to sitting). 
The ICP drops less abruptly and less pronounced after conversion of the VA shunt (VAS) 
to a VS shunt (VSS). Reproduced from (40), with permission. 
We felt inspired by the theoretical advantages and the promising early clinical 
results of the VS shunt. However, long-term clinical studies are scarce and the 
RVS shunt, nor the SinuShunt® are gaining terrain in the treatment of 
hydrocephalus. This urged us to perform a monocentric prospective clinical 
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trial (department of neurosurgery, Ghent University Hospital). The retrograde 
technique of El-Shafei was withheld as this was the best substantiated 
method, both clinically and experimentally. The methodology and results of 
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Abstract 
Since the 1950’s, hydrocephalus can be treated with CSF shunts, usually to the 
peritoneal cavity or to the right cardiac atrium. However, due to their 
siphoning effect, these shunts lead to non-physiological CSF drainage, with 
possible co-morbidity and high revision rates. More sophisticated shunt valve 
systems significantly increase costs and technical complexity and remain 
unsuccessful in a subgroup of patients. In an attempt to obtain physiological 
CSF shunting, many neurosurgical pioneers shunted towards the dural sinuses, 
taking advantage of the physiological anti-siphoning effect of the IJVs. Despite 
several promising reports, the ventriculosinus shunts did not yet become 
standard neurosurgical practice. In this mono-centric prospective clinical 
study, we implanted the retrograde ventriculosinus shunt, as advocated by El-
Shafei, in 10 patients. This article reports on our operation technique and long-
term outcome, including 4 extra patients in whom this shunt was implanted 
as a rescue, where all other options failed. Only in 3 patients, functionality of 
the retrograde ventriculosinus shunt was maintained with more than 6 years 
follow-up. We remain convinced that ventriculosinus shunting may be a safe 






shunts fail because present venous access devices are difficult to implant 
correctly and are too easily obstructed. After discussing possible causes of the 
frequent obstruction of present ventriculosinus shunts, a new dural venous 
access device is presented. An easy to implant and thrombogenic-resistant 
dural venous access device needs to be developed before ventriculosinus 
shunting can become general practice. 
Introduction 
In hydrocephalus (HC) the physiological evacuation of the CSF towards the 
dural venous sinuses is inhibited, either because of obstruction of its outflow 
from the cerebral ventricles towards the subarachnoid space ('obstructive' 
HC), or by limitation of its absorption at the level of the arachnoid villi into the 
blood stream of the dural venous sinuses ('communicating' HC) (1-5).  
The standard treatment of HC with ventriculoperitoneal or ventriculoatrial 
(VA) shunts has a failure rate of about 50% in the first two years after 
implantation (6-10). A major cause of shunt failure is over-drainage due to the 
siphoning effect of the CSF column in the vertically orientated catheter when 
a patient is in a sitting or standing position. By gravity, this CSF column creates 
aspiration like a piston falling in a cylinder. This siphoning leads to shunt-
related intracranial hypotension and aspiration of the choroid plexus into the 
ventricular catheter. Intracranial hypotension causes headaches, nausea, 
vomiting, malaise and may lead to slit-ventricle syndrome and even subdural 
haematoma. Aspiration of the choroid plexus is a main cause of shunt 
obstruction. In response, more sophisticated valves were developed, such as 
valves with programmable resistance, flow-regulating valves and anti-siphon 
devices. In spite of these, non-physiological CSF drainage and therefore non-





Moreover, these devices increase the financial cost, technical complexity and 
vulnerability of CSF shunts. 
A ventriculosinus shunt drains CSF to its natural absorption site, the superior 
sagittal sinus (SSS). Theoretically it reduces the risk of shunt failure in several 
ways (11, 12). First, excessive drainage is prevented by preservation of the 
natural, self-regulating anti-siphon effect of the IJV (11). Therefore, there is no 
need for sophisticated valves or anti-siphon devices. Second, the shunt system 
is short, less complex and confined to the skull, which minimizes the risk of 
mechanical failure and infection. Although a promising technique, early 
attempts were not successful due to thrombotic obstruction of the distal 
catheter positioned in the dural venous sinus (Gartner (13), Payr (14) and 
Dandy (1-3) at beginning of 20th century and Sharkey (15), Hash (16) and Wen 
(17) from 1960’s till 1980’s). I. El-Shafei claimed that implanting the distal 
catheter with the tip directed against the blood flow (‘retrograde’) solves the 
thrombotic obstruction issue. Subtle hydrodynamic related advantages would 
prevent regurgitation of blood in the distal catheter and preserve the delicate 
pressure gradient between the dural venous sinus and the ventricles (12). 
After extensive experimental and clinical work, El-Shafei evolved from the 
retrograde ventriculo-jugular to the RVS shunt and reported excellent results 
in retrospective clinical studies, up to a shunt survival rate of 95% after a mean 
follow up of over 6 years (18). In collaboration with the department of 
Hydraulics of Ghent University Civil Engineering, we implemented both a 
physical and numerical (computerized fluids dynamic) model of the RVS shunt 
(19). These models supported El-Shafei’s experimental work on the 
hydrodynamic principles of the RVS shunt. Similar efforts were realised by S.E. 






SinuShunt®, with an anterograde orientated dural venous sinus catheter (20-
23). 
Although inspired by the RVS shunt and the SinuShunt®, we wondered why, 
despite the potential advantages and the promising published clinical results, 
the RVS shunt nor the SinuShunt® are implanted on a regular base worldwide. 
We realized that many neurosurgeons are reluctant to operate on the dural 
sinus, due to the risk of major haemorrhage, air embolism (AE) or sagittal sinus 
thrombosis (SST). Interestingly, none of the published clinical reports 
mentions these complications. 
Therefore, we evaluated the RVS shunt in a mono-centric prospective clinical 
study for the treatment of communicating HC. This report summarizes the 
operation details and the follow-up of all 10 patients included in the study as 
well as of the 4 extra patients in whom the RVS shunt was used as a rescue 
operation. 
Materials and methods 
Inclusion/exclusion criteria 
Approval of Ghent University Hospital’s Ethical Committee was obtained to 
include 'communicating' HC patients during the year 2011 (using an extensive 
informed consent and a no-fault insurance). Every patient was eligible to be 
included, without restriction concerning age. Exclusion criteria included: 1) 
pregnancy, 2) infectious, cardiovascular, haemostatic or severe internal 
diseases. Inclusion was on voluntary basis. 
Surgical technique and materials 
Every included patient had a pre-operative computed tomography (CT) and/or 





neuronavigation (NN) was applied (Medtronic, StealthStation® Treon™ AxiEM, 
Minneapolis, MN, USA). Standard preoperative clinical and 
serological/clotting examinations were performed. 
Surgery was performed under general anaesthesia with tracheal intubation. 
The semi-sitting supine positioning was used, to retain the venous Psss slightly 
positive. After shaving, washing and disinfection of the surgical region, proper 
sterile draping of the operating field and Tegaderm® (3M, 2510 Conway Ave, 
St. Paul, MN, USA) on the scalp were applied to avoid cutaneous contact. 
Two semicircular scalp incisions and underlying burr holes were made: 1) a 
right or left parabregmatic and 2) a midline incision across the sagittal suture 
in the vertex region (about 10 cm posterior to bregma or about 3 cm anterior 
to lambda). In most patients, the superior sagittal sinus (SSS) diameter starts 
to widen posterior to bregma and reaches a large and useful diameter halfway 
between bregma and lambda, with 3-5 mm width and 6-8 mm height 
internally. Through the parabregmatic burr hole a ventricular catheter (VC; 
anti-block right angle VC, Phoenix / Vygon S.A., 5 Rue Adeline, 95440 Ecouen, 
France), was positioned in the frontal horn of the lateral ventricles. Specific 
care was taken to minimize CSF spilling: 
- The dura was perforated with a 2.0-2.5 mm wide round opening, applying 
monopolar coagulation on the VC’s stylet (without the VC); during 
introduction, the 3 mm diameter VC was stretched on its stylet, narrowing 
it; once its position in the frontal horn reached, the stretching was 
released and the catheter re-expanded to its original diameter, creating a 
‘watertight’ joint. If the closure seemed not watertight, a small amount of 






- The VC was kept blocked once positioned in a frontal horn of the 
ventricles. Any loss of CSF was compensated by intraventricular injection 
of an equivalent amount of physiological saline. 
 A unidirectional valve with 10 mm H2O resistance (Codman precision Hakim 
valve, J&J, 325 Paramount Drive, Raynham, MA 02767, USA) was flushed, 
connected with its proximal end to the VC and positioned between the two 
incisions in the subgaleal layer. At the bottom of the sagittal suture’s burr hole, 
the roof of the SSS was identified; if necessary the burr hole was widened 
laterally to have it in its centre. Then, a 3 mm wide and 1 cm long bevelled 
groove was punched out at the posterior border of the burr hole, in line with 
the trajectory of the SSS. This groove guided the catheter in the longitudinal 
direction of the SSS and prevented kinking. At the lateral border of this guiding 
groove, a 1 mm wide drill hole was made to apply a stabilising polyfilament 
polyester wire around the sagittal sinus catheter (SSC, Phoenix / Vygon atrial 
catheter ref A03, pliant tip of 3.0 cm length and 1.3 mm outer diameter). In 
neonates, infants and toddlers, the skull bone was too thin to create this 
groove and the SSC was stabilised with stitches through the periosteal layer. 
Once these steps taken, a longitudinal 4 mm slit incision was made in the roof 
of the SSS. With a venous hook, the slit incision was opened and lifted to 
introduce the tip of the SSC into the lumen of the sinus. If no resistance was 
felt, the pliant tip was fully introduced until the thicker catheter part (outer 
diameter of 2.5 mm) fitted into the slit incision of the sinus roof. If resistance 
was experienced (septa within the sinus (16, 24, 25)) the catheter was 
retracted and reintroduced. In case of persistent resistance, the burr hole was 
extended and the catheter introduced through a new slit incision in the sinus 
roof. Catheter patency was checked firstly by aspiration of blood and secondly 





gelatine sponge was applied on top of the catheter’s passage through the 
sinus roof to control possible bleeding. Repetitive flushing of the SSC with 
saline was performed to prevent blood regurgitation. After having replenished 
the ventricular volume with saline through the VC, SSC and valve were 
connected. Wounds were rinsed with 1/10 Isobetadine Dermicum®/water  
 solution and closed in separate layers. In all patients the SSC could be properly 
positioned with an SSS length of about 3 cm, in a retrograde direction. 
Postoperative follow up 
The postoperative follow up was based both on clinical and radiological 
examinations: 
- For children under the age of 2 years, the clinical examination included 
head circumference, frontal fontanel tension, eye movement 
examination, evaluation of factors of wellbeing (eating versus intake 
refusal or vomiting; active versus passive/apathetic behaviour; visual 
contact versus absence of visual contact; laughing versus irritability or 
crying). For older children and adults, complaints of headache, 
nausea/vomiting, malaise, fatigue were noted. Clinically the Glasgow 
coma scale, axial stability, visual functions/eye movements and 
orientation were observed. 
- Radiological examinations included XR to control integrity of shunt 
trajectory and CT scan or MRI scan to control position of VC and SSC, to 
prove patency of the SSS and to evaluate the ventricular dimensions and 
signs of transependymal CSF drainage. All patients had pre- and 
postoperative MRI and/or CT scan. Three patients with obstructed SSC 






iodine contrast injection through the obstructed SSC under fluoroscopy, 
to investigate the mechanism of its occlusion. 
Results 
Table 1: patients included in prospective group (1-10) and in rescue group 
(11-14) 
Age represents the age at the moment of the first RVS shunt operation [abbreviations 
used: patient (P), sex (S), female (F), male (M), (Hydrocephalus etiology (HC E), 
myelomeningocele (MMC), complications (C), neonatal sepsis (NNS), congenital (CON), 
chronic subdural hematoma (CSH), traumatic brain injury (TBI), tumor resection (TR), 
aneurysmal subarachnoid hemorrhage (ASAH), normal pressure hydrocephalus (NPH), 
tumor (T), Guidance (Guid) electromagnetic neuronavigation (EM NN), Doppler 
(Doppl), survival time (ST), retrograde ventriculosinus shunt (RVSS); 
ventriculoperitoneal shunt (VPS); ventriculoatrial shunt (VAS); obstruction (obstr), 
reoperation (R)] 
P S age HC E C Guid ST Failure R result 
1 F 6d MMC - - 21d / 85d SSC obstr Y VPS 
2 F 52d NNS - EM NN 46d SSC obstr N VPS 
3 M 84d CSH - Doppl. 6y+ - N RVSS 
4 F 293d CON - EM NN 6y+ - N RVSS 
5 M 16y TBI AE EM NN 21d SSC obstr N VAS 
6 M 36y TR - EM NN 100d SSC obstr N VPS 
7 F 55y ASAH - EM NN 7d / 7d SSC obstr Y VAS 
8 F 60y ASAH - EM NN 12d / 7d SSC obstr Y VPS 
9 M 63y ASAH - EM NN 4d SSC obstr N VPS 
10 M 86y NPH - - 112d SSC obstr N VPS 
11 F 3y MMC - - 12y+ - N RVSS 
12 F 15y T - - (68d) T growth N death 
13 F 16y TR - Doppl 14d SSC obstr N VAS 






In the prospective group, only 2 out of 10 patients benefited from a long 
lasting RVS shunt ST (Table 1). Both were young children and in both cases, 
the RVS shunt was successful without the need of reoperation (figure 1).  
 
Figure 1. profile skull X-ray of patient 4 at 5 months postop (A) and 4 years 11 months 
postop (B); black asterisk indicates the tip of the VC, white asterisk the shunt valve and 
black arrow the tip of the SSC 
In the RVS shunt failure group (in all cases because of an obstructed SSC), 3 
out of 8 patients underwent an operative revision of the obstructed SSC 
(Figure 2). None of the re-operated RVS shunts were lasting and all patients of 
the failure group were converted to a VP- or VA shunt. 
During surgery of a blocked SSC, visualisation of the catheter’s tip inside de 
SSS was technically impossible. Prior to removal of a blocked SSC, we 
remarked that pre-operative contrast injection demonstrated a sleeve around 
the catheter’s tip; limited amount of contrast fluid was leaking into the SSS, 
the rest oozed at the catheter’s SSS introduction point, from between the SSC 






one, or a combination of both. We considered it medico-ethically 
unacceptable to open the SSS roof widely or to introduce a Fogarty balloon 
catheter in order to remove the obstructed SSC together with its surrounding 
sleeve. Hence, the SSC was simply retracted out of the SSS and seemed – at 
close inspection – immaculate. In all 3 occasions of introduction of a new SSC 
through a slit incision at about 1 cm anterior to the former, the procedure 
remained uneventful. 
 
Figure 2 Kaplan-Meier graph, displaying the survival time (time to clinical proof of 
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In the rescue group, only in 1 out of 4 patients the RVS shunt remained 
undeniably functional. Perhaps one could include patient 12 in the successful 
group, as her HC control lasted until she died because of progressive malignant 
brainstem glioma. However, we considered a control period of 68 days to be 
too short to conclude. Patient 14 provided information concerning the 
physiological CSF drainage effect of the RVS shunt. 4 days before her RVS shunt 
surgery, she had an intraparenchymal ICP sensor implanted, being the bearer 
of a functional VA shunt with Integra OSV II valve but with ongoing intracranial 
hypotension in upright position. Her VA shunt was ligated 1 day before the 
RVS shunt surgery. Before ligation, her ICP ranged between 0 mm Hg in supine 
position to –15 mm Hg sitting or standing. After ligation, the ICP raised 
progressively up to 30 mm Hg. During the RVS shunt implant, the ICP dropped 
from 20 mm Hg to 11 mm Hg as the RVS shunt became functional. 2 days later, 
her ICP ranged from 0 mm Hg in supine position to –7 sitting or standing and 
the clinical signs of intracranial hypotension disappeared. It is to note that 
none of the patients received anti-thrombotic drugs, except for patient 10. 
This patient was on prophylactic warfarin because of cardiac atrial fibrillation. 
Discussion 
Despite being modest, this study provided answers to questions about 
technical feasibility, operative safety, physiological CSF drainage, and long-
term effectiveness of the RVS shunt. 
The implantation of the ventriculosinus shunt was technical feasible. A 
watertight closure of the dura around the ventricular catheter was obtained 
in all patients. The postoperative imaging confirmed that the sinus catheter 






to exactly locate the midline of the SSS through a standard burr hole. In some 
cases the burr hole needed to be extended; NN and US Doppler were helpful.  
In accordance with previous research (18, 22, 26), we consider the RVS shunt 
implantation a safe procedure. Only in 1 out of 17 procedures an onset of AE 
was noticed by an acute drop in the end tidal PCO2. Application of fibrin glue, 
combined with mild Trendelenburg table tilting, immediately solved the 
problem. In none of the patients an SST occurred, in the short nor in the long 
term follow up (Figure 2). All bleedings were controllable with gentle 
compression with some gelatine sponge and – if necessary – extra anti-
Trendelenburg tilt of the operation table. We encountered no wound healing 
problems, infections and operation related morbidity nor mortality. No shunt 
related problems other than obstruction of the SSC have occurred. In line with 
previous reports (18, 22, 26, 27), we found that the RVS shunt restored a 
physiological ICP, as was noted above concerning patient 14. In the 3 patients 
with already more than 6 years lasting patency of the RVS shunt, absence of 





hypertension was noted. In the infants, head circumference evolution 
stabilised on its percentile. 
 
Figure 3 axial (A) and sagittal (B) T1 with IV gadolinium cerebral MRI of patient 4, 1 
month postop; the open arrow indicates the tip of the SSC centrally in the SSS; the 
white arrow indicates the passage of the SSC through the roof of the SSS; the 
homogeneous contrast enhancement of the SSS excludes SST. 
However, rapid and frequent obstruction of the SSC proved to be a major issue 
leading to the interruption of the study after the inclusion of 10 patients. DSA 
examination of 3 patients with an obstructed shunt, revealed an impeding 







Figure 4 (A) instantaneous and (B) few seconds later contrast enhancement of SSC and 
SSS during venogram (iodine contrast injection through the SSC), 4 months postop; (C) 
T1 with IV gadolinium cerebral MRI 2 months after removal of SSC; the open white 
arrow indicates the tip of the SSC, the white star the SSS, the white arrow the passage 
of the SSC through the roof of the SSS, the black asterisk the transverse-sigmoid sinuses 
and the white triangle the burr hole above the SSS; note the homogeneous contrast 
enhancement of the sinuses. 
Although we were not able to harvest this sleeve for investigation, we suppose 
that it consisted of thrombus and/or of endothelial overgrowth.  
These results contradict the hypothesis of El-Shafei that implanting the SSC 
with its tip directed against the blood flow (‘retrograde’) solves the issue of 
thrombotic obstruction. According to El-Shafei, the beneficial effect of the 
retrograde position relies on two advantages. Firstly, the blood flow ‘hits’ the 
draining CSF column and stagnates at the shunt tip. According to Bernoulli’s 





pressure in the shunt rises by the amount of the dynamic Psss. In other words, 
the ICP is kept above the static Psss. This effect is called the ‘impact effect’ by 
El-Shafei (12, 19). This impact effect should preserve the delicate pressure 
gradient between the ventricles and the SSS, creating a continuous CSF 
outflow. Secondly, when the venous catheter is directed against the blood 
flow, CSF will be deflected and flow over the shunt surface. According to El-
Shafei, the resulting ‘CSF sleeve’ protects against clot formation (12) (Figure 
4). 
 
Figure 5 Drawing of retrograde orientated catheter in a vessel with laminar blood flow 
(big black arrows); the CSF continuously streaming out of the catheter (small black 
arrow) creates a molecular CSF layer on the outside surface of the catheter 
(transparent grey zone) and gets accumulated in the blood turbulences at the wake 
zone (WZ) of the intravascular part of the catheter (spirals); the pressure at the impact 
zone (IZ, PIZ) is the venous pressure (PV) augmented by the dynamic pressure of the 







The rapid and frequent obstruction in the failure group urged us to critically 
revise the hypothesis of El-Shafei. We identified two factors that may promote 
clot formation and shunt obstruction: 
- Decentralised position of the SSC tip – In the failure group, we noticed on 
the postoperative CT-scan imaging that the tip of the SSC was not 
“centrally” positioned in the SSS, but rather ‘laterally’, with its tip against 
the vessel’s wall (Figure 5). Despite our drilling of a guiding groove for the 
SSC, in accordance to the recommendations of Børgesen (1), this 
decentralised position of the SSC tip occurred in the majority of patients. 
We suspected that the lateral position of the SSC tip plays a major role in 
the frequent and rapid obstructions, as it has many disadvantages: 
o The velocity of the blood stream close to the wall of a blood vessel 
is very low. The velocity is at its maximum in the centre of the 
vessel. Therefore a tip against a vessel wall cannot benefit of the 
impact effect created by the retrograde orientation (19, 27). 
o In a blood vessel, the concentration of red blood cells is at its 
highest in the centre of the vessel and at its lowest at the border. 
The opposite is true as to the clot forming factors of blood, plasma 
and platelets, which are at their highest concentration against the 
vessel wall (28). 
o A device in contact with the endothelial wall, stimulates both the 






Possible causes of the lateral position: 
o As SSS septa might block the passage of the SSC, they might also 
deviate the catheter’s tip from its straight and central trajectory. 
o Both the RVS shunt and the SinuShunt® require a long distance 
SSC in the SSS. It is technically impossible to make sure that the 
tip of a long and flexible catheter is centrally positioned. 
 
Figure 6. (A) coronal and (B) sagittal iodine IV cerebral CT-scan of patient 8, 14 days 
after the first SSC implantation, just before the RVS shunt revision operation; the open 
white arrow indicates the tip of the SSC, the white triangle the subgaleal trajectory of 
the RVS shunt, the white arrow the passage of the SSC towards the SSS through the 
burr hole, the white asterisk the tip of the VC just passing through the foramen of 
Monro; note the eccentric position of the tip of the SSC against the sinus wall and the 
homogeneous contrast enhancement of the sinuses. 
- CSF inducing blood clotting – We suspected and proved in vitro, that CSF 
induces blood clotting (31). In clinical practice, this can be observed by the 
rapid formation of membranes around the CSF collection of a CSF leak, 






concentration of about 5-9% to have a thrombogenic effect. Physiological 
concentrations of CSF in the SSS are far below 5%, as CSF inflow is 
approximately 0.35 ml/min for a blood flow of more than 200 ml/min (18, 
22, 32). However, in specific circumstances the coagulation enhancing 
effect of CSF could be problematic. Typical situations are contact between 
CSF and foreign material (molecular layer of continuous CSF outflow 
around tip of SSC) and accumulation of CSF in ‘wake’ zones (in blood 
turbulences at the wake zone of the SSC). Consequently the ‘protective’ 
CSF sleeve around the tip of the SSC might have turned out to be 
thrombogenic. 
To address the issues mentioned above, we proposed a novel ‘dural venous 
sinus access device’ (DVSAD – Figure 6), designed to secure the catheter’s tip 




Figure 7. Drawing of the DVSAD with its intravascular tip (1), epidural base plate (2) 
and connecting catheter (3), inside the SSS (4) and compared with the standard SSC 





The device consists of a short intravascular tip with adaptable length, to 
determine the tip’s depth in the SSS centre. Its perpendicular introduction 
makes it easier to implant and reduces significantly the intravascular volume 
and surface. The stabilizing epidural base plate secures its position. The 
proximal extravascular catheter allows connection with the shunt’s valve. The 
distal opening of the intravascular catheter is oriented neutrally, 
perpendicular to the direction of the blood flow. In this position, CSF will 
immediately be carried away by the blood flow maintaining the contact 
surface between CSF and the intravascular tip minimal. Also, in the neutral 
position, the shunt tip will be minimally subjected to unfavourable flow 
conditions. 
The potential benefits of this novel DVSAD in the surgical-technical domain 
and for the prevention of thrombosis is currently being evaluated by in vitro 
and in vivo animal models. In case of positive results we will proceed with a 
human prospective clinical study.  
Conclusion 
The prospective clinical trial with the RVS shunt as described by El-Shafei was 
interrupted because of high failure rate due to blockage of the SSC. 
Nevertheless, operative feasibility and safety were proven, as was 
physiological drainage of CSF. Our goal to create a long-lasting and easily 
implantable RVS shunt remains. Therefore, the data obtained here formed the 
basis for a subsequent research project aiming at developing a new DVSAD, 
easily implantable and with its tip stabilized in the centre of the SSS, to be 
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Chapter 5. Factors that predispose to thrombotic 
complications 




After the - unexplained - disappointing results of the clinical study with the 
retrograde VS shunt we decided to take a step back and to evaluate the VS 
shunt in a suitable animal model.  
A large animal model is more suitable than the previously described canine 
models because the dimensions of the larger brain ventricles and SSS allow 
the usage of shunt systems that are comparable in size and design to their 
counterparts for human applications (1).  
We searched the anatomical literature and performed dissections on animal 
cadaver heads to identify a proper animal model. Dogs, pigs and cattle were 
excluded due to far backwards extending frontal sinuses that may impede 
frontal ventricular access. Remaining possible models were sheep, goats and 
horses or ponies.  
The SSS in goats has a triangular cross section. The base and height measure 
around 3 mm (Figure 1). In horses/ponies the SSS is significantly larger. The 
base of the triangular section, assessed 1 cm cranially of the confluens, 






dimensions correspond to those of the human SSS. Also, the dimensions and 
morphology of the lateral ventricles resemble these of humans.  
 
Figure 1. Dimensions of the caprine (upper) and equine (lower) SSS 
We concluded that horses or ponies are anatomically best suited to evaluate 
the ventriculosinus shunt. However, we anticipated some practical and safety 





vulnerable during general anesthesia than other species (2). This results in a 
higher morbidity and mortality but also limits the duration of the anesthesia, 
to be considered as a major drawback in a research setting. Also, the large 
dimensions of horses are an issue for several reasons. First, obtaining brain 
imaging would be cumbersome. Second, animals may become aggressive 
when anxious or in pain (2). In such situations, horses may impose a risk to 
themselves and their care givers. 
Based on these practical and safety issues we finally decided to use goats 
(Saanen breed), which are friendly and easy to manage.  
Manuscript 2 presents a non-hydrocephalic goat model that was developed to 
clarify factors that may predispose VV shunts to thrombotic complications. It 
may also be used to evaluate whether a new technique is feasible, safe and 
well tolerated. As explained in the manuscript, the induction of hydrocephalus 
is not required for the evaluation of these factors. The manuscript describes 
the anatomy and coagulation properties of the caprine model as well as the 
surgical technique and the results of the implantation of an El-Shafei shunt in 
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Abstract 
The ventriculosinus shunt is a promising treatment for hydrocephalus. 
Currently, different shunt techniques exist, and it is not clear whether one is 
preferable. This pilot study reports on a non-hydrocephalic goat model 
(Saanen breed) that provides opportunities to evaluate and optimize several 
aspects of the ventriculosinus shunt technique. Analysis of the coagulation 
properties of 14 goats by a viscoelastic coagulation monitor showed that goats 
have a hypercoagulable state compared to humans. This property can be 
partially counteracted by antiplatelet drugs. During implantation of a 
ventriculosinus shunt, a pulsatile reflux of blood was observed. After 
implantation, the animals recovered to their preoperative state, and none of 
them developed a superior sagittal sinus thrombosis. Evaluation of the shunts 
after 16 days showed an obstructing luminal clot. Several model-related 
factors may have promoted this obstruction: the absence of hydrocephalus, 
the hypercoagulability of caprine blood and the smaller dimensions of the 
caprine superior sagittal sinus. However, the pulsatile reflux of blood, which is 






been an important factor as well. In conclusion, the non-hydrocephalic goat 
model limits animal suffering and simplifies the study protocol. This model 
allows researchers to evaluate their implantation technique and shunt 
hardware but not the efficacy of the treatment or shunt survival.  
Introduction 
Hydrocephalus, or the accumulation of CSF in the brain, is treated with 
ventriculo-peritoneal or ventriculo-atrial shunts. An important drawback of 
these techniques is siphoning, in which the CSF column within the catheter 
exerts suction through gravity when the patient is in a sitting or standing 
position. This effect leads to shunt-related intracranial hypotension and 
aspiration of the choroid plexus into the proximal catheter (1). Intracranial 
hypotension causes headaches, nausea, vomiting and even subdural 
haematomas, while aspiration of the choroid plexus is a major cause of shunt 
obstruction (2). Despite the usage of expensive resistance valves and anti-
siphon devices, the rate of shunt failure—which requires surgical revision—
remains as high as 50% in the first 2 years (3).  
A more physiological, but still experimental, technique is the ventriculosinus 
shunt. This shunt drains CSF (CSF) to a natural resorption site, such as the 
superior sagittal sinus, and theoretically reduces the risk of shunt failure in 
several ways (4, 5). First, excessive drainage of CSF is prevented by the natural, 
self-regulating anti-siphon effect of the IJV. Second, the shunt system is 
shorter, less complex and confined to the skull, which minimizes the risk of 
mechanical failure and infection (6).  
The efficacy of the ventriculosinus shunt was evaluated in a few clinical studies 





several issues and uncertainties persist (11). First, authors do not agree on 
whether the tip of the shunt should be directed towards or against the 
direction of the blood flow (11). Second, problems with the implantation of 
the shunt system exceed 10% in most of the available studies (9, 11). A 
technical advance using the Seldinger technique was published, but this 
method was evaluated in only 1 patient (12). Third, when the shunt system is 
correctly implanted, obstruction of the intravascular catheter remains an issue 
(7, 9, 10). Based on their experience, different authors have proposed several 
prototypes of the ventriculosinus shunt with distinct features (13-15). It is not 
clear which of these shunt systems would be preferable (11).  
To optimize the implantation technique and to evaluate the different 
prototypes of the ventriculosinus shunt, an animal model would be an 
indispensable tool (16).  
The only model described to date to evaluate a ventriculosinus shunt is a 
hydrocephalic dog model that used only two animals, and has substantial 
shortcomings: the induction of hydrocephalus was not well-tolerated, and the 
implantation of the ventriculosinus shunt resulted in a thrombosis of the 
superior sagittal sinus (16). The only way to prevent venous congestion and 
sinus thrombosis in a canine model is an extended miniaturization of the 
intravascular catheter to fit the small size of the superior sagittal sinus (16). To 
facilitate the use of shunt systems that are similar in size and design to their 
human counterparts, a large animal model must be created (17). A 
hydrocephalic sheep model to evaluate ventriculoperitoneal shunts has been 






The purpose of this pilot study is to assess the suitability and feasibility of a 
goat model (specifically 'Saanen breed' goats, which are very similar to sheep) 
for evaluating the implantation technique and design of the ventriculosinus 
shunt. Since hydrocephalus is not required for addressing the research 
question, a non-hydrocephalic model was chosen. 
The study consists of a cadaver anatomical study, an in vitro coagulation assay 
(Sonoclot Analyzer ©) and an in vivo study. The cadaver anatomical study 
describes the relevant surgical anatomy of the caprine brain ventricles and 
superior sagittal sinus. The in vitro coagulation assay analyses the coagulability 
of the caprine blood. The in vivo study assesses the feasibility of the in vivo 
implantation of a ventriculosinus shunt. 
Materials and methods 
Animals 
The species was selected based on anatomical characteristics. In pigs and 
cattle, frontal access to the ventricles and superior sagittal sinus may be 
impeded by the pronounced caudal extension of the frontal sinuses. The 
remaining possible models included sheep, goats and horses or ponies. 
Ultimately, domestic dairy goats (Saanen breed) were chosen because of their 
manageability and short hair. All goats were purchased from dairy goat farms. 
The goats were 1 to 2 years old and weighed less than 65 kg. Only female goats 
were included because the more pronounced cornual processes of bucks 
could impede frontal ventricular access. 
Since the investigation was a pilot study, small sample sizes were chosen. The 
study consisted of a cadaver study (9 goats), an in vitro coagulation assay (14 





vitro coagulation assay were also used for the in vivo study; thus, 23 goats 
were used in total. The studies were conducted serially, and the goats were 
allocated to the experiments in order of acquirement.  
All experiments in this study were approved by the Ethics Committee of the 
Faculty of Veterinary Medicine of Ghent University (EC2012/187, EC2013/66, 
EC2013/129). The care and use of animals were in full compliance with the 
most recent national legislation (Belgian Royal Decree of 29 May 2013) (18) 
and the relevant European Directive (2010/63/EU) (19). 
For the cadaver anatomical study, the goats were euthanized directly after 
arrival at the research facility. The remaining goats were admitted to the 
animal facility at least 10 days prior to the start of the study for acclimatization 
and health checks (including clinical investigation, ultrasonographic 
examination of the abdomen and thorax, and blood and faeces analyses). The 
animals were housed in small groups (3-4 animals per cage). The cages 
measured 3 x 4 m. The bedding consisted of straw, and cage enrichment (an 
elevated platform) was provided in all cages. Natural light was provided by 
translucent windows, and the cage temperature was maintained between 15 
and 20 °C. The animals were fed hay and water ad libitum and supplemented 
with 450 g of nutritional pellets daily.  
Clinical evaluation of the animals was performed twice daily using a clinical 
scoring system. This scoring system was developed by the authors in 
cooperation with the Department of Internal Medicine of the Faculty of 
Veterinary Medicine of Ghent University. The score consists of objective (e.g., 
vital parameters, weight, and food intake) and subjective (e.g., general 






(20, 21). A perfectly healthy animal without signs of distress will score 0, while 
a very ill animal with signs of unbearable suffering will score 21. A total score 
of 6, or a maximum score for one of the parameters, was the threshold for 
therapeutic action to alleviate suffering.  
All animals fasted for 24 h before surgery and received an intramuscular 
injection of 2.5 mg trimethoprim and 12.5 mg sulfadiazine/kg body weight 
(Borgal® 24%, Virbac, Barneveld, The Netherlands) starting one day prior to 
surgery and daily until 4 days after surgery. If needed, postoperative pain and 
fever were treated with 48 mg meloxicam subcutaneously (Metacam, 
Boehringer Ingelheim, Germany).  
Euthanasia was performed by intravenous administration of 50 mg/kg sodium 
pentobarbital (20%) (Pentobarbital, Kela, Hoogstraten, Belgium) after 
intravenous premedication with 0.3 mg/kg midazolam (Dormicum, Roche 
Pharma, Brussels, Belgium) and 0.1 mg/kg morphine (Morphine HCL Sterop, 
Brussels, Belgium). The anaesthesia was intravenous propofol 2-4 mg/kg 
(Propovet, Parsippany-Troy Hills, New Jersey, United States).  
Cadaver anatomical study 
After euthanasia, the goats were frozen at –20 °C and decapitated. The heads 
were sawed in coronal slices of approximately 1 cm thickness. The superior 
sagittal sinus was inspected for septa or trabeculae and measured at the 
confluens sinuum and 1 cm rostral to the confluence. The rostral horns of the 
lateral ventricles were measured at the level of the coronal suture. A point on 
the coronal suture was determined where a catheter, which is inserted 





ventricle. The length of the intraventricular trajectory of a shunt placed in that 
manner was measured.  
In vitro coagulation assay  
The goats were anaesthetized on the morning of the operation in the 
operation theatre. Eight animals received 75 mg clopidogrel (Plavix, Sanofi, 
Machelen, Belgium) and 80 mg acetylsalicylic acid (Asaflow, Takeda, Sint-Jans-
Molenbeek, Belgium) perorally starting the day before the procedure. Six 
goats did not receive any antiplatelet drugs. Three millilitres of CSF and 15 ml 
of venous blood (citrated with 0.129 mole Na3-Citrate/l, Terumo, Heverlee, 
Belgium) were obtained by a sub-occipital puncture and a venipuncture, 
respectively. The samples were stored at room temperature and processed 
within 60 min. Because tissue factor is a potent activator of the extrinsic 
coagulation pathway, the first 1 ml of CSF and 3 ml of blood were not used for 
analysis. 
To assess the impact of CSF on coagulation, different concentrations of CSF 
were added to the blood samples (0 µl CSF/ml blood and 100 µl CSF/ml blood). 
Subsequently, the mixture was recalcified with 40 µl of 0.25 mol/l CaCl2 and 
analysed by a Sonoclot Coagulation Analyzer © (Sienco, Arvada, CO, USA). 
The Sonoclot Analyzer © is an in vitro method for the analysis of the 
coagulation process from the start of fibrin formation through polymerization 
of the fibrin monomer and platelet interaction and eventually to clot 
retraction and lysis. The system consists of an open-ended plastic probe, 
which vibrates vertically while immersed in a cuvette containing a 0.33-ml 
sample of whole blood, and the probe measures changes in the viscoelastic 






reflects the changes in viscoelasticity from a liquid to a solid state (22). Three 
parameters are defined: the activated clotting time (ACT), clot rate (CR) and 
platelet function (PF). The ACT is an expression of how long the sample 
remains completely in the liquid phase and corresponds to the time necessary 
for fibrinogen to be converted to fibrin monomers. The CR is the slope of the 
second peak/plateau of the curve, which corresponds to the polymerization 
of fibrin monomers; a faster fibrin polymerization will be reflected by a 
steeper slope. The PF represents the attachment of platelets to fibrin and the 
retraction of the clot (22). 
Statistical analysis was performed using SPSS Statistics® 22 (IBM Corp., 
Released 2013, IBM SPSS Statistics for Windows, Version 22.0, Armonk, New 
York, USA). 
The distribution of the Sonoclot parameters was evaluated using QQ-plots and 
a Shapiro–Wilk test  
To evaluate the effect of CSF on blood coagulation, the goats were considered 
one group independent of antiplatelet drug administration. Each of the 
Sonoclot parameters of pure blood was compared to the blood-CSF mixture 
using a paired-sample T test. 
The effects of antiplatelet drug administration on the Sonoclot parameters 
were evaluated by comparing the Sonoclot parameters of the goats that 
received antiplatelet drugs with the parameters of the goats that did not 
receive antiplatelet drugs. An independent sample T test was used.  






In vivo study 
Shunt implantation. A ventriculosinus shunt was implanted in 3 goats under 
general anaesthesia. The procedure started in the morning and was 
performed in the operation theatre. The animals received 75 mg clopidogrel 
(Plavix, Sanofi, Machelen, Belgium), 80 mg acetylsalicylic acid (Asaflow, 
Takeda, Sint-Jans-Molenbeek, Belgium) and 40 mg pantoprazole (Pantomed, 
Takeda, Sint-Jans-Molenbeek, Belgium) perorally starting 24 h before surgery 
until the end of the study.  
 
 
Figure 1. Positioning and incision 
Left: the goats were positioned prone with the head slightly elevated and fixated in a 
custom-built head 
clamp. Right: a linear incision was made, starting 2 cm rostral to the coronal suture 
and ending 2 cm caudal to the lambdoidal suture. The foramen magnum and the arch 
of the atlas were also marked as these are the anatomical references for a suboccipital 
puncture. 







A surgical plan was made based on a contrast-enhanced brain CT scan the day 
before surgery. As shown in Figure 1, the head of the animal was secured in a 
custom-built frame. Under sterile surgical conditions, a 10 cm midline skin 
incision was made that reached from 2 cm rostral to the coronal suture to 2 
cm caudal to the lambdoidal suture.  
A hole was drilled approximately 18 mm to the right of the midline on the 
coronal suture, and another hole was drilled on the midline just rostral to the 
lambdoidal suture. To introduce the ventricular catheter, an aiming device 
was used, which was similar to a device described in the literature (23). 
This device was placed over the burr hole parallel to the sagittal plane and 
perpendicularly to the surface of the skull in the coronal plane. In the sagittal 
plane, the appropriate angle was set, and the ventricular catheter (Codman 
Hakim Ventricular Catheter, inner diameter (ID) 1.4 mm and outer diameter 
(OD) 2.7 mm) was inserted into the rostral horn of the right lateral ventricle. 
The correct position was confirmed by the outflow of CSF. The catheter was 
connected to a Codman Hakim very low pressure valve® (Depuy Synthes - 
Codman Neuro, Raynham, Massachusetts) and obstructed by a clamp. 
The superior sagittal sinus was then identified. The roof of the sinus was 
punctured with an 18 G needle and/or incised with a surgical blade (n° 11). A 
peritoneal catheter (Codman Hakim Peritoneal Catheter, ID 1 mm and OD 2.2 
mm) was introduced over a length of 3 cm in the superior sagittal sinus against 
the direction of the blood flow. 
The correct position of the sinus shunt was confirmed both by injection of a 
0.9% sodium chloride solution and by aspiration of blood. The intravascular 
catheter was then connected to the valve after flushing the catheter with a 





catheter, and the system was inspected for drainage of CSF to the sinus or 
reflux of blood to the catheter system.  
In one goat, a spinal epidural catheter (Portex, Smiths-Medical, Hythe, United 
Kingdom, ID 0.55 mm and OD 1.03 mm), which was obliterated at its proximal 
end, was inserted in the superior sagittal sinus before implantation of the final 
catheter. After being inspected for blood reflux, the spinal epidural catheter 
was replaced by the final Codman Hakim peritoneal catheter.  
Postoperative evaluation. Postoperatively, head computed tomography was 
acquired to verify the correct position of the shunt components and the 
patency of the superior sagittal sinus. The animals were evaluated daily until 
two weeks after the implantation. This follow-up period was chosen because 
full recovery or major complications, such as a superior sagittal sinus 
thrombosis or infection, are expected to manifest within this period. For 
clinical evaluation, the scoring system described above was used.  
At the end of the follow-up period, the animals were anaesthetized, and the 
patency of the ventricular and intravascular catheters was assessed using 
water columns. At the end of this procedure, the animals were euthanized, 
and the superior sagittal sinus containing the intravascular catheter was 
explanted with the catheter left in place. The lateral wall of the superior 
sagittal sinus was opened to visualize the intravascular catheter. The correct 
position was verified, and the presence of clots was evaluated using a 
stereomicroscope. Subsequently, the catheters were removed along with the 
surrounding sinus wall, and the catheters were transversely cut in two equal 
parts and fixed in a HEPES buffer containing 2.5% glutaraldehyde solution 






with a 0.9% sodium chloride solution, air-dried, mounted on aluminium pin 
mounts and sputtered with platinum particles.  
The samples were then observed with a JEOL JSM-5600 LV scanning electron 
microscope (SEM) with the lumen facing the camera and evaluated at 
different magnifications.  
Results 
Cadaver anatomical study 
The mean weight of the animals was 45.3 kg (range 40-62 kg). 
Table 1 shows the dimensions of the superior sagittal sinus and the lateral 
ventricles.  
Table 1. 
Dimensions (mean values and 95% confidence intervals) of the superior sagittal sinus 
(SSS) and lateral ventricles. The dimensions of the superior sagittal sinus are expressed 
as latero-lateral x dorso-ventral distances. The dimensions of the ventricles are 
measured at the level of the coronal suture. 
 
Variable Dimension (mm) 
SSS at confluence of sinuses 5.5 (4.0-7.0) x 6.0 (4.7-6.8) 
SSS 10 mm rostral to confluence of 
sinuses 
2.8 (2.3-3.3) x 3.3 (2.6-4) 
Ventricle height  3.5 (2.6-4.4) 
Bifrontal ventricular diameter  16.6 (14.4-18.9) 
Intraventricular shunt trajectory  5.8 (4.6-7.0) 
Centre of burr hole to midline  12.0 (11.0-13.0) 






The confluence had variable dimensions. The mean latero-lateral diameter 
was 5.5 mm, and the dorso-ventral diameter was 6 mm. As seen in Figure 2A, 
the confluence frequently contains septa and trabeculae.  
Ten millimetres rostral to the confluence, the cross section of the superior 
sagittal sinus has a triangular shape (Figure 2B). The mean latero-lateral 
diameter (base) was 2.8 mm, and the dorso-ventral diameter (height) was 3.3 
mm on average. A septum was observed in only a few goats. 
The mean height of the lateral ventricles at the level of the coronal suture was 
3.5 mm. The mean bifrontal diameter at the same slice was 16.6 mm.  
A burr hole at the coronal suture should be placed 12.0 mm lateral to the 
midline to ensure that a catheter inserted perpendicularly to the tabula 
externa of the skull will enter the rostral horn of the ipsilateral ventricle. 
Following this trajectory, the distance between the internal tabula of the skull 
and the dorsal ependyma of the rostral horn was 18.9 mm, and the 








Figure 2. Anatomy of the caprine superior sagittal sinus and lateral 
ventricles. 
Figure 2a: septa in the confluence of sinuses. Figure 2b: cross section of the superior 
sagittal sinus 1 cm 
rostral of the confluence of sinuses in the same animal. 
Figure 2c: a catheter, inserted 12 mm lateral to the midline perpendicular to the tabula 
externa of the skull, will enter the ipsilateral rostral horn of the lateral ventricle. Figure 
2d: the tip of the ventricle catheter is inserted in the rostral horn of the right lateral 
ventricle (arrow). 
In vitro coagulation assay  
A normal distribution was assumed because the Shapiro–Wilk test was not 





addition of CSF to pure blood and the oral administration of antiplatelet drugs 
on the ACT, CR and PF are shown in Table 2. 
Table 2. Coagulation properties of goat blood. 
The influence of in vitro addition of CSF to pure blood and oral administration of 
antiplatelet drugs on the ACT, CR and PF are shown (mean value and 95% confidence 
interval). 
 
Variable ACT CR PF 
CSF 
0 µl CSF/ ml blood 130.4 (113.2-
147.7) 
53.9 (44.7-63.1) 3.3 (2.7-3.8) 




65.5 (56.0-74.9) 3.3 (2.8-3.9) 




108.8 (88.2-129.3) 66.4 (54.3-78.6) 3.5 (2.4-4.7) 
ASA + clopidogrel 146.7 (124.9-
168.4) 
44.5 (34.7-54.4) 3.0 (2.2-3.9) 
P-value 0.009 0.005 0.405 
 
After the addition of 100 µl of CSF per millilitre of blood, the ACT shortened 
from 130 seconds to 114 seconds, and the CR increased from 54 units/min to 






After oral administration of antiplatelet drugs, the ACT increased from 109 
seconds to 147 seconds, and the CR decreased from 66 units/min to 45 
units/min. There was no significant impact on the PF.  
In vivo study 
Shunt implantation. No specific obstacles were encountered during 
implantation of the shunt. When the transparent part of the Codman Hakim 
low pressure valve was inspected, spontaneous drainage of CSF to the 
superior sagittal sinus was observed directly after implantation of the shunt. 
Through the wall of the distal segment of the silicone catheter, a pulsatile 
reflux of blood to the shunt system was observed. This reflux disappeared 
after obliterating the catheter 1 cm proximally to its entrance in the superior 
sagittal sinus. No reflux was observed after introduction of a more rigid 
catheter with a smaller inner diameter.  
Clinical score. The average clinical score of the 3 animals during the last 5 days 
before surgery was 1.5. The clinical score increased to 3.2 immediately after 
surgery and to 3.5 on the first postoperative day. The average clinical score 
normalized starting on the second postoperative day (average score between 
day 2 and 5 after surgery: 1.33). 
CT imaging. CT imaging after surgery showed a correct position of the ventricle 
catheter in 2 animals. In the third animal, the ventricle catheter was 
positioned too deep. This suboptimal position had no clinical consequences. 
The intravascular catheter was correctly positioned in all animals. The distal 
part was always located in the ventral angle of the triangular section of the 
sinus (Figure 3). Clinically and radiographically (contrast-enhanced CT), there 







Figure 3. Position of the intravascular catheter in the superior sagittal sinus. 
Coronal (left) and sagittal (right) computed tomography imaging of the caprine head 
showing the 
position of the intravascular catheter and the ventricular catheter. The intravascular 
catheter was always positioned in the ventral tip (just above the falx) of the superior 
sagittal sinus. In this position the catheter touches the lateral walls of the sinus. The 
ventricular catheter was positioned too deep in this animal.  
A: intravascular catheter; B: ventricular catheter. 
Assessment of shunt patency. The assessment of the shunt system after 16 
days showed a patent ventricle catheter, but there was an obstructed 
intravascular catheter in all animals.  
Autopsy. Stereomicroscopic evaluation showed a correct position of the 
intravascular catheter in the three animals. However, the presence of a clot 
was visualized around all three catheters. This clot was situated at the site 
were the catheter enters the sinus, extending downstream (i.e., caudally) 
along the sinus roof (Figure 4a). The SEM evaluation of the lumen of the 
intravascular catheter showed the presence of an intraluminal clot in all 









Figure 4. Microscopic evaluation of the intravascular catheter. 
Figure 4a: evaluation with a stereomicroscope showed the presence of a clot (arrow) 
originating at the entry site of the catheters and extending downstream (i.e. caudally) 
along the sinus roof 
Figure 4b: scanning electron microscopic (SEM) views of the obstructed intravascular 
catheter. 
Left: SEM evaluation of a transverse section of the intravascular catheter showing the 
obstructing 
clot. Right: Higher magnification of the intraluminal clot showing fibrin network with 
red blood cells and 







Shunting CSF to its natural resorption site—the superior sagittal sinus—with a 
ventriculosinus shunt is a promising treatment for hydrocephalus (7, 8, 11). 
Different authors have evaluated this shunt in clinical series (7-9). Based on 
their experience, the authors have modified the technique and developed 
designated shunt hardware (12-15). Currently, it remains unclear which 
technique or shunt system is ideal (11). To maximize the chance of success, 
the ventriculosinus shunt should be optimized by evaluating and combining 
the most valuable characteristics of the available techniques. This process 
requires a suitable animal model (16).  
This pilot study reports on the characteristics and feasibility of a non-
hydrocephalic goat model. The purpose of this model is to enable the 
evaluation and optimization of different implantation techniques and 
prototypes of the ventriculosinus shunt.  
Strengths and limitations of the non-hydrocephalic caprine model 
The implantation of a ventriculosinus shunt in goats has been found to be 
feasible and safe. The anatomy and dimensions of the caprine brain ventricles 
and superior sagittal sinus allow for the implantation of ventriculosinus shunts 
that are closer in design and dimensions to shunts for human use (8). These 
characteristics are in contrast to the previously described canine model, in 
which the implantation of a distal catheter with a comparable outer diameter 
resulted in venous congestion and sinus thrombosis (16).  
Although the goat model resembles human anatomy, the dimensions of the 
caprine superior sagittal sinus are significantly smaller (24). Depending on the 






be necessary. The smaller superior sagittal sinus may also promote distal shunt 
obstruction, as the proximity of the sinus walls to the catheter tip may cause 
endothelial irritation and blood stasis, which are both known to enhance 
coagulation (25).  
In contrast to previously described animal models, (16, 17) hydrocephalus was 
not induced in this study. Injection of Kaolin by a sub-occipital puncture, which 
is the best documented method for the induction of hydrocephalus, causes 
chemical meningitis (26). This technique is associated with a high morbidity 
and mortality (17, 26-28). However, hydrocephaly is not required for the 
evaluation of the implantation technique and the design, dimensions and 
tolerance of current and potential new prototypes of the ventriculosinus 
shunt. The clinical impact of meningitis itself may even cloud the assessment 
of the tolerance for the shunt system. Thus, the use of a non-hydrocephalic 
model is an important refinement because it simplifies the study protocol and 
drastically reduces animal suffering. 
A major limitation of the non-hydrocephalic model is the impossibility to 
evaluate the efficacy and survival of the shunt system. The preserved 
physiological drainage of CSF causes the flow through the shunt system to be 
at least limited and inconsistent. This inconsistency leads to impaired clearing 
of fibrin deposits, which are known to result in catheter obstruction (29). This 
phenomenon partially explains why all implanted shunts were found to be 
obstructed after two weeks.  
In addition to the absence of hydrocephaly, the coagulation properties of the 
caprine model may promote shunt obstruction. Sonoclot analysis showed that 





human values(30),the ACT is 34% shorter, and the CR is 127% higher. This 
difference in coagulability was partly counteracted by administration of 
antiplatelet drugs, which reduced the relative difference in ACT to 11% and CR 
to 52%. The addition of CSF to blood enhances coagulation in humans (30). 
This effect appears to be more pronounced in goats, which may further 
increase the risk of shunt obstruction.  
Intra-operative evaluation of the ventriculosinus shunt 
The current study shows that an intra-operative evaluation of the shunt 
system may be useful for clarifying the causes of shunt failure, even in the 
absence of hydrocephalus. One could observe a pulsatile reflux of blood to the 
shunt system despite the use of a competent one-way valve and a retrograde 
position of the shunt. This reflux is probably caused by a combination of the 
compliance of the silicone shunt system distal to the valve, the pressure 
pulsations in the superior sagittal sinus and the inertia of blood corpuscles that 
hit the CSF column at the distal shunt tip.  
Pulsatile reflux of blood results in the development of a relatively static blood-
CSF mixture in the distal shunt system. Both stasis of blood and the interaction 
with CSF promote clot formation, which finally results in shunt obstruction 
(30).  
The reflux could be prevented by clamping the distal catheter close to its 
entrance in the superior sagittal sinus. In addition, reflux was not observed 
when a more rigid catheter with a smaller inner diameter was inserted in the 
sinus. Both manoeuvres reduce the compliance of the shunt system distal to 
the valve. These findings suggest that using a more rigid distal catheter with a 






In conclusion, the implantation of ventriculosinus shunts is feasible and safe 
in a non-hydrocephalic goat model. This model facilitates the intra-operative 
evaluation of the implantation technique, hardware and functions of the 
ventriculosinus shunt. The tolerance for the shunt system and possible 
postoperative complications can be monitored without interference of 
sequelae from the induction of hydrocephalus. However, in the absence of 
hydrocephalus, it is impossible to evaluate shunt efficacy and shunt survival. 
The development of a hydrocephalic goat model for this purpose may be used 
in future research.  
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Chapter 6. Pulsatile backflow of blood into the shunt 




A potential risk of VV shunts is backflow of blood into the distal (intravascular) 
catheter which results in a relatively static blood-CSF mixture that predisposes 
to thrombotic complications (obstructions or emboli). 
To prevent backflow of blood into a VA shunt, one-way valves are being used. 
For a VS shunt, blood backflow may be prevented by implanting the shunt in 
a ‘retrograde’ position according to El-Shafei (Figure 3, chapter 4) (1). In this 
position the blood flow ‘hits’ the draining CSF column and stagnates at the 
shunt tip. According to Bernoulli’s principle, kinetic energy is converted to 
potential energy and the static pressure in the shunt rises by the amount of 
the dynamic Psss. In other words, the ICP is kept above the static Psss. This 
effect is called the ‘impact effect’ by El-Shafei (1, 2).  
In the anterograde position, it can theoretically be expected that the ICP 
becomes lower than the static Psss. El-Shafei describes this as the ‘wake effect’ 
(1). Bernoulli’s principle cannot be used to calculate this effect, as the blood 
flow might not be laminar in the wake zone (2).  
El-Shafei claims that the impact effect protects against the development of 
intracranial hypotension and assures a constant drainage of CSF through the 
catheter, regardless of postural changes (1). The assumption is based on his 






pressure evolution when a patient changes his posture from supine to 
sitting/standing and back to supine (1) is illustrated in Figure 1. When the 
catheter is implanted anterograde (Figure 1, left) and the patient is in the 
supine position, the steady state ICP is slightly lower than the static Psss due 
to the wake effect. When the patient changes to the sitting or standing 
position, the Psss drops and the flow increases. The wake effect remains 
constant when the flow in the sinus doubles, as shown by numerical modeling 
(2). By consequence, CSF will be suctioned to the SSS and the ICP will drop.  
When the patient changes back to the supine position, the Psss increases again 
and becomes higher than the ICP. In this situation, blood will reflow into a 
valveless shunt system or if a valve is present, no drainage of CSF will occur 
until – due to the production of CSF – the ICP increases beyond the Psss again 
(1).  
When the catheter is implanted retrograde (Figure 1, right), the ICP is kept 
slightly higher than the static Psss due to the impact effect. When the patient 
verticalizes, the decrease in the sinus pressure is compensated by the increase 
of the flow and thus the increase of the impact effect. By consequence, no 
excessive drainage of CSF will occur and the ICP will remain higher than the 







 Anterograde Retrograde 
Situation/pressure (mmHg) Psss ICP Psss ICP 
1 3.2 1.8 3.1 3.2 
2 - 15.3 - 28,1 - 18.1 - 18 
3 Backflow observed No backflow observed 
Figure 1. Protective role of the impact effect in postural changes 
The SSS is represented by a cylinder. The sinus catheter penetrates the roof and ends 
with the tip in the center of the SSS. The catheter is inserted in the direction 
‘anterograde’ (left) or against the direction ‘retrograde’ (right) of the blood flow. The 
pressure evolutions due to changing the patient’s position from supine [1] to 
sitting/standing [2] and back to supine [3] are represented by color codes. The 
direction of the flow is indicated by an arrow. The flow rate is represented by the 
magnitude of the arrow. The experimental values/observations on which El-Shafei 






El-Shafei substantiated his theory also with intra-operative measurements in 
the IJV (45 patients) (3). When the shunt was implanted retrogradely, the ICP 
measuring 9 mmHg in the supine position, dropped to 3 mmHg when the 
patient was brought in a sitting position. Fifteen patients were kept in the 
sitting position during 30 minutes. The ICP remained stable. When the patients 
were switched back to the supine position, the ICP increased to 9 mmHg again. 
Experimental and numerical models endorse that the impact effect protects 
against backflow of blood due to positional changes and Valsalva maneuvers 
(1, 2). However, the protective effect was only partial and reflux of blood still 
occurred during provocation maneuvers (2). Also, the clinical superiority of the 
retrograde position remains unproven (4) and, although El-Shafei advocates 
that the impact effect prevents reflux of blood in all situations (1), he started 
adding a one-way valve to the shunt system himself (5).  
In the animal model (Chapter 5), pulsatile reflux of blood occurred regardless 
of the orientation of the distal catheter (anterograde or retrograde) and 
despite the presence of a competent one-way valve. A potential cause of this 
reflux is the interaction of pressure waves in the brain ventricles (proximal end 
of the shunt) and in the SSS or the right atrium (distal end of the shunt).  
Up to now, these pressure waves, originating from different events during the 
heart cycle, were neglected in experimental and numerical models (1, 2).  
This chapter discusses the methodology and results of a dynamic experimental 
model to evaluate whether the intracranial and venous pressure waves can 
cause backflow of blood to VV shunts. It also highlights remaining 
uncertainties that are currently addressed in the context of a master thesis 





ventriculovenous shunts in a numerical model; T. Billiet, J. Vandersteene, D. 
Van Roost, P. Segers).  
Materials and methods 
Assumptions 
To develop an experimental model some assumptions/simplifications were 
made. 
- Modelling of the brain and ventricular system as water  
The brain and CSF are mainly composed of water and can be considered 
incompressible. Brain and CSF can adequately be modelled by water (2). 
- The spinal compartment is not included in the model  
With regard to the research question, only the compliance added by this 
compartment is of importance (2). This was modeled by a windkessel. 
- Only the distal venous system (cortical veins and SSS) is included in the 
model 
The rest of the cerebral vascular system is only relevant to the research 
question as far as the ICP pulsations are concerned. These were modeled 
by a pump, connected to the intracranial compartment. 
As the shunt will be implanted in the SSS, only the flow conditions in this 
SSS are relevant to the research question.  The downstream venous 
system can be left out as long as the flow rate and the downstream 
pressure in the SSS are modelled correctly. 
- No production of CSF in the model 
The physiological CSF production rate is 0.35 ml/min. The difference 
between the pressure in the SSS at the position of the shunt tip and the 






production is taken into account as without CSF production. Due to the 
very low CSF flowrates, the changes in terms of impact or wake effect are 
negligible. However, the difference between the pressure in the CSF 
reservoir (ICP) and the pressure in the SSS at the shunt tip is increased by 
the pressure loss in the shunt. According to Poiseuille’s law, this pressure 
drop will be < 1mmHg. In accordance with previous literature (2), we 
decided not to include CSF production in the model. 
Experimental model  






Figure 2. Experimental set-up to evaluate the impact of intracranial and 
venous pressure waves 
a: schematic drawing. The model consists of a venous compartment [D-E-F-G-H-I] that 
is partially submerged in the cranial compartment [A-B-C]. The cranial compartment 
is formed by a rigid container [A], the compliance is set by a windkessel [B] and 
pulsations are applied by a computer-controlled pump [C]. A volumetric pump [E] 
generates a constant flow in the venous compartment. The glycerin-water mixture 
circulates from the blood reservoir [D] through a needle valve [F] and the distribution 
tubes to the cerebral veins [G] and the SSS [H]. From the SSS the mixture flows to the 
adjustable-pressure reservoir [I] and back to the glycerin-water mixture reservoir. The 
ventriculosinus shunt [J] connects the intracranial compartment and the superior 
sagittal sinus. The pressure is measured by pressure sensors [P or pattern filled 
rectangle in panel a], connected to the intracranial compartment and to the SSS. b: 
Schematic drawing of the venous system that is submerged in the cranial container 
(frontal view). The cerebral veins run upwards from the distribution tubes, cross the 
midline and are connected through a right-angle connector to the plexiglass block 
containing the SSS, which is mounted above the cranial container. c: Schematic 
drawing of the SSS. From the right-angle connector, the veins (dashed lines) run within 
the plexiglass to join the SSS at the appropriate distance from the origin and at an 
appropriate angle with the longitudinal axis of the SSS. The dimensions of the SSS 
progressively increase from proximal to distal. In between the origin (a point) and the 
marked sections [1 and 2] the dimensions of the SSS increase linearly. Distal to section 
2, these dimensions stay the same. d: schematic drawing of sections 1 and 2. 
Page 147 shows the actual set-up in three pictures (upper: overview; lower left: lateral 


















The model consists of two separate compartments. The first [A in Figure 2], a 
rigid container filled with water, models the brain tissue and CSF in the 
ventricles and subarachnoid space. These structures are incompressible and 
can adequately be modelled using water (2). A windkessel [B in Figure 2] was 
used to set the total compliance of the CSF reservoir to 0,008 ml/Pa (6). The 
windkessel accounts for the compliance of the spinal dura mater.  
The second compartment, the venous system [D-E-F-G-H-I in Figure 2], 
consists of the cerebral veins [G in Figure 2] and the superior sagittal sinus [H 
in Figure 2]. The SSS [Figure 2, c and d] was milled out of plexiglass. The 
dimensions are based on anatomical data found in literature. The total length 
is 252 mm (weighted average based on the number of patients in references 
(2, 7)). The triangularly shaped cross-section increases from proximal to distal. 
The dimensions of the section at the origin of the sinus, end of the sinus and 
in two specific places were based on reference (8), and between these 
sections a linear gradient was chosen. Twenty-two cerebral veins, 11 on each 
side of the SSS (weighted average based on the number of patients in 
references (7-9)), are embedded in the first container and join the superior 
sagittal sinus each at a specific place and individual angle (weighted average 
based on the number of patients in references (7, 10)).  
The pliant cerebral veins are modeled by a polyethylene shrink-film that was 
welded in a cylinder and shrunken to the right diameter (2.5 mm). To obtain a 
physiological venous volume, the length of the veins was chosen to be 74 mm. 
This volume was calculated based on the percentage of the cerebral blood 
flow that drains to the superior sagittal sinus and the total blood volume in 
the cerebral veins (11). Blood was modeled by a 40% glycerin and 60% water 





mPa s at 25 °C (2). A volumetric pump [E in Figure 2] brings the mixture into 
two distributors, from where it is divided over the 22 cortical veins. The 
downstream Psss is set to 7.5 mmHg by an adjustable-pressure reservoir [I in 
Figure 2] which captures the glycerin–water mixture. A silicone shunt [J in 
Figure 2] that is commonly used in clinical practice (Codman Hakim atrial 
catheter; internal diameter 1.0 mm and external diameter 2.2 mm; Johnson & 
Johnson Medical; Diegem, Belgium) connects the intracranial compartment 
with the superior sagittal sinus. Experiments were done with and without 
interposition of a one-way valve (Codman Hakim programmable valve; 
programmed on 2.2 mmHg; Johnson & Johnson Medical; Diegem, Belgium). 
Three luer lock connectors are mounted on the roof of the SSS making angles 
of 45, 90 and 135 degrees with the direction of the blood flow respectively. 
These luer lock connectors converged to a common entrance in the SSS, 190 
mm distal to its origin. The silicone shunt was then mounted on an 18 G needle 
(BD Microlance 3; 18G, 1½’’, 1.2x40mm; Erembodegem, Belgium) that was 
brought into the center of the SSS through each of the luer lock connectors 
sequentially. As such the needle opening was oriented retrograde, neutral or 
anterograde. The Psss was measured in each position. 
A pressure transducer was connected to the intracranial compartment and to 
the distal shunt (at the entrance into the SSS) using a 3-way luer lock valve 
(Discofix C; B Braun; Diegem, Belgium). Pressure curves where recorded with 
ViVitro QCTest software (ViVitro Labs; Victoria, Canada). The pressures were 
corrected for height differences between the sensors. To simulate 
hydrocephalus, the ICP was brought to 22.5 mmHg or 3000 Pa by adding water 
to the intracranial compartment with a syringe. A computer-controlled pump 






to the cerebral compartment. The pressure measurements were performed 
under static (no pulsations applied by the computer-controlled pump) and 
dynamic conditions. 
In the dynamic set up the computer controlled pump was programmed to 
generate pressure waves with an amplitude of 3-4 mmHg (12) and a frequency 
of 70 pulsations per minute (Figure 3).  
To simulate a person changing from upright to supine position, the pressure 
in the superior sagittal sinus was suddenly increased by 0.75 mmHg (100Pa) 
(13). To simulate a lumbar puncture the ICP was lowered by 0.75 mmHg 
(100Pa)(2).  
Results 
Constant flow experiments 
When, in the static situation, drainage is permitted through the 
ventriculosinus shunt, CSF flows from the reservoir to the SSS. CSF drainage 
stops when the ICP equalizes to the total Psss. With the shunt in the retrograde 
position, the stabilization pressure is 0.51 +- 0.1 mmHg higher than when the 
shunt is implanted in the anterograde position. 
Dynamic experiments 
In the dynamic situation, the pump generates pressure waves with a 
frequency of 70 pulses per minute and an amplitude of 3.3 +- 0.2 mmHg in the 
cranial compartment. These pulsations are effectively transferred through the 
cerebral veins to the SSS. The amplitude of the resulting pressure waves in the 







Figure 3. Experimental intracranial and venous pressure waves  
The pressure waves within the cranial compartiment and the SSS are shown (upper 
boxes: 4 cycli - 3.4s). The detailed views (lower boxes) show clearly that both curves 
cross at several points. 
After opening of the shunt, CSF drains to the SSS. The steady state situation is 
reached when the mean ICP equalizes the mean pressure in the SSS at the 
shunt tip. In the dynamic situation no difference was observed between the 
anterograde and retrograde position, in terms of mean pressure differences. 
The pressure at the shunt tip equals the static + dynamic (impact or wake) 
pressure in the SSS. However, in the steady state situation, the maximal ICP is 
higher than the maximal Psss, and the minimal ICP is lower than the minimal 
Psss (Table 4). Also, the pressure waves in the cranial and venous 
compartments are not identical in morphology nor in phase. By consequence 






several points (Figure …). The above relations between the ICP an Psss were 
identical in the retrograde and the anterograde position.  
Table 4. Difference between ICP and Psss at the shunt tip (minimum, mean and 
maximum) after reaching the steady state in the dynamic situation  
The mean difference and the 95% confidence interval are shown. Note that the 95% 
confidence interval of the mean difference in ICP and Psss encompasses 0. 
 Difference in ICP and Psss (ICP – Psss) [mmHg] 
 Minimum Mean Maximum 
Retrograde -0.4 (-0.6; -0.2) 0.1 (-0.2; 0.5) 1.2 (1.0; 1.4) 
Anterograde -0.6 (-0.7; -0.5) 0.1 (0; 0.3) 1.0 (0.8; 1.2) 
Provocation maneuvers  
Regurgitation of blood to the shunt system was observed in response to the 
provocation maneuvers (sudden increase in SSS pressure by 0.75 mmHg or 
100 Pa and sudden decrease in ICP by 0.75 mmHg or 100Pa). The backflow 
stopped when the Psss equalized the ICP. 
Influence of a one-way valve 
When a one-way valve with minimal differential pressure (+- 2.2 mmHg) was 
added to the shunt system, the ICP decreased faster and more pronounced as 
compared to a valveless system. The mean stabilization pressure after 
implanting a retrograde VS shunt measured 13.7 mmHg without valve versus 






Figure 4. Experimental influence of a one-way valve on the ICP 
The steady state ICP is lower after implanting an RVS shunt with a one-way valve 
compared to the same system without a valve.  
  
Discussion 
Backflow of blood to the shunt system is a potential risk to VV shunting that 
may cause shunt obstruction. The phenomenon is believed to be prevented 
by adding a one-way valve and by implanting the shunt with the tip directed 
against the blood flow (‘retrograde’) (1). However, thrombotic shunt 
complications remain the main reason that most neurosurgeons reserve VV 
shunts to patients in whom VP shunts are contra-indicated or not successful 
(14). The impact effect has proven to be only partially protective against 
backflow of blood, provoked by Valsalva maneuvers or changes in position of 






shunt was observed, regardless of the orientation (anterograde or retrograde) 
of the shunt and despite the presence of a competent one-way valve (15).  
Causes of pulsatile backflow 
The results of the present dynamical experimental model identify the 
pulsatility of the intracranial and venous pressure waves as the source of this 
reflux. In the experimental set-up, the mean intracranial steady state pressure 
equalizes the mean venous pressure after implanting a VV shunt. However, 
the maximal ICP is higher than the maximal venous pressure while the minimal 
ICP is lower than the minimal venous pressure. The intracranial and venous 
pressure wave curves, that differ in morphology and phase, do cross during 
the heart cycle which may result in an inversion of the flow in the VV shunt. 
This flow is suspected to be positive (this is from the ventricles to the venous 
system) in the beginning of the heart cycle but negative at the end. It is 
plausible that, as observed in the experimental model after the in vivo 
implantation of a VS shunt, CSF will drain to the venous system until the mean 
pressures at the proximal (ventricular) and distal (venous) end of the shunt are 
equal. 
The experimental finding that the intracranial and venous pressure waves 
differ in amplitude, morphology and phase, is in line with observations on 
patients in the intensive care unit for whom the intracranial, arterial and 
central venous (atrial) pressure waves are recorded simultaneously. The latter 
observations can be explained by the physiology of the intracranial and venous 
pressure waves: 
- The ICP waves reflect variations of the cerebral blood volume during the 





an arterial pulse wave that propagates to the cranial compartment. The 
suddenly increased cerebral arterial inflow is not immediately 
compensated by the venous outflow: due to the vascular resistance and 
the arterial compliance, the arteries dilate. The added intracranial arterial 
blood volume, increases the pressure due to the rigidity of the intracranial 
compartment (6, 16). 
- The pressure waves in the SSS are caused by the pulsatile cerebral venous 
drainage. This drainage becomes pulsatile due to the transmittance of the 
cerebral arterial pulse wave through the incompressible brain and CSF to 
the thin-walled cortical veins. These veins are compressed and blood is 
periodically ‘squeezed‘ into the SSS (17).  
- The atrial pressure wave reflects atrial contraction, ventricular contraction 
and atrial filling driven by systemic venous return (18). These events are 
represented by 3 atrial pressure peaks. 
As, after the implantation of a VV shunt, the intracranial and venous pressure 
waves will have the same mean but will differ in amplitude, morphology and 
phase, the curves will cross. When the ICP drops long enough beneath the 
venous pressure, the flow in the shunt may inverse which causes blood and 
recently drained CSF to enter the shunt system and form a relatively static 
blood-CSF mixture. Both stasis of blood and the interaction with CSF, known 
to promote coagulation, will finally result in clot formation and shunt 
obstruction (19).  
Measures taken so far to prevent backflow of blood to the shunt system - 
implanting the shunt with the tip directed against the blood flow (‘retrograde’) 






The impact effect, that was observed in the static experiment, disappeared in 
the dynamic situation. This may indicate that the pulsatile drainage of the 
cerebral veins into the SSS disturbs the linear laminar flow in the SSS, while 
the impact effect does rely on laminar flow conform the law of Bernoulli. 4D 
flow MRI imaging has shown that the flow is unidirectional laminar in the 
proximal part of the SSS (laminar flow in the SSS is supported  by longitudinal 
ridges on the luminal surface of the dural venous sinuses called chordae Willisii 
(20)), but non-laminar from the distal part of the SSS onwards (21). Ultrasound 
imaging of the proximal SSS of neonates also indicates multi-directional flow 
(personal communication with professor Paul Govaert, neonatologist). 
Also a one-way valve may not be sufficient to prevent pulsatile reflux of blood 
into the shunt caused by the intracranial and venous pressure waves (15). The 
combination of the intracranial and venous pressure waves causes variations 
of total pressure in the shunt. An important part of the shunt system is located 
outside the intracranial and venous compartment. This part is thus subjected 
to varying transmural pressure. The compliant silicone shunt system distal to 
the valve might distend and permit reflux of blood when the venous pressure 
becomes maximal.  
Cause of backflow to a ventriculosinus shunt during provocation manoeuvres 
As described in previous static experiments (1, 2), the impact effect only 
partially protects against reflux of blood when the steady state is disturbed by 
physiological changes in venous pressure (changing position, Valsalva 
maneuver) (2). Also, in our dynamic set-up, regurgitation of blood to the shunt 






First, although an impact effect was observed during the constant flow 
measurements, it was not measurable when intracranial pulsations were 
applied. The pulsatile drainage of the cortical veins into the SSS might cause a 
non-laminar flow, which may result in a diminution of the impact effect.  
Second, reflux might be caused by the loss of the normal, fixed relation 
between the central venous pressure and the ICP (see chapter 2, section on 
intracranial pressure). This relation is maintained by the adaptation of the 
diameter and thus the volume of the cerebral veins in function of the 
transmural pressure (22, 23). The transmural pressure is negative in the distal 
segment because the Psss is lower than the ICP in physiological situations (22). 
The radius of the distal segment will decrease, causing an increase in the 
resistance to flow and thus an increase in the pressure difference over the 
segment (24). The pressure proximal to the collapsed segment will thus be 
equalized to the ICP (25). When the Psss increases, the cerebral veins will 
open, adding volume to the intracranial compartment and thus increasing the 
ICP (22).  
Why the natural coupling between the ICP and the Psss was lost in the current 
and previous experimental models was not yet investigated. One can expect 
however that in case of a ventriculosinus shunt, the ICP will always be 
approximately equal to the Psss, resulting in the cerebral veins to be fully open 
at all times. As, in this situation, the cerebral veins cannot expand in response 
to an increase in Psss, the normal link between intravenous pressure and ICP 
will be lost. In this situation every increase in central venous pressure will 








Figure 5. Relation between the Psss and the ICP 
In physiological conditions (no ventriculosinus shunt present) the Psss is lower than the 
ICP and the cerebral veins (CV) are partially collapsed at their distal end. When the Psss 
increases (e.g. Valsalva maneuver) the distal part of the CV will open a bit more, 
increasing the intracranial volume and thus the ICP. 
When a ventriculosinus shunt is present the ICP almost equalizes the Psss and the CV 
are fully open. When the Psss increases, the CV cannot distend anymore, causing the 
Psss to rise above the ICP.  
This hypothesis suggests that, to prevent the ICP to drop below the pressure 
in the sinus and to maintain the physiological coupling between the 
intracranial and the venous pressure, one should use a valve with a certain 
opening pressure and not a very low pressure valve as advocated by El-Shafei 
(5). At present too much uncertainties persist to be able to calculate what the 






Result of using a one-way valve 
As the impact effect is only partially protective and as the intracranial - and 
venous pressure wave curves cross, a one-way valve is always necessary to 
prevent blood from entering the shunt system. However, we found that a one-
way valve has an influence on the functioning of the shunt and on the 
pressures in the different compartments. In the presence of a one-way valve, 
the ICP dropped more rapidly and more profoundly than observed without a 
valve. Despite the valve’s openings pressure of 2.2 mmHg, the ICP dropped 
even significantly below the Psss. As we did not find a sufficient explanation 
for this observation we repeated the measurements several times, but the 
results proved to be consistent. No issues with the test set-up were 
encountered, especially no leakage at the connection between the silicone 
catheter and the valve. 
The observation concerning the dropping ICP may be explained partially by 
the following factors: 
1) Is has been proven in previous literature (26) that intracranial 
pulsations cause the opening pressure of a valve to be lower than 
when constant pressure is applied. The inertia of the valve causes the 
closing pressure to be lower than the opening pressure. Thus, the 
valve opens when the ICP is maximal and permits drainage of CSF until 
the (lower) closing pressure is reached. Due to the inertia of the valve 
and the high frequency of the pulsations, the valve, once open, might 
not be allowed the time to close until the ICP is lower than the opening 
pressure during the whole heart cycle.  
2) When the ICP exceeds the venous pressure, CSF will drain to the SSS. 






reversed, blood will be prevented to flow back to the shunt system. In 
this way CSF is ‘pumped’ to the SSS until the ICP is equal or lower than 
the Psss at every point of the pressure curve (Figure 6).  
 
Figure 6. Theoretical effect of adding a one-way valve 
In the above figure two pressure curves are represented. The dotted line represents the 
ICP-curve and the full-line the venous pressure curve. The time is on the x-axis and the 
pressure on the y-axis. 
In the absence of a valve, blood will move in and out of the distal catheter as the 
pressure curves cross (upper graph). When a one-way valve is added, CSF will drain 





when the ICP drops under the venous pressure. By consequence, CSF will be ‘pumped’ 
to the venous system until the ICP is lower than the venous pressure at every point of 
the pressure cycle (lower graph).  
However, these factors cannot explain the full magnitude of the pressure drop 
that was provoked by the valve. The influence of a one-way valve on the 
function of a VV shunt and the pressures in the different compartments is 
currently the subject of a master thesis (ongoing master thesis; Cranial and 
venous pressure waves cause backflow in ventriculovenous shunts in a 
numerical model; T. Billiet, J. Vandersteene, D. Van Roost, P. Segers; see 
below). 
Strengths and weaknesses  
To our knowledge we are the first to evaluate the VV shunt under dynamical 
pressure conditions. The experimental set-up simulates the complex 
interaction between the ICP and the Psss. The anatomy of the cerebral veins, 
their entrance (location and angle) in the SSS and the dimensions of the SSS 
are modeled conform the available literature describing the in vivo situation. 
The results of the experimental set-up are somehow validated by the fact that 
these are in line with the observations during the animal experiment. 
However, at present, several weaknesses persist: 
1) In accordance with previous literature (2), no CSF infusion was applied 
to the model. Constant CSF production would result in a pressure loss 
over the shunt of about 0.4 – 0.8 mmHg. This is of the same magnitude 
as the differences in ICP and venous pressure that were observed 
during the heart cycle. CSF production might thus play a significant 






pressure curves in vivo. However, CSF production will not protect 
against backflow due to alterations in transmural pressure affecting 
the shunt system distal to the valve.  
2) The waveform of the pulsations in the cranial compartment is only a 
rough approximation of the in vivo situation. Although the ViVitro 
SuperPump is especially dedicated to the simulation of physiological 
cardiac flows, better suited waveforms could not be obtained.  
3) It was not verified whether the magnitude and the duration of the 
negative differential pressure (ICP < Psss) at the end of the hart cycle 
are sufficient to cause an inversion of the flow.  
4) It was not assessed whether using a valve with a certain differential 
pressure actually preserves the natural regulation mechanisms that 
maintain a physiological fixed relation between the intracranial and 
venous pressures. Likewise, it was not assessed what the ideal 
opening pressure of such a valve would be. 
Ongoing research 
The above weaknesses are currently being addressed in the context of a 
master thesis (ongoing master thesis; Cranial and venous pressure waves 
cause backflow in ventriculovenous shunts in a numerical model; T. Billiet, J. 
Vandersteene, D. Van Roost, P. Segers). The aim is to supplement the 
experimental set-up with a numerical model. Such a numerical model allows 
to apply pressure curves that are a far better approximation of the 
physiological situation. It also allows to further explore certain findings by 
manipulating the boundary conditions. The simulations are solved with the 






Figure 7. Constant flow simulations in the numerical model 
Upper left and right: three-dimensional geometry with a mesh applied.  
Middle left: flow velocity vectors in the SSS with a shunt in the anterograde position. 
Middle right: flow velocity vectors in the SSS with a shunt the retrograde position. 
Lower Left: pressure fields the SSS with a shunt in the anterograde position. 
Lower Left: pressure fields the SSS with a shunt in the retrograde position. 
1, SSS; 2, cortical vein; 3, shunt; 4, wake zone with low pressure, non-laminar flow and 
lower velocity; 5, impact zone with higher pressure, laminar flow and higher velocity; 






In the numerical model, the inlet veins, the SSS and the shunt are constructed 
three-dimensionally with exactly the same geometry as the experimental 
model (Figure7).  
To validate the model, it is solved with the same boundary conditions that 
were imposed on the experimental model. These results are compared to 
those obtained from the in vitro set-up. 
We already obtained results for the static situation. The constant flow 
simulations show that the pressure in the ventriculosinus shunt equalizes the 
total Psss, being 0.35 +/- 0.1 mmHg higher in the retrograde position 
compared to the anterograde position, which is comparable to the results of 
the in vitro model.  
Conclusion 
When a VV is implanted, CSF will drain to the venous system until the mean 
ICP equals the mean venous pressure. This steady state condition is in 
contradiction with the physiological situation were the ICP stays above the 
venous pressure at all times, and this causes backflow to a valveless shunt 
system during the steady state condition as well as during provocation 
maneuvers.  
Backflow during the steady state condition occurs because, although the ICP 
and the venous curves have the same mean value, they differ in amplitude, 
morphology and phase, causing alternating pressure differences over the 
shunt. Backflow during provocation maneuvers occurs because the normal 
adaptation mechanisms that ensure a fixed relation between the ICP and the 





The impact effect does not prevent backflow due to the intracranial and 
venous pressure waves and only partly protects against backflow during 
provocation maneuvers. Backflow to a valveless shunt system thus occurs 
regardless of the shunt’s orientation.  
A one-way valve does protect against backflow of blood due to alternating 
pressure differences over the shunt both during steady state conditions and 
provocation maneuvers. However, if the shunt system distal to the valve is 
sufficient compliant, it may still allow backflow due to alterations in 
transmural pressure. This kind of reflux can be prevented by reducing the 
compliance of the shunt system distal to the valve. The compliance of a 
catheter can be kept minimal by reducing the inner diameter, increasing the 
wall thickness and using a less compliant material.  
After incorporation of a one-way valve with a minimal opening pressure, CSF 
will be ‘pumped’ to the venous system until the ICP is lower than the total 
venous pressure at every point of the heart cycle. This unphysiological 
situation can be prevented by using a differential pressure valve.  
To render the experimental findings more robust they will have to be 
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Chapter 7. Procoagulant effect of CSF 




Draining CSF to the venous system causes blood-CSF-foreign material 
interactions. The influence of CSF on blood coagulation in general is not well 
established. Some authors suggest that CSF may enhance hemostasis as it 
contains proteins such as fibrinogen and tissue factor that may activate the 
clotting cascade (1-3). Consequently, the protective effect of the ‘constantly 
renewing CSF sleeve’, which has never been substantiated, was put in doubt. 
Therefore, in the experimental goat model, we evaluated the effect of adding 
CSF to blood on blood coagulation and found that CSF has a procoagulant 
effect.  
In this chapter we explore whether CSF also has a procoagulant effect in 
humans and if the blood-CSF-foreign material interaction prevents or 
promotes clot formation. These questions are addressed in 3 consecutive 
manuscripts. 
The first manuscript presents a suitable setup to evaluate the research 
question. In theory, animal- or in vitro models can been used (4). However, in 
vitro models that use human fresh blood are preferred over animal models, as 
the clotting and platelet function of animals and humans are essentially 
different (4-6). A suitable in vitro model should allow to infuse fluids, to 






conditions. Such a model was not found in previous literature. In the 
manuscript we present a new non-occlusive roller pump model that allows to 
adequately simulate the in vivo situation to which the distal (intravascular) 
part of the ventriculosinus shunt is subjected.  
The second manuscript addresses the quantitative assessment of clot 
formation on the shunt’s surface. These tiny clots are evaluated on SEM 
images which are 2D projections of the 3D objects. Due to projection effects, 
the cylindrical shunt surface and the covering clots will be represented 
distorted and scaled (7, 8). If not corrected, these projection effects will bias 
the quantitative assessment of the clots. The manuscript explores this 
problem and presents a Matlab Simulink® script to correct the projected SEM 
images in order to enable an accurate quantitative assessment.  
The third manuscript uses the new in vitro model and the Matlab Simulink® 
script, to evaluate the effect of CSF infusion on clot formation on the surface 
of retrograde implanted shunts. CSF infused shunts are compared to Ringer’s 
Lactate (RL) infused shunts and controls (no infusion fluid). The strong point 
of this dynamic experiment is the approximation of the in vivo situation. 
However, the set-up contains possible sources of bias: blood and CSF are not 
from the same donor, which may cause immunological reactions due to 
incompatibility, and the coagulation tests may be disturbed because of the 
need for heparinization. To address these weaknesses the manuscript 
combines the dynamic experiment with a static in vitro coagulation assay. This 
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Abstract 
Introduction: we present an experimental model to evaluate thrombus 
formation on catheters. The model allows infusion of fluids, correct 
positioning of the catheter and generation of realistic flow conditions. These 
factors may impact on the amount of clot formation. The model was applied 
on the intravascular catheter of the ventriculosinus shunt, an experimental 
treatment for hydrocephalus. 
Methods: a cerebrospinal fluid (CSF), Ringer’s Lactate (RL) or no fluid (control) 
infused catheter was inserted through the wall into a tubing. The tubing was 
filled with donor blood, circulated by a semi-occlusive roller-pump. The 
sixteen loops (6 CSF, 6 RL, 4 control) ran for 60 minutes each. We assessed the 
thromboelastogram of pure blood at the beginning to that of the infusion fluid 
- blood mixture at the end of the loops. Clot formation was assessed 







Results: the flow was 141 +/- 7.5 ml/min, the pressure wave had a maximum 
of 15 mmHg and a minimum of 5 mmHg. At the end of the experiment, the 
concentration of the infusion fluid in the tubing was 5.82%. In the control 
loops, the thromboelastogram was not significantly different before and after 
running the control loops, but RL and CSF infusion provoked an activation of 
coagulation, which was more pronounced in the latter. Compared to the 
control loops, there was more clot formation on the catheters in the CSF loops 
and less in the RL loops. There was less clot formation on the side of the 
catheters facing the blood flow than on the side that was hidden from the 
blood flow. 
Discussion: the significant differences, depending on infusion fluid and side of 
the catheter relatively to the blood flow, indicate that infusion fluid, flow 
conditions and position of the catheter in the vessel are worth modeling. 
Introduction 
Catheters are widely used to gain vascular access. Examples are central venous 
catheters, atrial lines and ventriculovenous shunts. These devices may suffer 
from thrombotic complications, making thrombogenicity testing essential in 
their preclinical evaluation trajectory.  
The Chandler Loop, a reference in vitro model to evaluate hemocompatibility 
and clot formation on intravascular devices (1), consists of a circular closed 
tubing filled with blood and a small amount of air. When the loop is rotated at 
a constant speed, the air bubble - which remains at the highest point - 
generates a ‘blood flow’ (2). The set-up allows to evaluate catheter related 
factors such as biomaterial and design but does not allow to mimic several 





example is the flow rate. Catheters are often inserted in major vessels 
enduring a high flow rate. However, in the Chandler loop the flow rate is 
limited, because at higher rotation speeds, the air bubble starts to rotate 
together with the tubing (2). A second example is the infusion of fluids through 
the catheter. This is only possible when the catheter is inserted through the 
tubing wall. Although theoretically possible, a major disadvantage of this 
approach would be the exposure of the catheter to an air-blood interface 
while rotating together with the tubing (2). This causes mechanical hemolysis, 
leucocyte induction, platelet activation and non-physiological shear forces 
that will bias the results (2-4).  
Animal models do allow to evaluate relevant in vivo conditions. However, the 
clotting and platelet function of animals and humans are essentially different 
which may influence the tests results, especially when evaluating the 
hemocompatibility of small bore catheters (2, 5, 6). As such more reliable 
results are obtained using fresh human blood for the evaluation of 
thrombogenicity of medical devices (2, 5, 6). 
In this manuscript we present a new non-occlusive roller pump model that 
allows fluid infusion through the catheter and generation of a full range of flow 
conditions. The model was applied to the ventriculosinus shunt, an 
experimental treatment for hydrocephalus (7, 8). This shunt, that drains CSF 
from the brain’s ventricles towards a dural venous sinus, consists of 3 
components. Its proximal ventricular catheter and its unidirectional valve are 
generally accepted and routinely used components of CSF shunts, but its distal 
venous catheter still requires research concerning thrombogenicity before 
implementing it on a regular base in human medicine. We wanted to assess 






characteristics could have an impact on the amount of thrombus formation on 
the shunt.  
Materials and methods 
Experimental set-up 
The experimental set-up is shown in figure 1. 
Figure 1. Set-up of the roller pump model 
A syringe pump [1] injects the infusion fluid through a catheter [2] into the tubing [3] 
reflecting the blood vessel. The tube is closed by a T-formed connector [4] linked to a 
pressure transducer and an overflow line [5]. The overflow line compensates for the 
injected volume by draining an equal amount of the infusion fluid-blood mixture to a 
dripping chamber. Blood flow is generated by a semi-occlusive roller-pump [6]. 
Depending on the orientation of the roller pump [round arrows] the blood flow 
[straight arrows] will be directed with or against the direction of the flow in the 
catheter (in the drawing the blood flow and the flow in the catheter have opposite 
directions). The silicone tube is partially submerged in a bath containing water [7] that 





This set-up was used to evaluate the intravascular catheter of a 
ventriculosinus shunt. Specific characteristics of the in vivo situation are the 
infusion of CSF through the shunt, the high flow in the SSS (150 ml/min) and 
the position of the shunt, directed against the blood flow (‘retrograde’) (9). 
A syringe pump (Ohmeda 9000; GE Healthcare, Madison, USA) injected CSF 
through the catheter (‘shunt’) at a rate of 2 ml/h. To evaluate the influence of 
CSF infusion on thrombus formation, two other groups were defined: Ringer’s 
lactate (RL) infusion and no infusion (‘controls’, CTRL). The CSF used in the CSF 
group was obtained from a patient with a ventriculo-external drainage and 
had a total protein concentration of 25.7 mg/dl. In the control group the shunt 
was purged with RL and subsequently closed at the extravascular end to 
prevent blood from entering the lumen of the catheter. The shunt, made of 
Tecothane (Lubrizol; TT-1074 A; 1.3 mm inner diameter × 1.9 mm outer 
diameter, 30 mm length) was inserted through the tubing wall and advanced 
for 25mm into the tubing lumen. The tubing consisted of phosphorylcholine-
coated silicon (length: 1 meter, inner diameter: 6.35 mm, outer diameter: 9.52 
mm; PHISIO coating, LivaNova, Mirandola, Italy). Fresh blood was collected by 
standard venipuncture from two healthy donors and immediately heparinized 
with 0.7 IU/ml. After rinsing the tube with RL, it was filled with donor blood 
and closed by connecting both ends with a polycarbonate connector with a 
luer lock. An overflow line, connected to the luer lock, allowed to compensate 
for the injected infusion fluid volume by draining an equal amount of the 
blood-infusion fluid mixture to a dripping chamber. The chamber is positioned 
14 cm above the tubing which results in a pressure of 140 mm H2O (10.3 mm 
Hg or 1373 Pa) equal to the physiological pressure in the superior sagittal sinus 






Bornem Belgium) was connected to the luer lock. A roller-pump (LivaNova, 
Mirandola, Italy) is set at 15 rotations per minute (RPM). A dynamic occlusion 
setting was used to obtain a blood flow of 150 mL/min at 15 RPM or 75% 
occlusion. The accuracy of the occlusion was validated by a calibrated cylinder. 
This non occlusive setting is non traumatic to blood (11).  
The blood flow is opposite to the outlet of the shunt. The shunt outlet is thus 
positioned ‘retrograde’ (Figure 3). All tubing outside the pump housing is 
submerged in a water bath to maintain blood temperature at 37 °C.  
The concentration of the infusion fluid in the loop depends on the infusion 
rate (Q), the outflow of the blood-infusion fluid mixture and the total 
intravascular volume (Vtot) (Figure 2). The volume percentage of the infusion 
fluid (V%inf) at a given time (t) is obtained by the following formula: 
 
The infusion rate was 2 ml/h or 0.033 ml/min, the total intravascular volume 
32 ml (volume tubing = πr2 x l = π x (0.635 cm / 2)2 x 100 cm) and the duration 
of the test 60 minutes. Thus, at the end of the experiment the volume percent 
of the infusion fluid was 60 min*0.033 ml/min/(32 ml+60 min*0.033 
ml/min)*100% = 5.82%. Sixteen experiments were performed (6 with CSF, 6 
with RL, 4 CTRL) and lasted 60 minutes each. The experiments were performed 
in separate runs of 4. Each run contained blood from the same donor and at 
least one experiment of each group (CSF, RL and CTRL).  
 






Figure 2: Calculation of the volume percent of the infusion fluid at a given 
duration of the experiment.  
After infusion of the infusion fluid [1] it circulates through the tubing [2] were it is 
mixed with blood [curved arrows]. The blood – infusion fluid mixture is drained to the 
dripping chamber [3]. The intravascular blood-infusion mixture is identical to the 
mixture that is drained to the dripping chamber. By consequence draining to the 
dripping chamber does not change the ratio between blood and CSF in the 
intravascular compartment. 
Vinf: infused volume (ml); t: duration of the experiment (min); Q: infusion rate (ml/min); 
Cinf: concentration of the infusion fluid in the tubing; Vtot: total volume in the tubing; 
Vout: volume of the blood-infusion fluid that is drained to the dripping chamber. 
A Sonoclot® Coagulation Analyzer was used to evaluate changes in blood 
coagulation between the start and the end of the experiment. This apparatus 
gives three values, activated clotting time (ACT), clot rate (CR, conversion of 








Figure 3. Retrograde position of the shunt in the vessel.  
The shunts are implanted against the blood flow. Two sides of the catheter are 
visualized: the impact side, defined as the flank facing the blood flow and the wake-
side, defined as the 180 degrees opposite flank (away from the incoming blood flow). 
After termination of the experiment, the catheter was cut out together with 
the surrounding tubing wall (to prevent abrasion of deposits) and prepared for 
SEM imaging. Two sides of the catheter are visualized: the impact side, defined 
as the flank facing the blood flow and the wake-side, defined as the 180 
degrees opposite flank (away from the incoming blood flow) (Figure 3). The 
SEM images were corrected for projection effects by a script (MATLAB 
Simulink version 8.6) that applies the appropriate mathematical formulas to 





method is described in detail elsewhere (12). Next, at each side of the shunt, 
the surface covered with clots was delineated (ImageJ for Windows, Version 
150, available for download at https://imagej.nih.gov/ij/index.html) and 
expressed as a percentage of the visualized total surface at the same side 
(Ratioimpact and Ratiowake respectively). Based on these ratios, Ratiototal 
(Ratioimpact + Ratiowake) was calculated. 
Statistical analysis 
Statistical analysis was performed using a commercial software package (SPSS 
Statistics® IBM Corp., Released 2013, IBM SPSS Statistics for Windows, Version 
22.0, Armonk, New York, USA). Baseline Sonoclot® parameters were 
compared to those obtained at the end of the experiment by a non-parametric 
Mann-Whitney U test. The amount of visualized shunt surface covered with 
clots is compared between the different infusion fluids (CSF, RL or no infusion 
fluid) by a non-parametric Mann-Whitney U test. A one-sample t-test was 
used to evaluate differences in clot formation on the impact and wake sides 
of the shunt (Ratioimpact - Ratiowake).  
Statistical significance is set at 5%. 
Results 
Evaluation of the In vitro test-setup 
The non-occlusive roller pumps generated an average blood flow of 141 +/- 
7.5 ml/min. 
The pressure inside the tubing increased until draining to the spillover 
reservoir began after which the pressure remained stable throughout the 






mmHg and a minimum (‘diastolic’ pressure) of 5 mmHg. At the end of the 
experiment 1.46 +/- 0.15 ml was collected in the spillover reservoir. No 
leakages were observed during the experiments.  
Coagulation parameters 
Sonoclot parameters are presented in table 1. No statistically significant 
differences were found for the control group. However, after infusion of both 
RL and CSF, the CR and PF increased significantly. There was a trend towards 
an increase in ACT in the control (p=0.285) and RL group (p=0.138), but this 
trend was absent in the CSF group (p=1). 
Table 1. Comparison of the difference of ACT/CR/PF values before and after 
the experiments for CSF, RL and CTRL, grouped by infusion fluid. 
ACT, activated clotting time; CR, clot rate; CSF, cerebrospinal fluid; CTRL, control (no 
infusion fluid); med., median; PF, platelet function; RL, Ringer’s lactate solution; *, 
comparing the start and stop value (before and after the loop) yielded a p-value < 0.05. 
 
 infusion fluid 
Parameter 
[median] 
CTRL RL CSF 
 ACT [s] 41.0 44.0 0.0 
CR [-] 3.5 4.2* 6.3* 







Evaluation of clot formation on the catheter surface 
Clot formation, defined as red blood cells and platelets embedded in a fibrin 
network, was observed on the surface of all catheters. The amount of clot 
formation was evaluated by calculating the ratio between the surface of the 
shunt covered by debris and the total visualized surface (RatioClot).  
Parameter RatioClot [-] 
Donor 1 0.45 +/- 0.11 
Donor 2 0.53 +/- 0.14 
CTRL 0.68 +/- 0.15 
RL 0.63 +/- 0.14* 
CSF 0.88 +/- 0.05* 
Impact 0.42 +/- 0.08** 
Wake 0.50 +/- 0.09** 
Table 2: the ratio between the catheter surface covered with clots and the 
total catheter surface depending on blood donor, infusion fluid and catheter 
side.  
Ratioclot: ratio between the catheter surface covered with clots and the total catheter 
surface; CTRL: control, no infusion; RL: infusion of RL; CSF: infusion of CSF; Impact: side 
of the catheter facing the blood flow; Wake: side of the catheter away from the 
incoming blood flow. * and **: the difference between the marked parameters is 






We searched for differences in the amounts of clot formation depending on 
donor (donor 1 versus donor 2), infusion fluid (CRTL, RL versus CSF), or side of 
the catheter surface (impact- versus wake side). The values of RatioClot for the 
different groups are shown in table 2.  
RatioClot did not differ between the two donors (P-value = 0.6). However, 
differences were found depending on the infusion fluid. The differences 
between RL and CSF are statistically significant (P-value = 0.009).  
When the impact and the wake side of the catheters were evaluated 
separately, RatioClot was higher on the wake side of the catheters (statistical 
significant, P-value = 0.008).  
Discussion 
To our knowledge this is the first in vitro experiment that allows to mimic the 
in vivo conditions to which intravascular catheters are subjected: the infusion 
of fluids through the catheter, the position of the catheter in the vessel and a 
realistic flow rate.  
The set-up was applied to the venous catheter of a ventriculosinus shunt, an 
experimental treatment for hydrocephalus. An evaluation was performed to 
know whether the drainage of CSF and the local flow characteristics impact on 
the amount of thrombus formation on the shunt.  
The infusion of fluids proved to have an influence. There was a trend towards 
less clot formation in the RL group compared to the CTRL group. Probably early 
deposits on the shunt’s surface are ‘washed away’ by the infused fluid. 





compared to the RL group. This is in line with previous literature showing that 
CSF enhances coagulation (13).  
Also, the position of the catheter in the vessel and the (local) flow conditions 
proved to be important. There was significantly less clot formation on the side 
of the shunt that faces the incoming blood flow compared to the 180 degrees 
opposite side that is ‘hidden’ from the flow. When the streamlines hit the 
shunt surface they deflect and cause shear forces that might clear clots in an 
early stage. Directly downstream from the shunt, some of the running fluid 
separates from the stream lines and is submitted to turbulences and 
stagnation (14). This slow, non-laminar flow promotes clot formation (9). 
Strengths and weaknesses of the model 
The usage of blood from different donors is a possible source of bias. This was 
attenuated by performing a control loop (without infusion of fluid) with each 
portion of donated blood and by distributing the different loops (RL; CSF and 
CTRL) equally between the donors.  
The infusion of fluids results in hemodilution that may bias the results. In the 
experiment with the ventriculosinus shunt, hemodilution was controlled by 
limiting the duration of the loops to 60 minutes and the infused volume to 
2ml. 
Even after this relatively short experiment, impurities were observed on the 
surface of every shunt. This was satisfactory as early-stage reactions, that 
consist of the adherence of proteins and platelets, are known to mediate the 






The infusion rate of 2ml/h is significantly lower than the physiological drainage 
of CSF (21 ml/h). However, even with this small infusion rate, significant 
differences were found in the amount of clot formation between shunts 
infused with RL versus CSF.  
By limiting the duration of the experiment and the infusion rate, the volume 
percentage of the infusion fluid was only 5,88% at the end of the experiment. 
This is significantly lower than 9 – 11%, the percentage known to be the 
threshold for infusion fluids like CSF and RL to affect coagulation (15). 
However, the coagulation properties changed during the experiment: 
In case of RL or no infusion, the ACT and the CR both increased. ACT is a 
measure of initial fibrin formation and represents the intrinsic limb of the 
coagulation cascade. Higher post-test ACT values can be explained by 
deprivation of fibrinogen and consummation of clotting factors during the in 
vitro test. The CR value is a measure for the rate at which fibrin monomers are 
polymerized into fibrin strings. The CR value increases in al post-test blood 
samples. This can be explained by the activation of thrombin, due to the extra-
corporal circulation of blood (16). 
After the infusion of CSF, the ACT remains stable while the CR and PF both 
increase. This finding confirms the coagulation enhancing effect of CSF (13) 
which seems to be dominant over the roller pump effects.  
The impact of CSF on overall coagulability may have reinforced the CSF-blood-
foreign material interaction. However, the opposite is true for RL. Although CR 
and PF increased more in the RL group compared to control, less clot 
formation was observed on the shunts. Thus, the coagulability enhancing 







We present an in vitro experiment that allows to model the in vivo conditions 
to which intravascular catheters are subjected. The set-up allows infusion of 
fluids, correct positioning of the catheter and generation of realistic flow 
conditions. Applying the model on the intravascular catheter of a 
ventriculosinus shunt proved that these factors may have an influence on the 
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Abstract 
Surfaces of medical devices are typically evaluated by scanning electron 
microscopy (SEM) (1-13) (1-13), which generates 2D projections of 3D objects. 
The projected images of surfaces, not perpendicular to the direction of the 
projection, will be distorted and scaled. This impedes a quantitative 
assessment of surface irregularities (regions of interest, ROI). In this paper a 
Matlab Simulink® script is presented that corrects SEM images of cylindrical 
surfaces for the above projection effects. The accuracy of the script was 
verified by evaluating the same ROI in different locations on a cylindrical 
object. Any given projected ROI became progressively smaller when it was 
moved from the center to the periphery of the cylindrical surface. Thus, when 
expressed in relation to the total visualized surface, the ROI is overrated in the 
center and underrated in the periphery of the projected images. The relative 
difference, that was found to be as high as 60%, decreased to 10% after 
correcting the images. The script was then applied to an in vitro experiment. 
Analyzing the corrected images yielded results that were statistically strongly 






differences between the uncorrected and corrected images supports the 
conclusion that ROI tend to be located in the periphery of the cylindrical 
surface.  
Introduction 
Surfaces of medical devices can be evaluated for “regions of interest” (ROI) (1-
13). Specific examples of ROI are deposit formation in ventriculoperitoneal 
shunts, clot or biofilm formation on catheters and coating irregularities on 
coronary artery stents (1-13). This evaluation may be part of assessments of 
general biocompatibility and thrombogenicity, which are compulsory 
according to the relevant ISO standards (14).  
Surfaces of medical devices are typically analyzed by scanning electron 
microscopy (SEM). The generated SEM images, which are 2D projections of 3D 
objects, allow a qualitative evaluation (1-13). However, quantitative 
evaluation will be biased due to deformation and scaling of surfaces that are 
not perpendicular to the direction of the projection (15, 16).  
This paper investigates how projection affects evaluation of ROIs on cylindrical 
surfaces. It presents a Matlab Simulink® script that corrects the projected 
images to enable a more accurate quantitative assessment. 
Materials and methods 
Image correction 
It is assumed that the cylindrical object is mounted with its longitudinal axis 
perpendicular to the SEM’s direction of view. The generated image will be a 
projection of half of the cylinder. Surfaces situated away from the image 






Figure 1. Scaling of 
surfaces due to projection 
The grey and the black ROIs 
each cover an equal true 
surface of the cylindrical 
object. However, on the 
projected image plane, the 
grey surface is scaled to only 
one half of the black surface. 
 
 
The aim is to correct the projected image in a way that it corresponds with the 
projection of a cylinder that has been ‘unrolled’ to adjust for the projection 
distortion. The concept is shown in Figure 2. A circle segment s (length = βR, β 
in radians) will have a projected length k; k has to be corrected to k’, 
corresponding to the length of s. k’ is a function of k and β, as expressed in 
equation 1. Half a cylinder (radius R) has a real length of πR, which should be 
the total length of the projected segment. 
The length of k’ is given by k’(k,β) = βR = sin-1(k/R)R [equation 1], which is not 
a linear function (15, 16). Thus, the correction, needed when the projected 
circle segment is further away from the image center, will be more important.  
In computational terms the image transformation is implemented using 
matrices (Figure 3). Each element of the matrix corresponds to a pixel in the 
projected image. The number of rows correlates with the length of the 
longitudinal axis of the cylinder, while the number of columns correlates with 






elements, an 8 bit integer between 0 and 255, represents the grey value of the 
corresponding pixel.  
 
Figure 2. Correction of the projected image 
A segment s of a circle is vertically projected to k. Due to the projection, the original 
length of s is downscaled to the length of k. The aim is to correct the image, so that in 
the corrected image the length of k’ corresponds to the original length of the circular 
segment s 
A script (Matlab Simulink® version 8.6, MathWorks Inc., Natick, 
Massachusetts, USA) was written to transform the matrix of the projected 
image into a matrix that represents the unrolled image (15, 16). The corrected 
matrix will have more columns than the original, because the visualized total 
surface - half a cylinder - has a projected length of 2R while the unrolled length 






Figure 3. Image transformation using matrices. 
First, the projected image (not shown) is represented as a matrix (upper left) composed 
of 4 rows (longitudinal axis of the cylinder) and 23 columns (projection of the arc). The 
value of each of the resulting 92 pixels represents the grey value of the corresponding 
dot of the image. For visual reasons, only 0 and 1 are used. Second, the corrected 
matrix is generated (lower left). The corrected matrix has more columns than the 
original matrix and the original elements are progressively more spread out when 
going from the center to the periphery (principle of unrolling according to equation 1). 
The last row of the corrected matrix (letters a-k) at the bottom of the left image gives 
the column names. The empty columns in the matrix correspond to the black lines in 
the image (right, uncorrected side). Third, the value of the empty elements is 
calculated using a bilinear interpolation model that uses the average of the two 
adjacent translated pixel values. Finally, the corrected image is generated based on 
the corrected matrix (right, corrected side).  
The value of the elements of the additional columns (which are empty and 
need to be calculated) is calculated using a bilinear interpolation model, for 
which the code block uses the average of two adjacent translated pixels (15, 







A black dot is drawn on the surface of a cylinder (medical device) to determine 
a ROI using SketchUp® 2017 software (Trimble Inc., Sunnyvale, California, USA) 
(Figure 5). Starting with the circle in the center of the image, the cylinder is 
rotated counter clockwise in steps of 5° to move the ROI progressively to the 
periphery of the image. The maximal rotation angle is limited to 60° to prevent 
the circle from crossing the plane of view, which would bias the assessment. 
The surface areas of the projected cylinder and covering ROI are assessed 
using ImageJ® software (National Institutes of Health, 9000 Rockville Pike, 
Bethesda, Maryland 20892, USA) and the ratio between these surfaces is 
calculated. Both the uncorrected (‘projected image’) and corrected (‘unrolled 
image’) images are assessed and the difference between the obtained ratios 
is calculated. Likewise, the difference between the relative projected surface 
areas of the ROI in the center versus the periphery of the cylindrical surface is 
calculated.  
Practical example – implementation  
The setup of the in-vitro experiment is discussed in detail elsewhere (17). In 
summary, a roller-pump assures circulation of blood through a silicone tube, 
representing a blood vessel. A catheter, directed against the direction of the 
blood flow, was inserted through the tube wall (Figure 4). Two sides of the 
catheter are defined: the impact side, which is facing the incoming blood flow, 
and the wake side which is the 180° opposite flank (the side away from the 






Figure 4. Position of the catheters in the in-vitro experiment 
The catheter is inserted through the wall of a silicone tube that represents a blood 
vessel. The tip of the catheter is aimed against the direction of the blood flow (arrow). 
The impact side faces the blood flow. The wake side is the side away from the incoming 
blood flow. 
After the experiment, both the impact and wake sides of the catheters were 
evaluated by SEM imaging. The total shunt surface and the ROI (here the 
covering debris on the shunt) were delineated using the ImageJ® software 
package. An assessment was made before and after correction of the images, 
by two different investigators. Interobserver variability was ruled out by 
interobserver control methods (agreements on which ROI to delineate and 
delineation done by two independent observers). No trends or statistically 
significant differences were found between the observers. The area of the ROI 
was expressed as a percentage of the catheter’s total visualized surface 
resulting in “Ratio Impact” and “Ratio Wake”. “Ratio Total” was defined as the 
total surface of the ROI (cell debris) at both sides of the shunt divided by the 
total shunt surface. 
A statistical analysis was performed using SPSS Statistics® 22 (IBM Corp., 
Released 2013, IBM SPSS Statistics for Windows, Version 22.0, Armonk, New 






Total was objectified by one-sample Kolmogorov-Smirnov tests. A one-sample 
t-test was used to compare the ratios obtained before and after correction of 
the image. For all tests, statistical significance was set at 5% and strong 
statistical significance at 0.1%.  
Results 
Calculational example 
When the circle put upon the cylinder is projected to a 2D plane, it is observed 
as an oval object. After correction with the Matlab Simulink® script it is 
observed as a circle again (Figure 5). 
Starting with the circle in the center of the image, the cylinder is now rotated 
counterclockwise in steps of 5 degrees to see stepwise differences. The 
projected surface of the circle progressively decreases as it is displaced to the 
periphery of the image. This phenomenon is clearly less pronounced after 







Figure 5. Schematic representation of the calculational experiment  
Left: a cylindrical object, comprising a circular ROI, is turned to move the ROI from the 
image center (upper row) to the periphery (lower row). The degrees of rotation are 
limited to prevent the ROI to be rotated out of the field of view. 
Middle: After SEM projection along the Z-axis, both the total visualized surface and the 
circular ROI are represented distorted due to scaling along the X-axis. The circular ROI 
is represented as an oval. The distortion of the ROI is far more pronounced when the 
ROI is located in the periphery (lower row) versus the center (upper row) of the image.  
Right: The Matlab Simulink script corrects the SEM images. The total visualized surface 
(represented as a rectangle) is wider along the X-axis in the corrected images. The ROI 
is correctly represented as a circle.  












0 2.86619384 2.03183 
5 2.84230138 2.048334 
10 2.74130629 2.080918 
15 2.70761053 2.025509 
20 2.56965804 2.057953 
25 2.45784106 1.956758 
30 2.291043 1.950369 
35 2.11973143 1.938867 
40 1.89857141 2.024634 
45 1.71782113 1.941526 
50 1.49548276 1.801682 
55 1.31393807 1.828629 
60 1.07337045 1.829391 
 
Table 1: Influence of 
peripheral dislocation of the 
circular object on its 
projected surface.  
The projected surface of the 
circular object is expressed as a 




The projected relative surface of the circle is compared between the projected 
images and the unrolled images and expressed as a percentage of the total 
visualized surface. When the circle is in the central position, the relative 
surface is higher on the projected images. The opposite is true when the circle 
is located at the periphery of the projected surface. At 39.44° rotation, the 
relative surface area of the circle is equally observed on the projected and 









Figure 6. Results of the calculational experiment 
Left: Difference between the projected versus unrolled surface of the circular object, in 
function of the peripheral displacement. Right: The relative difference between the 
surface of the circular object in a given position (rotation angle X degrees) is compared 
to that in the central position (rotation angle = 0 degrees) for the projected images 
(solid dots and dashed line) and unrolled images (open dots and dashed line). This 
represents the scaling or error of the images and thus the opportunity for correction.  
As it is known that the circle has in reality the same surface area in both 
positions, the difference between the central and peripheral measurements 
represents the error of the image that has been used. The relative error made 
after assessment of the projected surface of the circle relatively to the total 
visualized surface is shown in Figure 6 – right side. The error increase is not 
linear: it increases faster towards the periphery of the image. The maximal 
possible rotation that still allowed visualization of the total circle is 60 degrees. 
The relative error at this point is 60% for the projected images versus 10% for 







Practical example to prove applicability 
The mean ratios obtained on the projected versus the unrolled images are 
shown in Table 2. The ratio was always higher when assessed on the unrolled 
images. The Ratio Difference (Ratio unrolled – Ratio projected) was clearly 
different from zero. This difference was strongly statistically significant (P < 
0.001).  
Table 2: The ratio of deposits expressed as a percentage of the total 
visualized surface as observed on the projected and unrolled images.  
 Projected  Unrolled Difference 
RatioImpact  0.43  0.69  0.26* 
RatioWake  0.52  0.77  0.25* 
RatioTotal  0.48  0.74  0.26* 
*P < 0.001 
Discussion 
Irregularities, deposits or ROIs in general on the surface of medical devices are 
typically evaluated by SEM (1-13), which generates 2D projections of 3D 
objects. Surfaces of the 3D object that are not perpendicular to the direction 
of the projection will be represented distorted and scaled on the final SEM 
image (15, 16). This phenomenon, if not corrected, impedes a quantitative 
assessment of the visualized irregularities. However, a quantitative 
assessment enables a more objective evaluation and statistical analysis. In the 
present paper, the effects of projection and the way to correct these are 
elaborated for cylindrical objects.  
The effects of projection are assessed by analyzing a circle with a fixed surface 





cylinder (modeling the medical device). The circle is progressively displaced 
from a central to a peripheral position (along the X-axis) on the cylindrical 
surface (Figure 5). The projected surface area of the circle decreases in a 
quadratic relation with the peripheral dislocation. This finding is explained by 
the progressive increase in angle between the cylindrical surface and the 
direction of the projection. In the very center of the cylinder (X = 0) this angle 
equals 90° (Figure 7). By moving away from the center, the angle increases 
progressively until it equals 180° in the extreme periphery. On the projected 
images, the very center of the cylinder will thus be represented at its true size, 
while the periphery is progressively underrated (Figure 7). So, the central 
image will be relatively overrated in comparison to the periphery and vice 
versa.  
The cylinder was mounted with its longitudinal axis parallel to the Y-axis, 
perpendicular to the direction of the projection (Z-axis). By consequence, 
moving the circle along the Y-axis will not affect the projected surface area. 
The fact that scaling occurs along the X-axis but not along the Y-axis results in 
distortion of the ROI. In our theoretical example, the circle is projected as an 
oval with the long axis being the original length along the Y-axis and the short 
axis the underrated length along the X-axis (Figure 7). 
When the angle between the surface of a medical device and the direction of 
the projection is fixed, the projection will affect both ROI and total visualized 
surface equally. In this case, a biased quantitative assessment can be 
prevented by expressing the surface of deposits relatively to the total 
visualized surface. However, in the experiment described above, the ratio 
between the surface area of the circle and the total visualized surface 






understand this phenomenon, one should study the absolute values that 
compose the ratio. The projection of the total visualized surface is a fixed value 
that equals 2R times the length of the cylinder. As described above, the 
projected surface of the circle (in Figure 5) and thus the ratio between the 
surface of the circle and the total visualized surface of the cylinder, decreases 
when the circle is moved towards the periphery of the cylinder.  
 
Figure 7. Projection effects 
Left: Scaling of a surface under a fixed angle with the direction of projection. The 
absolute values of a part of the surface and the total surface are altered equally by the 
projection. By consequence, the ratio between a part of the surface and the total 
surface is not altered by the projection. 
Right: Scaling of a cylindrical surface. The angle between the surface and the direction 
of the projection plane increases progressively from central to peripheral. As the 
surface will be scaled in function of the angulation with the direction of the projection, 
scaling of central parts of the cylindrical surface will be less pronounced than scaling 
of peripheral parts. By consequence, the ratio between a part of the surface and the 
total surface decreases from central to peripheral. 
It is important to note that when the circle is located in the center of the 
image, it will be less underestimated and when it is located peripherally it will 





ratio between the circle and the total visualized surface will be overrated 
when the circle is located in the image center and underrated when it is 
located at the periphery of the cylinder (Figure 7).  
These projection effects cause an important bias in the quantitative 
assessment when performed on the projected images: the relative difference 
between the surface ratio of the same deposit in a central versus peripheral 
position is around 60% when analyzed in a classical way. To prevent this biased 
measurement, the projected images are corrected to correspond to half a 
cylinder that has been unrolled onto a plane. A Matlab Simulink® script was 
written to apply the appropriate formulas (see equation 1) (15, 16). After 
applying the script, the oval projection of the circle is corrected to represent a 
circle again and the relative difference between the surface ratio of the same 
ROI in a central versus peripheral position decreased to 10%, thus decreasing 
the error significantly. These findings proof both the accuracy of the script and 
the importance of the correction to obtain unbiased quantitative analyses.  
The impact of the Matlab Simulink® correction is illustrated by applying the 
script to SEM images of catheters that have been in contact with blood during 
an in-vitro experiment. The amount of shunt surface covered with clots was 
statistically strongly different when assessed on the projected versus the 
unrolled images. Additional information about the distribution of the deposits 
was obtained by combining both results: the ratio between the total surface 
of the deposits and the total visualized surface is always significantly higher 
when assessed on the corrected images. As described above, central clots will 
be overrated while peripheral clots will be underrated when these are 






Simulink® correction indicate that clot formation occurred predominantly on 
the peripheral parts of the catheters. This correlates with the influence of the 
blood flow that hits the very center of the shunt’s impact side with maximal 
power, washing away adsorbed proteins and platelets. Further away from the 
midline, the blood will be diverted resulting in a slow non-laminar flow and 
even turbulence which predisposes to clot formation (18).  
Conclusion 
Quantitative assessment of irregularities, deposits and ROIs in general on a 
cylindrical surface are biased when performed on SEM images due to 
projection effects. This bias can be overcome by accurately calculated 
correction of the projected images. By comparing the uncorrected and 
corrected images, information about the distribution of ROIs can be obtained. 
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Abstract 
Object: The effect of CSF on blood coagulation is unknown. Enhanced 
coagulation by CSF may be an issue in thrombotic complications of 
ventriculoatrial and ventriculosinus shunts. This study aims to assess the effect 
of CSF on coagulation and its potential effect on thrombotic events affecting 
ventriculovenous shunts. 
Methods: Two complementary experiments are performed. In a first static 
experiment, the effect on coagulation of different CSF mixtures is evaluated, 
using a viscoelastic coagulation monitor. A second dynamic experiment 
confirms the amount of clot formation on the shunt surface in a modified 
Chandler loop. 
Results: CSF concentrations of 9% and higher significantly decrease the 
activated clotting time (ACT) (164.9 s at 0% CSF; 155.6 s at 9% CSF; 145.1 s at 
32% CSF). Increased clot rates (CR) are observed starting at a concentration of 
5% (29.3 at 0% CSF, 31.6 at 5% CSF; 35.3 at 32% CSF). The modified Chandler 






deposits when the shunts are infused with CSF instead of Ringer’s lactate 
solution (90% versus 63%). The amount of clot formation at the side facing the 
blood flow or ‘impact side’, tends to be lower than at the side facing away 
from the blood flow or ‘wake side’ (71% versus 86%). 
Conclusion: Addition of CSF to blood accelerates coagulation. The interaction 
CSF-blood-foreign material promotes clot formation which may result in 
thrombotic shunt complications. Further development of the 
ventriculovenous shunt technique should focus on preventing CSF-blood-
foreign material interaction and stagnation of CSF in wake-zones. 
Introduction 
The effect of CSF on blood coagulation is not well established. Some authors 
suggest that CSF may enhance hemostasis as it contains proteins such as 
fibrinogen and tissue factor that may activate the clotting cascade (1-3). This 
prothrombotic status is an advantage in case of brain injury or subarachnoid 
hemorrhage but could be potentially harmful when CSF is shunted to the 
venous system as happens for the treatment of hydrocephalus (4).  
Ventriculoatrial shunts have a similar effectiveness and complication rate as 
ventriculoperitoneal shunts (5-8). However, thromboembolic complications 
are one of the reasons that most neurosurgeons reserve the former technique 
to patients in whom ventriculoperitoneal shunts are contra-indicated or not 
successful (4).  
Ventriculosinus shunts have several advantages over the classical 
ventriculoperitoneal or ventriculoatrial shunts. First, overdrainage is 
prevented by maintaining the natural, self-regulating anti-siphon effect of the 





confined to the skull, which minimizes the risk of mechanical failure and 
infection4. While some authors describe excellent long term results, others 
report that obstruction due to clot formation in and around the distal shunt 
tip remains an issue (10, 11). 
The impact of the CSF-blood-shunt interaction on this kind of thrombotic 
complications is still under debate. CSF, due to its composition, may enhance 
clot formation (1-3). To attenuate clot formation, some authors recommend 
to implant the ventriculosinus shunts with the tip opening directed against the 
blood flow (‘retrograde’) in order to deviate the CSF flow around the distal 
shunt tip. The resulting ‘constantly renewing CSF sleeve’ is believed to be 
protective against clot formation (10). 
The present study assesses the impact of CSF on blood coagulation and the 
impact of CSF-blood-foreign material interaction on thrombotic shunt 
complications. 
Materials and Methods  
Two complementary experiments are performed: a static experiment to 
evaluate the impact of CSF on the coagulability of blood and a dynamic 
experiment to assess the impact of CSF on clot formation on an intravascular 
shunt. 
Static experiment 
The study protocol is approved by the independent ethics committee of the 
Ghent University Hospital (registration number EC/2016/0560). Participation 
in the study is proposed to every patient – not threated with anticoagulants 
or antiplatelet drugs – undergoing a lumbar puncture (LP) or 






trisodium citrate/L, Terumo, Heverlee, Belgium) are collected from each 
patient. As the puncture itself may contaminate the first sample of each 
patient, these first samples are never used for the study. Immediately after 
the collection of at least a second sample from any selected patient, CSF is 
added to blood from the same patient in increasing concentrations (Table 1).  
Table 1. Preparation of the 5 different blood-CSF mixtures.  
Mixture no. 1 2 3 4 5 
Blood (µL) 900 900 900 900 900 
Buffered Trisodiumcitrate  
0.109 mole/L (µL) 
100 100 100 100 100 
Calcium solution (µL) 40 40 40 40 40 
CSF (µL) 0 10 50 100 500 
V% CSF (= VCSF/VTotal x 100%) 0 0.952 4.587 8.772 32.468 
V CSF / V blood (%) 0 1.111 5.556 11.111 55.555 
The different blood-CSF mixtures are recalcified (40 µL of 0.25 mol/L CaCl2 
solution) and analyzed by a Sonoclot® Coagulation Analyzer (Sienco®, Arvada, 
CO, USA). The Sonoclot® signature reflects the viscoelastic changes during the 
transition from liquid whole blood to a solid blood clot (Figure 1). It consists of 







Figure 1. Sonoclot signature. 
The activated clotting time (ACT) is how long the sample completely stays in the liquid 
phase and corresponds to the time necessary for fibrinogen to be conversed to fibrin 
monomers. The clot rate (CR) is the slope of the second peak/plateau of the curve 
which corresponds to the polymerization of fibrin monomers: the faster the fibrin 
polymerization, the steeper the slope. The platelet function (PF) is determined by the 
time to the peak (TP), to which it corresponds inversely proportionally, and by the peak 
amplitude (PA) of the curve, to which it corresponds proportionally. It represents the 







Dynamic in vitro experiment  
The experimental setup, that is described in detail elsewhere (12), is shown in 
figure 2.  
 
Figure 2. Setup of the dynamic experiment. 
A silicone tube filled with blood simulates a blood vessel. Circulation of blood is 
achieved by a roller-pump. The tubing is partly submerged in a warm water bath to 
maintain a blood temperature of 37 °C. A catheter (‘shunt’) is inserted through the wall 
of the tubing and connected to a syringe pump. This pump simulates the hydrocephalic 
lateral ventricle and ensures infusion of CSF or RL. To compensate for the infused 
volume, an overflow tank is connected. 1 syringe and syringe pump, 2 shunt catheter, 






A roller-pump, set in non-occlusive modus, circulates heparinized whole blood 
(collected from two healthy donors) through a phosphorylcholine-coated 
silicon tubing (LivaNova, Mirandola, Italy) that is partly submerged in warm 
(37°C) water. A syringe pump infuses a Ringer’s lactate (RL) solution or CSF 
(collected from a patient with a ventriculoexternal drainage) through a 
Tecothane (Lubrizol, Ohio, USA) catheter (‘shunt’) that is inserted through the 
wall of the tubing. The control shunts (no infusion) are purged with RL and 
subsequently closed at the extravascular end to prevent blood from entering 
the lumen of the shunt. The infused volume is compensated by an overflow 
tank. The blood flow goes against the direction of the shunt insertion, the 
shunts are thus oriented ‘retrograde’ (Figure 3).  
 
Figure 3. Shunt insertion in tubing and definition of impact and wake side. 
The tip of the shunt is directed against the blood flow or ‘retrograde’. The solid black 
arrows represent the direction of the blood flow in the tubing, whereas the white 
arrows represent the direction of the infusion of CSF or RL. The impact and wake sides 
of the shunt are defined relatively to the direction of the blood flow.  
Each Chandler loop runs for 60 minutes. A total of 13 loops are performed (5 






The coagulability of the pure blood at the beginning of the experiment is 
compared to that of the infusion fluid - blood mixture at the end of the 
experiment by a Sonoclot® Coagulation Analyzer. 
At the end of the experiment, the shunts are removed together with the 
surrounding tubing wall and prepared for scanning electron microscopic (SEM) 
evaluation. The samples are mounted in a horizontal position and analyzed 
with an 18-fold magnification. Two sides of the shunt are visualized: the 
impact side, defined as the flank facing the blood flow and the wake-side, 
defined as the 180 degrees opposite flank (away from the incoming blood 
flow).  
SEM images are 2D projections of 3D cylindrical objects. As can be seen in 
figure 4, debris more distant from the image center present a smaller 
projection surface than debris closer to the midline section, although in reality 
both can have the same surface area. 
To correct for this bias, a specific script, written in MATLAB Simulink version 
8.6 is executed. This script applies, to the projected surface areas, the 
appropriate mathematical formulas to simulate to ‘unroll’ the cylinder instead 







Figure 4. Bias due to 2D projection of a cylindrical object. 
Two depositions that cover an equal true surface of the shunt are shown (black 
and light grey surface). On the projected scanning electron microscopic image, 
the outlined surface resembles only half as big as the solid surface due to 2D 
projection of the cylindrically shaped surface 
At each side, the surface covered with clots is delineated (ImageJ for Windows, 
Version 150, available for download at https://imagej.nih.gov/ij/index.html) 
and expressed as a percentage of the visualized surface at the same side 
(Ratioimpact = Aclot impact/Aimpact x100%; Ratiowake = Aclot wake/Awake x100%). Next, the 
total surface of the clots (impact side + wake side) is expressed as a percentage 
of the visualized total surface (Ratiototal = (Aclot impact + Aclot wake) /(Aimpact + Awake) 
x100% ) 
Statistical analysis 






In the static experiment, a parametric paired two-sample t-test is used - after 
objectifying normality - to compare each of the Sonoclot parameters (ACT, CR 
and PF) of pure blood (0% CSF) with those of the different blood-CSF mixtures 
(1%, 5%, 9% and 32% CSF). 
In the dynamic experiment, the Sonoclot parameters of the donor blood 
before the start of the experiment are compared to those of the blood-
infusion fluid mixture after the experiment by a non-parametric Mann-
Whitney U test. The amount of visualized shunt surface covered with clots is 
compared between the different infusion fluids (CSF, RL or no infusion fluid) 
by a non-parametric Mann-Whitney U test. A one-sample t-test is used – after 
objectifying normality – to evaluate if there is a difference between clot 
formation on the impact and the wake sides of the shunt (Ratioimpact - 
Ratiowake).  
Statistical significance is set at 5%. 
Results  
Static study 






Table 2. Study population characteristics 
AD, Alzheimer’s disease; APTT, activated partial thromboplastin time; CD, cognitive 
dysfunction; CP, cerebral palsy; CSF, cerebrospinal fluid; CVA, cerebrovascular 
accident; ELD, external lumbar drainage; FTD, frontotemporal dementia; INR, 
international normalized ratio; LP, lumbar puncture; MS, multiple sclerosis; N/A, 
information not available; NOSD, neuromyelitis optica spectrum disorder; PTT, 
prothrombin time; SAH, subarachnoid hemorrhage; VED, ventriculoexternal drainage; 
WM, white matter lesions. 
pat age  CSF  diagnosis platelets Protein  Coagulation  
 (y)   (103/µL) (mg/L) (INR, APTT, PTT) 
1 59 LP FTD 201 38.6 Normal 
2 59 LP CP 201 50.0 Normal 
3 43 LP WM 227 25.2 Normal 
4 29 ELD rhinoliquorrhea N/A 71.5 N/A 
5 68 LP NOSD 307 151.9 N/A 
6 47 LP CD 637 40.5 N/A 
7 48 LP Vasculitis 253 115.2 Normal 
8 50 LP CVA 183 58.1 Normal 
9 61 VED SAH 394 N/A Normal 
10 70 VED SAH 413 N/A Normal 
11 68 LP Neurosyphilis 178 41.4 Normal 
12 70 LP AD 105 N/A Normal 
13 39 LP Narcolepsy 235 18.6 Normal 
14 58 LP AD 180 N/A Normal 
15 19 LP MS 260 17.5 Normal 
 
The results of the Sonoclot® coagulation analysis of the different blood-CSF 






Table 3. Results of the patient study and comparison of ACT/CR/PF values for 
different CSF concentrations in the blood-CSF mixtures. 
ACT, activated clotting time; CR, clot rate; CSF, cerebrospinal fluid; PF, platelet 
function. *P < 0.05. 
 % of CSF 
Parameter 0.0 1.0 5.0 9.0 32.0 
ACT (mean) 164.9 160.4 158.9 155.6* 145.1* 
CR (mean) 29.3 30.9 31.6* 31.3* 35.3* 
PF (mean) 3.7 3.8 3.3 3.5 4.1 
CSF concentrations of 9% and higher significantly decrease the ACT and CSF 
concentrations of 5% and higher significantly increase the CR. No significant 
effect on the PF is found. 
Dynamic in vitro experiment (modified Chandler loop) 
Hemodilution. The concentration of the infusion fluid increases during the 
experiment and depends on the infusion rate trough the shunt and the 
evacuation of the infusion fluid-blood mixture by the overflow tank. The 
calculated concentration of the infusion fluid at the end of the experiment 
equals 5.88%, as each loop runs for 60 minutes, the total blood volume is 32 
ml and the infusion rate is set at 2 mL/h (12). 
Sonoclot® coagulation analyzer. The differences of the Sonoclot parameters 







Table 4. Comparison of the difference of ACT/CR/PF values before and after 
the experiments for CSF, RL and CTRL, grouped by infusion fluid. 
ACT, activated clotting time; CR, clot rate; CSF, cerebrospinal fluid; CTRL, control (no 
infusion fluid); med., median; PF, platelet function; RL, Ringer’s lactate solution. 
*P < 0.05. 
 
 Infusion fluid 
Parameter CSF RL CTRL 
ACTdifference (med.) 0.0 44.0 41.0 
CRdifference (med.) 6.3 4.2* 3.5 
PFdifference (med.) 2.3 1.4 1.0 
 
The ACT is higher after the experiment in the RL and CTRL group. In the CSF 
group there is no difference (before - after) for the ACT. Both the CR and the 
PF increase during the experiment and this increase is more pronounced in 
the CSF group. 
Differences in clot formation in function of infusion fluid. RL-infused shunts 
show less clots and CSF-infused shunts show more clots than control shunts. 







Table 5. Impact of the infusion fluid on the amount of clot formation on the 
different shunt surfaces (Ratioimpact, Ratiowake or Ratiototal).  
The amount of clot formation tends to decrease when shunts are perfused with RL but 
tends to increase when shunts are perfused with CSF. Clot formation on CSF-perfused 
shunts is significantly higher than on RL-perfused shunts (marked with an asterisk). 
Statistical significance was also reached when the Ratiowake of CTRL shunts was 
compared to that of CSF-perfused shunts (marked with a double asterisk). 
CSF, cerebrospinal fluid perfused shunts; CTRL, control (no infusion fluid); med., 
median; RL, Ringer’s lactate perfused shunts; Ratioimpact, total surface of clots on the 
impact side divided by the total visualized surface of the impact side of the shunt; 
Ratiowake, total surface of clots on the wake side divided by the total visualized surface 
of the wake side of the shunt; Ratiototal, total surface of clots on the impact + wake side 
divided by the total visualized surface of the impact + wake side of the shunt 
 
 Infusion fluid 
Parameter RL CTR  CSF 
Ratioimpact (med.) 0.59 0.62 0.89* 
Ratiowake (med.) 0.71 0.75 0.93** 





Figure 5 shows the differences between the ratios, depending on the 
infusion fluid. 
 
Figure 5. Boxplot of different ratios separated for infusion fluid. 
For each infusion fluid the different ratios are displayed as a boxplot. Ratio impact, total 
surface of clots on the impact side divided by the total visualized surface of the impact 
side of the shunt; Ratiowake, total surface of clots on the wake side divided by the total 
visualized surface of the wake side of the shunt; Ratiototal, total surface of clots on the 
impact + wake side divided by the total visualized surface of the impact + wake side of 
the shunt); CSF, cerebrospinal fluid; RL, Ringer’s lactate solution; CTRL, control group 






Ratioimpact, Ratiowake and Ratiototal are significantly higher for CSF shunts in 
comparison with RL shunts. Ratiowake is significantly higher for CSF shunts in 
comparison to control shunts. 
Orientation. Considering CSF and RL shunts to be one group, Ratioimpact (med. 
= 0.71) tends to be lower than Ratiowake (med. = 0.86). The difference is 
statistically not significant (borderline: P = 0.067). 
Discussion 
The effect of CSF on blood coagulation may be an issue in thrombotic 
complications of ventriculoatrial and ventriculosinus shunts (4). 
Ventriculoatrial shunts have a similar effectiveness and complication rate as 
ventriculoperitoneal shunts (5-7, 13). However, thromboembolic 
complications are one of the reasons that most neurosurgeons reserve the 
former technique for patients in whom ventriculoperitoneal shunts are 
contraindicated or not successful(4). The ventriculosinus shunt is a promising 
new treatment for hydrocephalus. However, obstruction due to clot formation 
in and around the distal shunt tip remains an issue (10, 11).  
To assess the effect of CSF on blood coagulation and the role of the CSF-blood-
shunt interaction in distal shunt obstruction, two complementary experiments 
are performed. 
The first experiment evaluates the effect of CSF on the thromboelastogram by 
analyzing different blood-CSF mixtures. The second, a modified Chandler loop, 







Influence of CSF on hemostasis 
The first experiment shows that adding CSF to blood makes blood 
hypercoagulable. This is demonstrated by accelerated conversion from 
fibrinogen to fibrin after CSF addition and gradual shortening of the ACT. These 
effects become statistically significant at CSF concentrations of at least 5-9%. 
Interestingly the same critical concentration is found in the modified Chandler 
loop. The increase in CR and the higher platelet activation are most likely due 
to thrombin formation on the surface of the activated platelets (14) and is only 
found in the group where CSF was infused.  
It is unclear which factors contribute to the influence of CSF on hemostasis. 
CSF contains coagulation proteins and tissue factor, a potent activator of the 
extrinsic coagulation pathway (15). In healthy individuals, there is an 
imbalance between the CSF concentration of tissue factor and that of tissue 
factor pathway inhibitor, making CSF procoagulant. Apart from these clotting 
factors, immunoglobulins and other immunological factors like C3 can cause 
neuro-inflammation leading to a procoagulant state (1). In pathological 
conditions, the concentration of coagulation proteins and the imbalance 
between tissue factor and tissue factor pathway inhibitor even increase, 
resulting in a more pronounced procoagulant effect of CSF (16). Apparently, 
further research is necessary to elucidate this mechanism. 
Based on our results we can endorse the finding of clinical series that under 
normal circumstances shunting CSF to the dural venous sinuses or superior 
vena cava will not lead to sinus or caval thrombosis (17, 18). Concentrations 
of CSF in the superior sagittal sinus and superior caval vein are below 5%, as 
CSF inflow is approximately 0.35 mL/min for a blood flow of more than 200 






enhancing effect of CSF can be problematic. Typical situations are contact 
between CSF and foreign material, accumulation of CSF in ‘wake’ zones and 
formation of a CSF-blood mixture in the distal shunt tip at higher than 
physiologically harmless concentrations. 
Foreign material 
Some authors implant the ventriculosinus shunt against the direction of the 
blood flow. CSF drained by a shunt in this position will flow along the shunt’s 
surface resulting in a ‘constantly renewing CSF sleeve’ (Figure 6). This CSF 
sleeve is believed to protect against clot formation by preventing adherence 
of proteins and platelets to the foreign material’s surface (10, 20). 
 
Figure 6. CSF sleeve effect. 
The white arrows represent the CSF ‘sleeve’. This sleeve is formed by CSF draining along 
the shunt surface due to the blood flow that is oriented in the opposite direction. The 
solid black arrows represent the direction of the blood flow in the blood vessel.  
The protective effect of a constantly renewing ‘fluid sleeve’ is confirmed by 
the reduced clot formation on RL-infused shunts compared to controls. 
However increased clot formation was observed on CSF-infused shunts. So, a 
CSF fluid sleeve is – contradictory to the protective effect of a fluid sleeve in 





proteins such as fibrinogen, fibronectin and globulins. Once adhered, these 
will attach platelets through the GPIIb/IIIa platelet receptor which mediates 
the further coagulation process (14, 21).  
Wake zones 
A wake zone, characterized by a slow and non-laminar flow, develops directly 
distally to an object placed in the bloodstream (Figure 7) (20). 
 
Figure 7. Hydrodynamic principles of flow past a cylindrical object. 
When a cylindrical object is placed in the blood flow, blood will wrap around the object. 
When it reaches the broadest point of the object, blood will detach from the surface. 
At this point it will be dragged towards the wake side which causes a slow and non-
laminar flow. 
The current study endorses the hypothesis of previous literature that, due to 
the characteristic flow conditions, more clot formation occurs on the ‘wake 
side’ of a shunt (4, 19). This procoagulant effect may be reinforced when CSF 
is drained to a wake zone. The local slow and non-laminar flow may result in 
accumulation of CSF which promotes hemostasis. 
Distal shunt tip 
When blood regurgitates into the shunt system, it will become stagnant and 






blood-CSF mixture in the distal shunt system may even increase this risk 
further.  
In the absence of a one-way valve, regurgitation of blood may occur due to a 
sudden increase of the pressure in the superior sagittal sinus or a decrease of 
the ICP (Valsalva maneuver or lumbar puncture respectively) (22, 23).  
Shunt material and design 
Several shunt related factors, such as material and design, may have an 
influence on clot formation.  
The shunt material should be bio- and hemocompatible. Silicone and 
polyurethanes are typical materials with a suitable profile (24). In this study, 
Tecothane, a non-coated aromatic polyether urethane, is used. Although 
Tecothane is known to have a superior hemocompatibility (25), clot formation 
was visualized on the surface of all shunts. Different coatings may be used to 
further reduce the thrombogenicity of biomaterials (26). Typical examples are 
phosphorylcholine and heparin (26, 27). Phosphorylcholine may counteract 
the procoagulant effect of CSF by preventing protein adhesion to the foreign 
material’s surface (27, 28). Heparin eluting and non-eluting coatings exist(26). 
Heparin eluting coatings have a limited duration of action and are developed 
to reduce clot formation in the acute setting (26). There is good quality 
evidence that a heparin eluting coating - which has mainly been evaluated on 
central venous catheters in children – has no beneficial effect on catheter 
patency (29, 30). Heparin non-eluting coatings have theoretically a permanent 
antithrombotic effect and are known to reduce thrombus formation on 
vascular grafts and vascular stents (26). In conclusion, both a 





the general thrombogenicity of venous shunts and may also counteract the 
procoagulant effect of CSF. 
Besides the material, also the shunt design might affect the amount of clot 
formation. The results of this study indicate that wake zones should be held 
as small as possible, contact between CSF and shunt material should be 
minimized and CSF should be prevented from entering the distal shunt tip. 
Wake zones can be reduced by reducing the volume of the intravascular 
catheter. Contact between CSF and shunt material can be minimized by not 
implanting the shunt retrograde. Ideally the distal shunt tip should be oriented 
perpendicular to the blood flow (neutral position). In this way CSF will not 
drain along the shunt surface nor will it drain to wake zones. CSF can be 
prevented from entering the distal shunt tip by using a one-way valve and 
keeping the compliance of the shunt system distal to the valve minimal. 
Strengths and limitations of the study 
To our knowledge this is the first study to address the question as to how the 
interaction between CSF, blood and foreign material affects clot formation.  
Especially the combination of a static and a dynamic experiment is a strong 
point of this study.  
The static experiment is designed to minimize confounding factors. The blood 
and CSF come from the same donor to exclude possible immunological 
reactions due to incompatibility. The coagulation tests are not disturbed 






The dynamic experiment is designed to approximate the in vivo situation. 
Special attention is paid to the flow conditions, the position of the shunt in the 
vessel and the infusion of CSF through the shunts.  
However, not all the aspects of the in vivo situation are modeled. The 
influence of the endothelium covering the wall of the blood vessel is maybe 
the most important factor that is not addressed. An intact endothelium 
counteracts coagulation, but when the endothelium is damaged or irritated, it 
releases thrombogenic factors(4, 31). Endothelial damage is unavoidable 
when the shunt is implanted. Irritation may occur at the insertion site of the 
shunt and at the shunt tip when positioned against the vessel wall.  
Although the duration of the dynamic experiment is limited by the progressive 
dilution and degradation of blood products, clot formation is visualized on all 
shunts. This early-stage reaction consists of the adherence of proteins and 
platelets and is known to mediate the further coagulation process (14). 
Over-dilution is avoided by maintaining the concentration of the infusion fluid 
beneath 6%, which is well below the concentration of 11% that is known to 
have an influence on hemostasis(32). 
Conclusions  
Adding CSF to blood enhances coagulability starting from a concentration of 
5-9%. When CSF is shunted to the venous system, concentrations are generally 
below this critical threshold. However, in some specific situations CSF may 





To prevent clot formation around the shunt tip (external shunt obstruction), 
contact of CSF with the outer shunt surface and accumulation of CSF in wake-
zones should be avoided.  
To prevent luminal clot formation (internal shunt obstruction), blood should 
be prevented from entering the shunt tip using an appropriate one-way valve.  
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Chapter 8. Evaluation of the efficacy of novel hydrocephalus 
treatments  




This thesis is a first step in a larger research project aiming at the development 
of a new, long-lasting VS shunt. New prototypes can be evaluated, with regard 
to dimensions, implantation technique, safety and tolerance, in the non-
hydrocephalic experimental goat model presented in Chapter 5. However, in 
order to be able to evaluate the (long term) efficacy of new prototypes to treat 
hydrocephalus, a hydrocephalic model will be necessary. 
Manuscript 6 presents a hydrocephalic goat model to evaluate the short- and 
long-term efficacy of a new VS shunt. To approximate the treatment 
conditions in humans, a model of non-obstructive hydrocephalus is 
preferable.  
At present, the most frequently used technique to induce hydrocephalus is a 
cisternal injection of kaolin (1, 2). The technique is generally referred to as 
being simple, reproducible and inexpensive (1, 2). It was recently used in 
various species, including rats (3), dogs (4) and sheep (5). Based on the above 
we decided to apply this technique to the goat model. Two different injection 
sites were evaluated: the interpeduncular cistern (6) and the cisterna magna 
(7-9).  As described in the manuscript, the technique effectively produced 






the chemical meningitis, caused by kaolin to provoke hydrocephalus, was 
considered unacceptably high. This issue is seldom reported as a major finding 
in previous literature. In fact, the issue was ‘extracted’ from previous literature 
by a post hoc review of the experimental data. In this way we also found that 
small animals like mice and rats seem to tolerate the kaolin injection better 
than larger animals like dogs and sheep. To our knowledge, this finding was 
not published before.  
Manuscript 6 thus not only reports on the details of the kaolin injection 
technique and the character of the resulting hydrocephalus, it also addresses 
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Abstract 
Hydrocephalus is treated with ventriculo-peritoneal or ventriculo–atrial 
shunts, which have a failure rate of 50% in the first two years. A hydrocephalic 
large animal model is presented that allows evaluation of novel treatments. 
Hydrocephalus was induced in 9 female domestic dairy goats (Saanen breed) 
by injection of a 25% kaolin/sodium chloride solution into the interpeduncular 
cistern (IC) (n=3) or into the cisterna magna (CM) (n=6). The animals 
developed a severe aseptic meningitis that was expressed clinically by reduced 
food intake, refusing to stand, spasticity of the legs, pressing of the head and 
for some animals even seizures. Two out of 9 animals (22 %) died before 
hydrocephalus could be diagnosed. Six of the remaining 7 animals (86 %) 
developed hydrocephalus. The increase in intracranial pressure was 
comparable between the two groups (9.3 mmHg to 15.1 mmHg). Two of the 3 
animals of the IC group and none of the animals of the CM group developed 
ventricular dilatation. In contrast with other species, an outflow channel 
between the spinal central channel and the lumbo-sacral subarachnoid space 






ventricular outflow and thus the development of obstructive hydrocephalus. 
This anatomical characteristic makes goats especially suited for the 
development of a model of non-obstructive hydrocephalus. However, the 
kaolin injection provoked a pronounced aseptic meningitis that had an 
unacceptable high clinical impact and clearly overshadowed the resulting 
hydrocephalus symptoms. The development of better tolerated techniques 
may be the subject of further research. 
Introduction 
Hydrocephalus, the accumulation of CSF in the brain, can be caused by 
obstruction of the CSF flow within the ventricular system (obstructive 
hydrocephalus), by an impeded CSF flow through the distal arachnoid spaces 
or by damage to the normal resorption capacity (the two latter being non-
obstructive, communicating or malresorptive hydrocephalus) (1). Obstructive 
hydrocephalus is treated by endoscopic third ventriculostomy, while the 
current treatment of non-obstructive hydrocephalus consists of drainage of 
CSF to the peritoneal cavity or to the right atrium of the heart by a ventriculo-
peritoneal or ventriculo-atrial shunt (2). An important drawback of such 
shunts is siphoning: in a sitting or standing position of the patient, the CSF 
column within the catheter – through gravity – exerts suction, leading to 
shunt-related intracranial hypotension and aspiration of choroid plexus into 
the proximal catheter (3). Intracranial hypotension causes headaches, nausea, 
vomiting and even subdural hematomas while aspiration of choroid plexus is 
a major cause of shunt obstruction (2). The rate of shunt failure - necessitating 
surgical revision - remains as high as 50% in the first 2 years, despite the usage 
of expensive resistance valves and anti-siphon devices (4). As shunt failure is 





that there remains a rationale for ongoing hydrocephalus research (5). To 
evaluate current and novel treatment techniques a suitable animal model will 
be indispensable (6). A large animal model is more suitable than canine models 
described in earlier studies as the dimensions of larger brain ventricles allow 
the usage of shunt systems that are similar in size and design to their 
counterparts for human use (7). A non-hydrocephalic goat model, allowing to 
evaluate whether a new technique for hydrocephalus treatment is feasible, 
safe and well tolerated, has been described in previous literature (6). 
However, to evaluate the long term efficacy of any new solution, a 
hydrocephalic model will be unavoidable (6). To approximate human 
treatment conditions, a model of non-obstructive hydrocephalus is 
preferable.  
This paper reports on the technique and results of the induction of 
hydrocephalus in goats by kaolin injection. Two different injection sites were 
evaluated: the interpeduncular cistern (8) and the cisterna magna (9-11).  
Materials and methods 
Animals 
The study was designed as a pilot study to identify a suitable hydrocephalic 
large animal model to evaluate hydrocephalus treatments. The species was 
selected based on anatomical characteristics. In pigs and cattle, a frontal 
access to the ventricles and superior sagittal sinus may be impeded by the 
pronounced caudal extension of the frontal sinuses. Remaining possible 
models were sheep, goats and horses or ponies. Finally, domestic dairy goats 
(Saanen breed) were chosen because of their manageability and short hair. All 






weighted less than 60 kg. Only female goats were included to be able to house 
the animals together.  
Since the investigation was a pilot study, small sample sizes were chosen. The 
study consisted of a cadaver study (6 goats) and an in vivo study (9 goats). The 
studies were conducted serially and the goats were allocated to the different 
experiments in order of acquirement.  
All experiments in this study were approved by the local Ethics Committee of 
the Faculty of Veterinary Medicine of the Ghent University (EC2012/187, 
EC2013/66). Care and use of animals were in full compliance with the most 
recent national legislation (Belgian Royal Decree of 29 May 2013) (12) and 
European Directive (2010/63/EU) (13). 
For the cadaver anatomical study, the goats were euthanized directly after 
arrival at the research facility. The remaining goats were admitted to the 
animal facility at least 10 days prior to the start of the study for acclimatization 
and health checks (clinical investigation, ultrasonographic examination of 
abdomen and thorax, blood and feces analysis). These animals were housed 
in little groups (3-4 animals per cage). The cage measured 3 m x 4 m. The 
bedding consisted of straw and cage enrichment (an elevated platform) was 
present in all cages. Natural light was provided by translucent windows, and 
the cage temperature was kept between 15 and 20 °C. The animals were fed 
hay and water ad libitum, supplemented with 450 g nutritional pellets a day.  
Clinical evaluation of the animals was performed twice daily. The evaluation 
consisted of objective (e.g. vital parameters, weight, food intake) and 





All animals were fasted 24 h before surgery and received an intramuscular 
injection of 2.5 mg trimethoprim and 12.5 mg sulfadiazine/kg body weight 
(Borgal® 24%, Virbac, Barneveld, The Netherlands) starting one day prior to 
surgery and daily until 4 days after surgery. If needed, postoperative pain and 
fever were treated with 48 mg meloxicam subcutaneously (Metacam, 
Boehringer Ingelheim, Germany).  
Euthanasia was performed by intravenous administration of 50 mg/kg sodium 
pentobarbital 20% (Pentobarbital, Kela, Hoogstraten, Belgium) after 
intravenous premedication with 0.3 mg/kg midazolam (Dormicum, Roche 
Pharma, Brussels, Belgium) and morphine 0.1 mg/kg (Morphine HCL Sterop, 
Brussels, Belgium) intravenously (IV) and induction of anesthesia with IV 
propofol 2-4 mg/kg (Propovet, Parsippany-Troy Hills, New Jersey, United 
States).  
Anatomical cadaver study 
After euthanasia, the goats were frozen to –20 °C and decapitated. The heads 
were sawn in coronal slices of about 1 cm thickness. The slices were 
photographed with and without a scale bar. The contours of the ventricles and 
the brain were delineated at the level of the coronal suture and the ratio 
between the ventricular surface and the total brain surface was calculated 
using ImageJ software (ImageJ for Windows; National Institutes of Health, 
9000 Rockville Pike, Bethesda, Maryland 20892, USA; Version 150, available 
for download at https://imagej.nih.gov/ij/index.html). ImageJ provides a tool 
to measure surface areas of a plain image in two dimensions. By delineating 
the periphery, ImageJ calculates the surface area as measured by the number 






In vivo study 
The day before the suboccipital puncture, the first three goats were 
anesthetized and a head computed tomography (CT) scan was performed. This 
was not the case for the subsequent 6 goats. 
For the suboccipital puncture, the goats were anesthetized and correctly 
positioned. To reach the interpeduncular cistern (interpeduncular cistern 
group, n = 3), the goats were positioned with the neck in a neutral position 
(Figure 1).  
To reach the cisterna magna (cisterna magna group, n = 6), the goats were 
positioned with the neck in maximal flexion. A sterile surgical skin incision was 
made in the neck 3 cm caudal to the external occipital protuberance. Under 
radioscopic guidance a spinal needle (15 G) was advanced into the cisterna 
magna. A pressure transducer (DTXPlus; Argon; Bornem Belgium) was 
connected and the ICP was measured. In the last 6 goats, the ICP was 
measured simultaneously with the Central Venous Pressure (CVP) within the 
superior caval vein and the arterial Partial Pressure of Carbon Dioxide (PaCO2) 
within the auricular artery using an anesthesia monitor (Datex Ohmeda S/5) 
and a blood gas analyzer (Radiometer ABL 5). A PaCO2 of 40-45 mmHg and a 







Figure 1. Suboccipital puncture to reach the interpeduncular cistern 
Upper left: The goats were positioned prone with the neck in a neutral position, 
supported on a towel roll. A needle was inserted through a small skin incision 3 cm 
caudal to the occipital protuberance and advanced under radioscopic guidance into 
the cisterna magna. Through this needle a catheter was inserted and advanced, still 
under radioscopic guidance, around the brainstem to reach the interpeduncular 
cistern. Upper right: Sagittal slice through the cranio-cervical junction in the same 
goat. A white silicone catheter was inserted through the needle and left in place to 
mark the entry point into the cisterna magna (arrow). Lower left: fluoroscopic image 
showing the catheter curving around the brainstem (arrows) to end into to the 
interpeduncular cistern (circle). Lower right: image after injection of contrast agent.  






After completion of the ICP measurement a catheter was advanced through 
the spinal needle to reach the interpeduncular cistern (IC) in the first three 
goats (IC group). In these goats a spinal needle with a lateral opening (Tuohy 
needle, Ascenda intrathecal catheter spinal revision kit; Medtronic; Brussels 
Belgium) was used for the suboccipital puncture. The opening was turned to 
the right lateral side of the goat and, still under radioscopic guidance, a spinal 
catheter (Ascenda intrathecal catheter; Medtronic; Brussels Belgium) was 
inserted through the needle and advanced around the brain stem to end into 
the interpeduncular cistern (Figure 1). In the 6 subsequent goats (CM group) 
the procedure below was performed directly through the spinal needle (with 
the tip in the cisterna magna). Thus in this group no catheter was inserted 
through the needle. 
Once the final position was reached 3-4 ml CSF was evacuated and 1-3 ml of 
Iodine contrast (Omnipaque, GE Healthcare, Diegem, Belgium) was injected 
under fluoroscopic monitoring to verify the correct position of the catheter or 
needle respectively. Subsequently, 4ml (interpeduncular cistern group) or 3ml 
(cisterna magna group) of a 250 mg/ml kaolin (Sigma Aldrich, Overijse, 
Belgium)/Sodium Chloride solution was slowly injected.  
All 9 goats were scheduled for ICP measurement conform the protocol 
described above on day 7. The 3 goats of the 4 ml kaolin group were scheduled 
for a head CT after the ICP measurement and were to be euthanized 
afterwards. The 6 subsequent goats (interpeduncular cistern group) were split 
into two groups: 3 goats were to be euthanized directly after the 
measurement, while the remaining 3 goats were to be followed for 21 days to 
observe the natural history of the hydrocephalus. The latter 3 goats were 





afterwards. Euthanasia was performed earlier when necessary due to the 
animal’s condition. 
Statistics 
The normal distribution of the parameters was assessed using QQ-plots and a 
Shapiro-Wilk test. An independent T-test was used to compare the increase in 
ICP between the IC and CM group. A paired T-test was used to analyze the 
increase in ICP (IC and CM group considered as one), and the ratio between 
the surface of the ventricles and the surface of the brain as measured on CT 
imaging. An independent sample T-test was used to evaluate whether there 
was a difference between the ratio of the ventricle to brain surface as 
measured during autopsy of non-hydrocephalic and hydrocephalic goats.  
Results 
Anatomical cadaver study 
The ratio between the ventricular surface and the total brain surface at the 
level of the coronal suture amounted to 0.026 (0.13-0.040). 
Interpeduncular cistern group 
In this group (n=3) 4ml of the kaolin solution was injected into the 
interpeduncular cistern. No specific problems were encountered during the 
procedure. In the first days after the injection, the goats were periodically 
paddling and experienced seizures. In between these episodes and after the 
first days, the main symptoms were a lowered head, head pressing, refusing 
to stand, fore leg stiffening and weakness, decreased reactivity and reduced 
food intake.  
The ICP and the ventricular size before and 7 days after the injection of kaolin 






The mean baseline ICP was 3.33 (0-7.13) mmHg. The ICP increased only in one 
goat above the 95% confidence interval of the baseline values. The ratio 
between the ventricular and brain surface increased from 0.030 (0.018-0.040) 
to 0.085 (0.00-0.29). This increase was statistically not significant (P-value 
0.338). In two goats, the ventricular size increased above the 95% confidence 
interval of the baseline values. 
The CT-scan 7 days after the kaolin injection and the autopsy showed deposits 
of kaolin predominantly anteriorly of the pons and medulla oblongata but also 
in the cisterna magna in two goats (Figure 2). 
 
Figure 2. Kaolin distribution 
7 days after injection into 
the prepontine cistern 
A: Axial head-CT showing the 
hyperdense kaolin around the 
medulla spinalis [*]. S, skull; C1, 
atlas; C2, dens axis. 
B: Transverse section through 
the upper medulla spinalis and 
meninges in the same animal. 
The kaolin deposition around 
the medulla can be seen [*]. 
Note the canalis centralis of the 






One animal developed obstructive hydrocephalus with marked ventricular 
dilatation (Figure 3).  
 
Figure 3. Obstructive 
hydrocephalus 
Coronal slices showing 
different parts of the 
ventricular system of the 
goat that developed 
pronounced obstructive 
hydrocephalus. Top: rostral 
horns, Lower left: temporal 
horns, Lower right: 
aqueduct. 
 
In this animal kaolin was not predominantly observed anteriorly of the brain 
stem but in the fourth ventricle, along the olfactory nerve and in the olfactory 
bulb (Figure 4). The ICP did not increase to a value above the upper limit of the 








Figure 4. Axial CT images showing the distribution of kaolin 
Axial CT images showing the distribution of kaolin (white spots indicated by the white 
arrows) in the animal that developed obstructive (upper row) versus non-obstructive 
(lower row) hydrocephalus. From left to right: level of the foramen magnum, level of 
the caudal fourth ventricle, level of the olfactory nerve, level of the olfactory bulb. 
Cisterna magna group 
In this group (n=6) 3ml of the kaolin solution was injected into the cisterna 
magna. No specific surgical problems were encountered during the procedure. 
During orotracheal intubation, one goat experienced massive aspiration of 
gastric reflux and died shortly after the induction due to asphyxia. 
In the 5 goats that survived, the ICP was measured by suboccipital puncture 7 
days after the injection of kaolin. In one goat, the suboccipital puncture was 
cumbersome and no ICP measurement could be obtained. After the puncture 
the goat was tetraplegic and had to be euthanized. The autopsy showed 
subarachnoidal and brainstem bleeding. By consequence ICP measurements 
were obtained in 4 of the 6 animals of the second group. 





Table 1: ICP and brain morphometric measurements 
The ICP and ventricular size before and after the development of hydrocephalus are 
shown. IC: interpeduncular cistern; CM, cisterna magna; ICP before: ICP before the 
induction of hydrocephalus; ICP after: ICP at least 7 days after the induction of 
hydrocephalus; CT: computed tomography; Ventricles before: ratio between ventricle 
surface and brain surface as assessed on a coronal slice at the level of the foramen of 
Monro before the induction of hydrocephalus; Ventricles after: ratio between ventricle 
surface and brain surface as assessed on a coronal slice at the level of the foramen of 
Monro at least 7 days after the induction of hydrocephalus; Asterisk: values that 
increased above the upper limit of the 95% confidence interval of the baseline values; 
x: missing value; /: value cannot be assessed. 
ID Group ICP ICP-a Mod Ventricles-b Ventricles-a 
1 IC 2 2 CT 0,032 0,177* 
2 IC 3 18* CT 0,024 0,024 
3 IC 5 7 CT 0,031 0,055* 
4 CM 16 x Autopsy / x 
5 CM 12 20* Autopsy / 0,030 
6 CM 12 21* Autopsy / 0,043* 
7 CM 14 x Autopsy / 0,018 
8 CM 15 14 Autopsy / 0,017 
9 CM 16 24* Autopsy / 0,024 
The mean baseline ICP increased from 13.8 (10.5-17.0) mmHg to 19.8 (13.0-
26.4) mmHg. The ICP increased to a value above the upper limit of the 95% 
confidence interval of the baseline values in 3 of the 4 animals.  
The increase in ICP in the interpeduncular cistern group was almost equal to 






When all animals were considered as one group, the ICP increased from 9.3 
mm Hg to 15.1 mm Hg. The increase in ICP was statistically significant (P-value 
0.036).  
The goat that died due to gastric reflux aspiration and the goat that became 
tetraplegic after the ICP measurement (see above) were part of the group that 
was planned to survive for 21 days. Consequently, only in one goat the ICP 
could be measured 21 days after the kaolin injection. In this goat the ICP 
before the injection was 16 mm Hg. It increased to 24 mm Hg on day 7 and 
decreased subsequently to 18 mm Hg on day 21. 
The ratio between the ventricular and brain surfaces was assessed during 
autopsy. This ratio did not differ between the 9 animals that were injected 
with kaolin and the 6 non-hydrocephalic animals of the cadaver study (0.027 
(0.015-0.040) and 0.026 (0.13-0.040) respectively). 
Histology 
A histological sample of the dura adjacent to the kaolin deposits showed 
aseptic meningitis with granuloma formation. The granulomas consisted of 







Figure 5. Histology of the dura after 7 days 
A: Histological sample of normal dura; B: Sagittal section through the craniocervical 
junction showing the kaolin deposition and a thickened hyperemic aspect of the dura 
mater; C and D: Histological samples of the dura adjacent to the kaolin deposits 
showing aseptic meningitis with granulomas that consist of kaolin containing 
macrophages. M, medulla oblongata; *, inflamed dura mater; x, granulomas 
The kaolin itself was observed in the subarachnoid space where it provoked 
perivascular inflammation. At the surface of the brain parenchyma, focal 
perivascular inflammatory infiltrates were observed (cuffing).  
In the goats that developed increased ICP, the ependymal layer of the 
ventricles was flattened and denuded in some areas. Leukomalacia, focal 






This is consistent with transependymal resorption of CSF. The choroid plexus 
of the fourth ventricle was edematous.  
Discussion 
Non-obstructive hydrocephalus is treated with ventriculo-peritoneal or –atrial 
shunts, which have a failure rate that is as high as 50% in the first 2 years (4). 
The aim of this study was to present a hydrocephalic goat model to endorse 
the development of novel techniques that may lower this unacceptably high 
failure rate. To approximate human treatment conditions, a model of non-
obstructive hydrocephalus was preferred. Two different techniques were 
evaluated: in the first animals (interpeduncular cistern group, n=3), 4ml of a 
25% kaolin solution was injected into the interpeduncular cistern - anteriorly 
to the brain stem - to prevent occlusion of the fourth ventricles’ outflow (‘first 
group’) (14). In the subsequent animals (cisterna magna group, n=6) 3ml of a 
25% kaolin solution was injected into the cisterna magna, which is a more 
standard and well-documented technique to induce hydrocephalus in small 
domestic animals such as rats and dogs (9-11).  
Two animals died during the experiment. One goat due to asphyxia after 
massive aspiration of gastric reflux during orotracheal intubation. A second 
goat due to brainstem bleed after a cumbersome suboccipital puncture.  
In the remaining goats (n=7), the kaolin injection provoked pronounced 
aseptic meningitis that caused hydrocephalus in 6/7 (86%) of the goats.  
Hydrocephalus 
The hydrocephalus was characterized by ventricular dilatation (2/6 
hydrocephalic goats – both belonging to group 1) or an increased ICP (the 





Such a variable degree of ventricular dilatation within the same species and 
also in between species was described in previous literature and probably 
relates to the pathophysiology of a kaolin induced hydrocephalus: kaolin 
provokes aseptic meningitis that causes meningeal thickening and arachnoid 
adhesions that impede the normal CSF flow (9). This may lead to acute 
obstructive or latent non-obstructive hydrocephalus, depending on the 
location of the CSF-flow obstruction (9). Acute or obstructive hydrocephalus is 
due to obliteration of the fourth ventricle’s outflow and is characterized by a 
steep rise in ICP and a marked ventricular dilatation (9, 15). Latent or non-
obstructive hydrocephalus is caused by a more downstream obstruction of the 
subarachnoid space or damage to the normal absorption capacity. It is 
characterized by a more gradual increase in ICP and less pronounced 
ventricular enlargement. (9, 10, 15) Injection of kaolin into the basal cisterns 
probably causes a variable combination of both types.  
The variability of the ventricular dilatation within species can be explained by 
the variable obstruction of the fourth ventricular outflow, which was more 
pronounced in the animals that did develop ventricular dilatation in the 
current study.  
There is also variability of the ventricular dilatation in between species. The 
ventricular dilatation in goats and sheep is less pronounced than described in 
other species (7, 9, 16). Why a kaolin injection into the basal cisterns in goats 
and sheep produces such mild ventricular dilatation was not investigated. 
However, a similar issue was encountered in rabbits (17). In contrast with most 
other species, goats and rabbits have in common a persisting open outflow 
channel between the spinal central canal and the lumbosacral subarachnoid 






foramina of Luschka (a median foramen of Magendie does not exist in goats), 
thus eliminating the factor that contributes the most to the ventricular 
dilatation (17).  
The persisting open outflow channel between the spinal central canal and the 
lumbosacral subarachnoid space makes goats very suitable as a model of 
latent non-obstructive hydrocephalus as it helps to prevent the obstruction of 
the fourth ventricular outflow. 
The injection in the interpeduncular cistern, which is more complicated to 
reach, does not present an advantage over the injection into the cisterna 
magna to prevent an obstructive hydrocephalus. It is striking that ventricular 
dilatation was only seen in the animals of the interpeduncular cistern group, 
as kaolin was deliberately injected anteriorly of the brainstem to prevent 
obstruction of the fourth ventricular outflow. The ventricular dilatation was 
very pronounced (to >300% of the original volume) in one animal. The 
distribution of kaolin in this goat suggests intraventricular injection, which is 
possible if the caudal medullary velum was perforated by the suboccipital 
puncture. Only in this goat, a kaolin plug was observed in the fourth ventricle 
(Figure 4). This plug obstructed not only the lateral foramina of Luschka, but 
also the origin of the central canal at the obex. Interestingly in this goat, kaolin 
was also observed along the olfactory nerves and even in the olfactory bulb 
(Figure 4). In earlier studies, the nerve sheet of the olfactory nerve was found 
to drain up to 30% of the CSF towards the extracranial lymphatic system in 
sheep (which are very similar to goats) (21, 22). The kaolin around the 





The fact that no increased ICP was measured in the animals that developed 
ventricular dilatation may be explained by the location of the ICP 
measurement. When the outflow of the fourth ventricle is obstructed, a 
gradient may develop between the intraventricular and extraventricular CSF 
compartments, causing the ventricles to dilate. Although such a pressure 
gradient was not observed in kaolin induced hydrocephalic dogs (9), it was 
found in sheep (7), which are very similar to goats. By consequence the ICP 
measurements in the cisterna magna in this study may have led to 
underestimation of the intraventricular pressure in the goats that developed 
ventricular dilatation. 
The natural evolution of the induced hydrocephalus is unclear as only one 
animal was followed for an extended period (21 days). In this goat the ICP 
initially increased but spontaneously decreased again to nearly normal values. 
The reason for this finding, that was also described in previous literature, is 
not clear (9). Possibly the arachnoidal adhesions (generated due to the aseptic 
meningitis) partially disappear or compensating mechanisms develop 
spontaneously. 
Aseptic meningitis 
The injection of 4ml kaolin in the interpeduncular cistern (n=3) provoked 
pronounced aseptic meningitis, which had an unacceptably high impact on the 
animals’ clinical status. The main symptoms included head pressing, spastic 
paresis of the four legs, paddling and convulsions. In order to reduce animal 
suffering, the dose was lowered and in the subsequent animals (n=6) only 3ml 
of the kaolin solution was injected into the cisterna magna. The latter protocol 






The lower dose of kaolin provoked a milder, but still unacceptable clinical 
picture. In both groups, the important discrepancy between the severity of the 
meningitis and the mildness of the hydrocephalus made it difficult, if not 
impossible to adequately monitor the developing hydrocephalus clinically.  
The pronounced clinical impact of the aseptic meningitis was also a major 
issue in previous studies. Although kaolin injection into the cisterna magna 
seems to be relatively well tolerated by mice and rats (23, 24), this is not the 
case for larger animals like dogs, ferrets and sheep (7, 9, 16). In the latter 
species the clinical signs were comparable to those observed in the current 
study and the mortality rate - typically 30-40% - was even higher (9, 16, 25). 
The very pronounced clinical impact of suboccipital kaolin injection in the 
current and previous studies should urge the development of techniques that 
do not rely on meningitis to produce hydrocephalus. The injection of a silicone 
elastomer into the interpeduncular cistern seems an interesting option (8).  
Conclusion 
In contrast to other species, an outflow channel between the spinal central 
channel and the lumbo-sacral subarachnoid space persists in goats. This 
anatomical characteristic may be especially convenient for the development 
of a model of induction of non-obstructive hydrocephalus because it protects 
against the development of obstructive hydrocephalus.  
Although the suboccipital injection of kaolin was effective in producing non-
obstructive hydrocephalus, it provoked a pronounced aseptic meningitis that 
had an unacceptable clinical impact and clearly overshadowed the resulting 





depend on meningitis to induce hydrocephalus may be the subject of further 
research.  
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Chapter 9. Discussion 
 
 
At present, the mainstay treatment for hydrocephalus is draining CSF to the 
peritoneal cavity with a VP shunt. Alternatively, liquor may be drained to the 
venous system by a VA shunt or a VS shunt.  
The VA shunt, a classical treatment of hydrocephalus besides the VP shunt, 
has some advantages over the latter (1). First, confirmation of the correct 
placement of the distal catheter is possible intraoperatively. Second, the 
right atrium provides a consistent low pressure outlet: an advantage gaining 
progressively more importance, as obesity, that may cause high abdominal 
pressure and therefore dysfunction of VP shunts, becomes a global epidemic 
(2). 
The VS shunt, an experimental treatment of hydrocephalus, preserves the 
natural anti-siphon effect of the IJV and restores a physiological ICP (3-6). As 
this technique may prevent the most important causes of failure of VP- and 
VA shunts, it has theoretically the potential to become the new standard of 
care. 
However, VV shunts suffer from thrombotic complications, which is the main 
reason why most neurosurgeons reserve VA shunts only for patients for whom 
VP shunts are contra-indicated or not successful and why they are even more 






The high incidence of thrombotic complications cannot be explained on the 
basis of a foreign body in the venous system alone, as patients with for 
example pacemaker leads do not suffer equivalent rates of thromboembolism 
(10). Up to now, it remains uncertain which characteristics predispose VV 
shunts to thrombotic complications. To clarify this issue, we performed in vivo 
and in vitro evaluations of VV shunts.  
In the experimental non-hydrocephalic goat model we identified two 
characteristics, specific to VV shunts, that predispose to thrombotic 
complications: 
1) During the implantation of VS shunts we observed a pulsatile reflux of 
blood to the shunt system regardless of its orientation (anterograde 
or retrograde) and despite the usage of a one-way valve; 
2) Adding CSF to blood had a procoagulant effect. 
Reflux of blood into a VV shunt was evaluated in an experimental model. It 
proved to be caused by the dynamic pressures at the proximal (ventricular) 
and distal (venous) ends of the shunt. The pressure waves in the brain 
ventricles and the SSS originate from the phase difference between the 
cerebral arterial inflow and venous outflow during the heart-cycle (11). The 
atrial pressure wave has 3 peaks reflecting atrial contraction, ventricular 
contraction and atrial filling driven by systemic venous return (12). After 
implanting a VV shunt, CSF will drain to the venous system until the mean 
ventricular pressure equalizes the mean venous pressure. However, the 
proximal and distal pressure waves differ in amplitude, morphology and 
phase, causing alternating pressure differences over - and pulsatile reflux of 





in the shunt promotes clot formation and shunt obstruction or thrombo-
embolic complications. 
To verify if the procoagulant effect of CSF also exists in humans and whether 
it may have an impact on the amount of clot formation in and around a VV 
shunt, we performed two complementary experiments. A static experiment 
evaluated the effect on coagulation of different blood-CSF mixtures, using a 
viscoelastic coagulation monitor. A dynamic experiment confirmed the 
amount of clot formation on the shunt surface in a modified Chandler loop. 
We found that adding CSF to blood enhances coagulability starting from a 
concentration of 5-9%. When CSF is shunted to the venous system, 
concentrations are generally below this critical threshold. However, as 
discussed below, CSF may concentrate in specific situations, resulting in 
accelerated clot formation and shunt obstruction or thrombo-embolic 
complications.  
After the unexpected and disappointing results of the clinical trial with the VS 
shunt, we hypothesized that also the position of the shunt tip against the sinus 
wall is a predisposing factor for shunt obstruction (6). Theoretically the risk of 
clot formation is minimal in the center of a vessel as a result of several factors. 
First, due to shear stress the blood velocity is minimal at the wall and maximal 
in the center of the sinus. Second, platelets and clotting factors tend to 
migrate to the side while red blood cells are predominant in the center (13). 
Third, irritation of the endothelium by a catheter stimulates endothelial 
overgrowth and the release of hemostatic proteins (14) . 
To ensure an optimal position of the shunt tip in the SSS, Baert and colleagues 






Manuscript 1 Figure 6) that, when correctly implanted, secures the shunt tip 
in the center of the sinus (15).  
 
Figure 1. Ventriculosinus shunt with DVSAD 
Left: the ventriculosinus shunt containing the DVSAD 
Right: close-up of the DVSAD in the superior SSS [1]. It consists of an intravascular tip 
[2], a stabilizing epidural base plate [3] and an extravascular catheter [4].  
Below we discuss several factors concerning the further development of this 
device, taking into account possible reflux due to pressure waves at the 
proximal and distal end of the shunt and the procoagulant effect of CSF. 
Although the device is developed to access the SSS, the central position of the 
shunt tip and the recommendations below also count for VA shunts (for 





Orientation of the distal shunt opening 
The disappointing results of the prospective clinical trial with the retrograde 
VS shunt, urged us to reevaluate the advantages of the retrograde orientation 
that, according to El-Shafei, are essential in preventing thrombotic shunt 
obstruction (3, 4, 16-18): 
1) Impact effect: the blood flow causes the ICP to remain higher than the 
static Psss. This assures a constant drainage of CSF and prevents 
regurgitation of blood to the shunt system (17). 
2) CSF sleeve: the draining CSF is deflected by the blood stream and flows 
over the catheter surface, forming a constantly renewing CSF sleeve. 
According to El-Shafei, the CSF sleeve discourages clot formation (17). 
3) Flow conditions: the shunt tip is located in an impact zone. The stream 
lines hitting the impact zone cause shear stress and clear developing 
clots. After hitting the impact zone the streamlines deflect and move 
on, without stagnation of blood (17). 
Impact effect  
Experimental and numerical models substantiated that the impact protects 
against reflux of blood due to positional changes and Valsalva maneuvers (17, 
19). However, the protective effect was only partial and reflux of blood still 
occurred during provocation maneuvers (19). The above experimental and 
numerical models were static, neglecting the intracranial and venous pressure 
waves.  In the experimental model described in the present thesis, the impact 
effect could only be objectified in the static situation. When pulsations were 
applied, the impact effect disappeared. These results indicate that the laminar 






pressure waves caused pulsatile reflux of blood into the shunt system, 
regardless of the orientation (retrograde or anterograde) of the shunt.  
CSF sleeve 
The beneficial effect of the constantly renewing CSF sleeve has never been 
substantiated. We found that, although a fluid sleeve does discourage clot 
formation, the coagulation promoting properties of CSF still result in a net 
thrombogenic effect. 
Flow conditions 
A quantitative comparison of clot formation on the impact and wake side of 
the shunts after running the modified chandler loop showed that, in 
accordance to El-Shafei’s theory (17), less clot formation occurred on the 
impact side. 
Conclusion 
The retrograde position has no real hydrodynamic advantage, as the impact 
effect only partially protects against reflux of blood due to positional changes 
and Valsalva maneuvers and does not protect against reflux of blood due to 
ventricular and venous pressure waves (19). Knowing that the CSF sleeve 
enhances clot formation, the retrograde position may promote, rather than 
prevent, clot formation and should thus be discouraged. However, we cannot 
recommend the anterograde position either. In this position the shunt tip is 
located in a wake zone were blood will stagnate and CSF will accumulate (17). 
Both effects will promote clot formation and may result in obstruction of the 






Based on the above findings we suggest a neutral - perpendicular to the blood 
flow - orientation of the DVSAD distal opening. In this position, CSF will 
immediately be carried away by the blood flow. The contact between CSF and 
the shunt surface will thus be minimal and CSF will not accumulate in wake 
zones. Also, in the neutral position, the shunt tip will not be subjected to 
unfavorable flow conditions.  
One-way valve 
As positional changes, Valsalva maneuvers and the interaction between 
ventricular and venous pressure waves cause reflux of blood into a valveless 
shunt system, a one-way valve is always needed (19).  
However, a one-way valve has consequences on the relation between the 
venous and cranial pressures, as it will allow CSF to drain to the venous system 
whenever the ICP becomes higher than the venous pressure, but will prevent 
blood to return in the opposite situation. By consequence CSF will drain to the 
venous system until the ICP is lower than the venous pressure during the 
complete hart cycle. Also, when orienting the shunt tip neutrally, one should 
realize that the shunt volume locally reduces the vessel’s cross-sectional area. 
This results in an increase in flow velocity and, in conformity with Bernoulli’s 
principle, a local decrease in pressure. The above effects will render the ICP to 
be lower than the static venous pressure during the whole heart cycle. This 
situation, which is the opposite of the physiological relation, may eliminate 
the capacity of the ICP to adapt to the venous pressure and may cause 
symptoms of intracranial hypotension. In normal circumstances the cranial 
pressure is 1.6 times higher than the Psss (20). This causes the distal part of 
the cerebral veins to collapse. As explained in Chapter 5, the collapsed part of 






The added intracranial blood volume will cause the ICP to increase and remain 
higher than the Psss. It is thus essential that the ICP remains significantly 
higher than the venous pressure in the steady state condition, to preserve this 
natural regulation mechanism and to prevent reflux to the shunt system when 
the venous pressure suddenly increases (Valsalva maneuver) (17). This can be 
achieved by using a valve with a certain differential pressure instead of a very 
low pressure valve as currently advocated for VS shunting (4, 5). 
Distal catheter  
In the animal model, pulsatile reflux of blood was observed, despite the usage 
of a competent one-way valve. This reflux is caused by a combination of the 
compliance of the silicone shunt system distal to the valve, the ventricular and 
venous pressure waves and the inertia of blood corpuscles that hit the CSF 
column at the distal shunt tip. By consequence it can be prevented by a one-
way valve, but only if the valve is implanted close to the entrance of the distal 
catheter in the venous structure and when the compliance of the shunt system 
distal to the valve is kept minimal. The former can be achieved by using a 
stiffer material and by reducing the shunt’s diameter (according to Laplace’s 
law). 
Strengths  
The goal of this experimental work was to clarify causes of thrombotic 
complications of VV shunts. The two essential results are the thrombogenic 
effect of the CSF and the pulsatile reflux of blood due to the interaction 
between the ventricular (proximal end of the shunt) and venous (distal end of 





Each of these findings was confirmed by two complementary experiments 
with different methodologies.  
The thrombogenic effect of the CSF sleeve was objectified in a static 
(viscoelastic coagulation monitor) and a dynamic (modified Chandler loop) 
model. 
The static experiment was designed to minimize confounding factors. The 
blood and CSF came from the same donor to exclude possible immunological 
reactions due to incompatibility. The coagulation tests were not disturbed 
because there is no need for heparinization.  
The dynamic experiment was designed to approximate the in vivo situation. 
Special attention was paid to the flow conditions, the position of the shunt in 
the vessel and the infusion of CSF through the shunts.  
The pulsatile reflux of blood to the shunt system was observed in the 
experimental goat model and confirmed by an experimental in vitro model. 
Also, the first results of the numerical model that is currently being developed, 
are compatible with a pulsatile reflux. 
We are convinced that the double confirmation of our essential findings 
makes these more robust. 
Recommendations for future research 
This thesis identifies the procoagulant properties of CSF and the pulsatile 
backflow of blood to the shunt system as predisposing factors for thrombotic 
complications of VV shunts. It also discusses a promising novel venous access 






that theoretically would circumvent the above mentioned predisposing 
factors for thrombotic complications. 
At present no in vivo or in vitro experimental data exist that prove or indicate 
that this device or the suggested modifications to its design are effective in 
preventing thrombotic complications. 
Future research can now focus on the in vitro and in vivo evaluation of 
prototypes of the DVSAD and the suggested modifications to its design. To do 
so, the models presented in this thesis can be used. There are however some 
limitations. 
The size of the SSS of the goat allowed the usage of a sinus catheter that is 
identical to the catheter used by El-Shafei in humans. However, the SSS of the 
goat is considerably smaller than that of humans and the length of the 
intravascular catheter of the DVSAD should be adjusted so that it ends with its 
tip in the center of the sinus. By consequence evaluation of the DVSAD in a 
goat model will require extensive miniaturization of the device.  
The combination of the small SSS and the hypercoagulable state of goats may 
excessively promote shunt obstruction. This mainly interferes with the 
assessment of the long-term effectiveness of the DVSAD. However, in a first 
stage, the implantation technique and the tolerance to the device have to be 
evaluated. We consider the non-hydrocephalic goat suitable for this purpose.  
A hydrocephalic animal model will be indispensable to assess the efficacy of 
the DVSAD to treat hydrocephalus and to evaluate the long term shunt 
survival. Goats have anatomical characteristics that may be convenient for the 





technique used in this thesis, a suboccipital injection of kaolin, was effective 
in producing a non-obstructive hydrocephalus, it provoked a pronounced 
aseptic meningitis that had an unacceptable clinical impact and clearly 
overshadowed the resulting hydrocephalus. The development of better 
tolerated techniques that do not depend on meningitis to induce 
hydrocephalus may be the subject of further research.  
In conclusion, the goat model may be useful in the research and development 
process of the DVSAD, but the final testing of the (long term) efficacy of the 
device will utterly be reserved for a human prospective clinical trial. 
The impact of adding a one-way valve to the shunt system and the best 
differential pressure to preserve the physiological coupling between the ICP 
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CSF, that is produced by the choroid plexus, flows through the cerebral 
ventricles to the subarachnoid space where it is absorbed to the SSS. 
Hydrocephalus develops when the CSF flow is hampered or when the 
absorption capacity is diminished. At present, the pathology is treated by 
draining CSF to the peritoneal cavity or the right atrium of the hart by a VP- or 
VA shunt. VA shunts suffer from thrombotic complications, which is the main 
reason why most neurosurgeons reserve the technique for patients for whom 
VP shunts are contra-indicated or not successful. Unfortunately, the present 
treatment of hydrocephalus has a failure rate of about 50% in the first two 
years after implantation. An important cause of shunt failure is siphoning by 
which the CSF column within the catheter exerts suction through gravity when 
the patient is in a sitting or standing position. This effect leads to shunt-related 
intracranial hypotension and aspiration of the choroid plexus into the proximal 
catheter. Intracranial hypotension causes headaches, nausea, vomiting and 
even subdural haematomas, while aspiration of the choroid plexus is a major 
cause of shunt obstruction. Complex and expensive devices to counteract 
siphoning exist but are not always sufficient.  
The VS shunt drains CSF to its natural resorption site, the SSS. The technique 
prevents siphoning by preserving the natural, self-regulating anti-siphon 






Although a promising technique, early attempts were not successful due to 
thrombotic obstruction of the distal catheter. El-Shafei claimed, based on 
extensive experimental and clinical work, that he solved this issue by 
implanting the sinus catheter with the tip directed against the blood flow 
(‘retrograde’). According to El-Shafei, this position has the following 
advantages: 
1) The ICP remains always higher than the static pressure in the sinus 
due to the impact effect. This assures a constant drainage of CSF and 
prevents regurgitation of blood to the shunt system. 
2) The draining CSF is deflected by the blood stream and flows over the 
catheter surface, forming a constantly renewing CSF sleeve. According 
to El-Shafei, the CSF sleeve discourages clot formation. 
3) The shunt tip is located in an impact zone (facing the blood flow). The 
stream lines hitting the impact zone cause shear stress and clear 
developing clots. After hitting the impact zone, the streamlines deflect 
and move on, without stagnation of blood. However, in the wake zone 
(the 180° opposite site, facing away from the incoming flow) some of 
the running fluid separates from the stream lines and stagnates. 
Stagnation of blood promotes clot formation. 
El-Shafei reports excellent clinical results with a shunt survival rate of 95% 
after a mean follow up of over 6 years. However, the protocol of his follow up 
is not clear. 
These promising results are in stark contrast to the results of the small 
prospective trial conducted in our center were 80% (11/14) of the RVS shunts 





different results is not clear. The surgeon who performed all surgeries, 
carefully respected the technical recommendations of previous literature, and 
even went to Cairo to learn the technique from professor El-Shafei himself. 
Our results are however in line with the experience of other colleagues that 
used the technique in a very limited number of patients as a rescue operation 
(personal interviews). Furthermore, it is striking to us that VS shunts did not 
become the standard of care, despite the substantial potential advantages and 
the promising early clinical results. On the contrary, it has become very quiet 
about this technique, that neurosurgeons seem to be reluctant to use.  
Up to now, it remains uncertain why VV shunts (VA shunts and VS shunts) 
suffer from thrombotic complications. We wanted to clarify this issue, as a 
first step in a bigger research project aiming at the development of a new, 
long-lasting VS shunt. 
We already hypothesized that the position of the shunt tip against the sinus 
wall is a predisposing factor for shunt obstruction. Theoretically the risk of 
clot formation is minimal in the center of a vessel as a result of several 
factors. First, due to shear stress the blood velocity is minimal at the wall and 
maximal in the center of the sinus. Second, platelets and clotting factors tend 
to migrate to the side while red blood cells are predominant in the center. 
Third, irritation of the endothelium by a catheter stimulates endothelial 
overgrowth and the release of hemostatic proteins. 
In the present thesis we identified two characteristics, specific to VV shunts, 
that predispose to thrombotic complications. During an experimental non-
hydrocephalic goat model, we observed pulsatile reflux of blood into the shunt 






orientation (anterograde or retrograde). We also found that adding CSF to 
blood enhances blood coagulation.  
A dynamic experimental model proved that the interaction of pressure waves 
at the ventricular (proximal) and venous (distal) end of the shunt causes 
alternating pressure differences over the shunt that result in pulsatile reflux 
into the distal catheter. The resulting relatively static blood-CSF mixture in the 
shunt, promotes clot formation and shunt obstruction. Pulsatile reflux of 
blood also occurred in the presence of a one-way valve. The combination of 
the intracranial and venous pressure waves causes variations of total pressure 
in the shunt. As the silicone shunt system distal to the valve is compliant, it 
might distend and permit reflux of blood when the transmural pressure 
becomes maximal.  
The procoagulant effect of CSF was confirmed by evaluating the coagulability 
of different blood-CSF mixtures, using a viscoelastic coagulation monitor. A 
dynamic roller pump model (modified Chandler loop) confirmed that the 
procoagulant effect of CSF effectively results in more clot formation on the 
surface of VV shunts. It also confirmed that more clot formation occurs at the 
wake side of shunts compared to the impact side.  
To ensure an optimal position of the shunt tip in the SSS, we developed a new 
DVSAD (Chapter 4, Figure 7) that, when correctly implanted, secures the shunt 
tip in the center of the sinus.  
Taking into account possible reflux due to pressure waves at the proximal and 
distal end of the shunt and the procoagulant effect of CSF, some suggestions 
concerning the further development of the device can be made. Although the 





the recommendations below are also valid for VA shunts (for example 
providing access to the distal superior caval vein).  
Pulsatile reflux can be prevented by a one-way valve, but only if the 
compliance of the shunt system distal to this valve is kept minimal. This can 
be achieved by implanting the valve close to the entrance of the shunt in the 
venous structure, by reducing the inner diameter of the distal catheter and by 
using a stiffer material to manufacture this catheter.  
A one-way valve with a minimal differential pressure will render the ICP to be 
lower than the static venous pressure during the whole heart cycle. This 
situation, which is the opposite of the physiological relation, may eliminate 
the capacity of the ICP to adapt to the venous pressure and may cause 
symptoms of intracranial hypotension. By consequence we recommend using 
a valve with a certain differential pressure instead of a very low pressure valve 
as currently advocated for VS shunting. What exactly the ideal opening 
pressure should be is the subject of ongoing research in the context of a 
master thesis. 
The procoagulant effect of CSF will have a minimal impact when the distal 
opening of the shunt is oriented neutrally, meaning perpendicular to the 
direction of the blood flow. In this position, CSF will immediately be carried 
away by the blood flow. The contact between CSF and the shunt surface will 
thus be minimal and CSF will not concentrate in wake zones. Also, in the 
neutral position, the shunt tip will not be subjected to the unfavorable flow 
conditions of a wake zone.  
The in vitro and in vivo models described in this thesis provide a roadmap to 






account. The prototypes can be evaluated, with regard to dimensions, 
implantation technique, safety and tolerance, in the non-hydrocephalic 
experimental goat model. However, in order to be able to evaluate the (long 
term) efficacy of new prototypes to treat hydrocephalus, a hydrocephalic 
model will be necessary. Goats have anatomical characteristics that may be 
especially convenient for the development of a model of non-obstructive 
hydrocephalus. However, although the technique used in this thesis, a 
suboccipital injection of kaolin, was effective in producing a non-obstructive 
hydrocephalus, it provoked a pronounced aseptic meningitis that had an 
unacceptable clinical impact and clearly overshadowed the resulting 
hydrocephalus. The development of better tolerated techniques that do not 








Cerebrospinaal vocht (CSV) wordt geproduceerd door de plexus choroideus in 
de laterale hersenventrikels. Het stroomt doorheen het ventrikelsysteem naar 
de subarachnoïdale ruimte rond de cerebrale hemisferen en wordt vandaar 
geresorbeerd naar de sinus sagittalis superior (SSS). Hydrocephalie ontstaat 
wanneer het evenwicht tussen aanmaak en afvoer van CSV wordt verstoord 
ten nadele van de afvoer. Deze aandoening wordt momenteel behandeld met 
VP- en VA shunts, die het CSV afvoeren naar respectievelijk de peritoneale 
holte of het rechter atrium van het hart. VA shunts zijn progressief in onbruik 
geraakt naar aanleiding van trombotische complicaties. Momenteel worden 
zij door de meeste chirurgen enkel nog gebruikt wanneer VP shunts gecontra-
indiceerd of niet succesvol zijn. Alhoewel VP shunts frequent geïmplanteerd 
worden sinds de jaren 1950 blijft het percentage shunt falen hoog. Ruim de 
helft van de shuntpatiënten ondergaat een chirurgische revisie gedurende de 
eerste twee jaren na implantatie. Een belangrijke oorzaak van shunt falen is 
het sifon effect waarbij, door de inwerking van de zwaartekracht op de 
vloeistofkolom in de distale katheter, een aanzuigeffect effect ontstaat 
wanneer de patiënt zit of staat. Dit aanzuigeffect leidt tot intracraniële 
hypotensie en aspiratie van de plexus choroideus in de proximale katheter. 
Intracraniële hypotensie resulteert in hoofdpijn, nausea en braken en 
faciliteert het ontstaan van subdurale hematomen. Het aanzuigen van de 
plexus in de proximale katheter is de meest frequente oorzaak van 
shuntobstructie. Sinds 1950 werden verschillende complexe en dure medische 
hulpmiddelen ontwikkeld die het sifon effect tegengaan. Met deze 
hulpmiddelen is de groep patiënten die lijden aan overdrainage gereduceerd 






De ventriculosinus shunt draineert CSV naar de fysiologische resorptieplaats, 
de SSS. Hierbij wordt het natuurlijke, zelfregulerende antisifon effect van de 
vena jugularis interna behouden. De eerste klinische experimenten met de 
techniek waren niet succesvol omwille van shuntobstructie door 
klontervorming aan de distale tip. Om deze reden werd de techniek 
aanvankelijk verlaten. Vele jaren later verklaarde El-Shafei dat klontervorming 
aan de distale shunttip kan vermeden worden door de shunt tegen de richting 
van de bloedstroom (‘retrograad’) te implanteren. Volgens El-Shafei heeft 
deze positie de volgende voordelen: 
1) Wanneer de bloedstroom botst tegen de drainerende CSV kolom 
wordt de kinetische energie van de bloedproducten omgezet naar 
potentiële energie. Hierdoor blijft de intracraniële druk steeds hoger 
dan de statische druk in de SSS. Dit wordt ‘het impact effect’ genoemd 
door El-Shafei. Het impact effect verzekert een constante drainage 
van CSV en voorkomt reflux van bloed naar het shuntsysteem. 
2) CSV stroomt, direct na het verlaten van de shunt en onder invloed van 
de bloedstroom, over het shuntoppervlak. Het vormt op deze manier 
een zichzelf vernieuwende CSV mof over de katheter. Volgens El-
Shafei beschermt deze CSV mof tegen klontervorming. 
3) De shunttip bevindt zich in een ‘impact zone’, dit is de plaats waar de 
stroomlijnen botsen tegen het shuntoppervlak en afbuigen. Door de 
wrijving met het shuntoppervlak worden zich ontwikkelende klonters 
weggespoeld. In de ‘wake zone’, die zich direct stroomafwaarts van 
de shunt bevindt, zal een deel van het bloed de laminaire stroming 





El-Shafei beproefde de techniek bij meer dan 100 patiënten en rapporteerde 
een shunt overleving van meer dan 95% na ruim 6 jaar follow up. Het is echter 
onduidelijk hoe zijn patiënten postoperatief precies opgevolgd werden.  
Deze veelbelovende resultaten staan in schril contrast met de resultaten van 
een kleine prospectieve klinische studie bij ons op de dienst die na 4 maanden 
werd gestaakt omwille van een onaanvaardbaar hoog aantal shuntobstructies 
(11/14 of 80% van de patiënten). De oorzaak van de shuntocclusie was telkens 
klontervorming ter hoogte van de distale shunt tip. Het is onduidelijk waarom 
onze resultaten zo ver afwijken van deze van El-Shafei. Gezien de chirurg, die 
alle implantaties uitvoerde, voor aanvang van de studie zelf naar Caïro reisde 
om de techniek van professor El-Shafei te leren lijkt het weinig waarschijnlijk 
dat een verschillende chirurgische techniek de oorzaak is. Onze resultaten 
komen wel overeen met deze van collega’s die de VS shunt implanteerden bij 
een beperkt aantal patiënten waarvoor zij geen andere 
behandelingsmogelijkheid zagen (persoonlijke communicatie). Het is verder 
verwonderlijk dat de VS shunt, ondanks de belangrijke theoretische voordelen 
en de bemoedigende gepubliceerde klinische resultaten geen ingang vindt in 
de behandeling van hydrocephalie. Integendeel, het is de laatste jaren erg stil 
geworden rond de VS shunt en neurochirurgen lijken terughoudend om deze 
techniek te gebruiken.  
In overeenstemming met vroegere literatuur verdenken wij de perifere positie 
van de shunttip, tegen de bloedvatwand, als voorbeschikkende factor voor 
klontervorming. Theoretisch is de kans op klontervorming minimaal in het 
centrum van een bloedvat omwille van verschillende factoren. Door wrijving 
met de wand zal de stroomsnelheid minimaal zijn in de periferie en maximaal 






stollingsfactoren en bloedplaatjes zich aan de wand en rode bloedcellen zich 
in het centrum van het bloedvat bevinden. Verder veroorzaakt het contact 
tussen de sinuskatheter en de bloedvatwand irritatie van het endotheel. Het 
endotheel zal hierdoor woekeren en hemostatische proteïnen vrijzetten.  
In deze thesis identificeerden we enkele karakteristieken, specifiek voor VV 
shunts, die voorbeschikkend zijn voor trombotische complicaties. 
Tijdens het dierexperiment (niet-hydrocephaal geitmodel) stelden we een 
pulserende terugstroom naar de distale katheter vast. Deze terugstroom deed 
zich voor ondanks de retrograde positie van de shunt en de aanwezigheid van 
een competente eenrichtingsklep. In dit experiment bemerkten we ook dat de 
interactie met CSV de bloedstolling bevordert.  
In een dynamisch experimenteel model bewezen we dat de interactie tussen 
dynamische drukgolven in de hersenventrikels (proximale shuntuiteinde) en 
in de SSS of het rechter atrium (distale shuntuiteinde) aanleiding geven tot 
alternerende drukverschillen over de shunt. Deze alternerende 
drukverschillen resulteren in een pulserende terugstroom van bloed naar de 
distale katheter. Hierdoor ontstaat een relatief statisch CSV-bloed mengsel. 
Zowel stase van bloed als de interactie met CSV zijn voorbeschikkend voor 
klontervorming. De pulserende reflux doet zich ook voor als een 
eenrichtingsklep wordt gebruikt. Dit is enkel mogelijk als het shuntsysteem 
distaal van de klep voldoende compliant is om uit te zetten wanneer de 
transmurale druk in de shunt toeneemt. In dat geval zal een kleine 
hoeveelheid bloed het systeem binnendringen. 
Het stolling bevorderend effect van CSV werd bij de mens bevestigd door de 





coagulatie monitor. In een dynamisch rollerpomp model werd daarenboven 
aangetoond dat dit effectief aanleiding geeft tot meer klontervorming op het 
oppervlak van VV shunts. In dit model werd ook vastgesteld dat er meer 
klonters gevormd worden op het shuntoppervlak dat zich in de ‘wake’ zone 
bevindt in vergelijking met het shuntoppervlak dat zich in de ‘impact’ zone 
situeert.  
Gebaseerd op de hypothese dat de positie van de shunttip tegen de 
bloedvatwand klontervorming bevordert, ontwikkelden Baert en collega’s een 
DVSAD waarbij de shunttip in het centrum van de SSS gestabiliseerd wordt. 
De bevindingen van deze thesis, de pulserende terugstroom van bloed en het 
coagulatie bevorderend effect van CSV, hebben implicaties voor de verdere 
ontwikkeling van het DVSAD. 
De pulserende terugstroom van bloed kan enkel voorkomen worden door een 
éénrichtingsklep indien de compliantie van het shuntsysteem distaal van deze 
klep minimaal gehouden wordt. Factoren die hiertoe bijdragen zijn het 
implanteren van de klep nabij de intrede van shunt in de SSS, het verkleinen 
van de diameter van de distale katheter en het vervaardigen van deze katheter 
uit een weinig compliant materiaal. 
Een éénrichtingsklep met een minimale openingsdruk zal de intracraniële druk 
doen dalen tot onder de veneuze druk. Deze niet fysiologische relatie 
veroorzaakt mogelijks intracraniële hypotensie en interfereert met de 
natuurlijke regulatiemechanismen die de intracraniële druk doen stijgen 
wanneer de veneuze druk toeneemt. Om deze reden raden wij aan een klep 
te gebruiken met een hogere openingsdruk. Wat de ideale openingsdruk zou 






Het stolling bevorderend effect van CSV zal een minimale impact hebben 
wanneer de distale shunttip neutraal, d.w.z. onder een hoek van 90° met de 
bloedstroom, geïmplanteerd wordt. In deze positie is er slechts een zeer 
beperkte contactzone tussen het CSV en het shuntoppervlak, bevindt de 
shunttip zich niet in een wake zone en zullen de bloedproducten niet het 
shuntsysteem binnendringen, onder invloed van hun traagheid.  
Prototypes van het DVSAD kunnen geëvalueerd worden met de in vitro en in 
vivo modellen die in deze thesis besproken worden. Het niet-hydrocephaal 
diermodel laat toe de dimensies, de implantatietechniek en de veiligheid van 
de prototypes te evalueren. Voor de boordeling van de (lange termijn) 
effectiviteit van het DVSAD zal een hydrocephaal model nodig zijn. Omwille 
van anatomische eigenschappen zijn geiten goed geschikt voor de 
ontwikkeling van een diermodel voor niet obstructieve hydrocephalie. De 
techniek die in deze thesis gebruikt werd induceerde effectief een niet 
obstructieve hydrocephalie maar de klinische impact van de chemische 
meningitis was van dien aard dat wij deze als onaanvaardbaar hebben ervaren. 
De ontwikkeling van minder invaliderende technieken, die niet afhankelijk zijn 
van een chemische meningitis om hydrocephalie te induceren, kan deel 
uitmaken van toekomstig onderzoek. 
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